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Abstract
Imatinib has undoubtedly revolutionised the treatment of chronic myeloid 
leukaemia (CML) and hence has become first-line treatment. At the time of carrying out 
this work, the only data available on the efficacy of imatinib for newly diagnosed CML 
patients were from a single clinical trial, IRIS. In a complete population study in our 
geographical area, following two years of imatinib treatment, the complete cytogenetic 
response (CCR) rate was only 51%, which is considerably worse than IRIS.
Clinical decisions would be greatly facilitated if it was possible to accurately 
predict a patient’s probability of achieving a CCR, and in particular to identify those 
destined to subsequently progress to blast crisis while on imatinib treatment. In 
identifying patients likely to achieve a CCR on imatinib treatment the most promising 
biomarker investigated was the pCrkL/CrkL ratio. 100% of patients with a pCrkL/CrkL 
ratio of less than 25 achieved a CCR, whilst no patient with a ratio greater than 25 
achieved a CCR; the latter all required a change in treatment. A patient’s BCR-ABL1 
transcript type can provide additional information, but neither this or the pCrkL/CrkL 
ratio are predictive of blast crisis.
The role of ALOX5 was investigated for the first time in human CML. In contrast 
to published data in a mouse model, ALOX5 expression appears down-regulated in CML 
due to low levels of the LTB4 receptor BLT1. These data suggest caution when 
extrapolating mouse model data to human CML.
PP2A is a phosphatase and tumour suppressor which regulates cell proliferation, 
differentiation and survival. The predictive value of assessing PP2A and/or its inhibitory' 
proteins was investigated. CIP2A is a novel inhibitor of PP2A. Patients with a high 
CIP2A protein level at diagnosis have a 100% probability of progressing to blast crisis, 
with the mean time to progression being 13 months; this contrasts with a zero progression 
rate in patients with low diagnostic CIP2A protein levels. CIP2A acts by inhibiting PP2A, 
resulting in the stabilisation of c-Myc. Via its role in cell cycle promotion and cellular 
proliferation, c-Myc may then contribute to disease progression by promoting 
aneuploidy. In summary, CIP2A is a prospective biomarker of blast crisis in CML and 
may be a useful therapeutic target. As a result of this study identification of patients who 
will subsequently progress into blast crisis is now possible.
Acknowledgements
I would like to thank both my supervisors Professor Richard Clark and Dr Robert Harris. 
Without their support, belief and guidance this degree would have not been possible, for 
which 1 am very grateful.
There are many individuals within the Section of Haematology who deserve my thanks. 
Some have contributed scientific input and discussion, whilst others have simply lent 
time and listened. In particular I would like to thank Dr Athina Giannoudis for her help 
and support.
All of this work would not have been possible without the support and encouragement of 
my family. My heartfelt thanks go to my husband Chris, my Mum and my sister 
Stephanie.
2
Declaration
This thesis is the result of my own work, except were indicated. The TaqMan qRT-PCR 
assays were performed by Dr Athina Giannoudis. hOCTl mRNA expression experiments 
were performed by Dr Athina Giannoudis and Mrs Gemma Austin. The LTB4 ELISA 
assay was performed in collaboration with Miss Elizabeth McDonald. The BCR-ABL1 
protein FACS assay was performed in collaboration with Miss Jemma Fagan.
3
Table of contents
Publications.......................................................................................................................21
Presentations.....................................................................................................................22
Abbreviations....................................................................................................................24
CHAPTER ONE - General introduction................................................................... 28
1.1.0 INTRODUCTION...................................................................................................29
1.1.1. Chronic myeloid leukaemia - a brief history...................................................... 29
Figure 1.1. The Philadelphia chromosome.......................................................... 30
1.2.0. CML - IN THE CLINIC...................................................................................... 32
1.2.1. Epidemiology........................................................................................................32
1.2.2. Pathogenesis.........................................................................................................32
1.2.3. Clinical features....................................................................................................33
1.2.4. Diagnosis.............................................................................................................. 34
1.3.0. MOLECULAR PATHOGENESIS OF CML....................................................36
1.3.1. Normal ABL1.......................................................................................................36
Figure 1.2. Structure of the A BL1 protein........................................................... 37
1.3.2. Normal BCR.........................................................................................................37
Figure 1.3. Structure of the BCR protein............................................................. 39
4
1.3.3. BCR-ABL1 39
Figure 1.4. Breakpoint cluster region of the BCR-ABL1 fusion gene............. 41
1.3.4. Does the BCR-ABL1 transcript type offer any additional prognostic 
information in the imatinib era?....................................................................................41
1.4.0. BCR-ABL1 TYROSINE KINASE ACTIVITY AND SIGNALLING 
PATHWAYS.................................................................................................................... 42
1.4.1. Increased proliferation.........................................................................................42
1.4.2. Reduced apoptosis............................................................................................... 44
1.4.3. Genomic instability and DNA repair.................................................................. 45
1.4.4. Altered adhesion properties.................................................................................47
1.4.5. Arrest of differentiation.......................................................................................47
1.5.0. TREATMENT........................................................................................................48
1.5.1. Defining clinical response...................................................................................48
1.5.2. Treatment in the pre-imatinib era....................................................................... 49
Figure 1.5. Development of treatment for chronic myeloid leukaemia........... 50
1.5.3. Stem cell transplantation.....................................................................................51
1.5.4. BCR-ABL1 targeted therapy...............................................................................52
1.5.5. Imatinib................................................................................................................. 53
Figure 1.6. Schematic diagram of imatinib binding to BCR-ABL1..................54
Figure 1.7. IRIS study design................................................................................56
5
1.5.6. Imatinib dose escaiation 58
1.5.7. ELN recommendations........................................................................................ 59
Table LL Evaluation of response to imatinib treatment...................................60
1.5.8. Dasatinib............................................................................................................... 61
Figure 1.8. Imatinib, dasatinib and nilotinib chemical structure..................... 62
1.5.9. Nilotinib............................................. 62
1.6.0. CLINICAL LABORATORY PROGNOSTIC FEATURES...........................64
1.6.1. Prognostic scoring methods - pre-imatinib era................................................. 64
1.6.1.1 Sokal score.....................................................................................................64
1.6.1.2. Hasford/Euro score...................................................................................... 65
1.6.2. Prognostic scoring method - imatinib era........................................................... 65
1.6.2.1. EUTOS (European Treatment and Outcome Study for CML) score..... 65
1.6.3. Chromosome 9 deletion....................................................................................... 66
1.6.4. Timing of response...............................................................................................67
1.6.5. Drug transporters..................................................................................................68
1.6.6. Plasma imatinib monitoring.................................................................................69
1.6.7. Imatinib resistance and BCR-ABL1 kinase domain mutations.........................70
1.6.8. CrkL a surrogate marker of BCR-ABL1 tyrosine kinase activity......................72
Figure 1.9. BCR-ABL1 and CrkL signalling pathway......................................... 74
6
1.6.8.1. Current approaches for detecting and assessing CrkL phosphorylation
status...............................................................................    74
1.6.9. Predicting disease progression.............................................................................76
1.6.9.1. Microarray analysis...................................................................................... 76
1.6.9.2. TWIST1........................................................................................................ 78
1.7.0. LEUKAEMIC STEM CELLS AND ALOX5.....................................................79
\J.\.ALOX5...................................................................................................................79
Figure 1.10. Arachidomc acid metabolism pathway.........................................80
1.7.2. Leukotriene B4 (LTB4)....................................................................................... 80
1.7.3. LTB4 receptor — BLT1........................................................................................ 81
1.7.4. The role ofALOXS role in asthma and coronary heart disease....................... 81
\.l.5.ALOX5 and Cancer...............................................................................................82
\.1.6.ALOX5 and CML..................................................................................................83
1.8.0. THE ROLE OF PROTEIN PHOSPHATASE 2A (PP2A) IN CML............84
1.8.1. PP2A structure and biology.......... ..............  84
1.8.1.1. Catalytic subunit - PP2Ac...........................................................................84
Figure 1.12. PP2A protein structure.................................................................... 85
1.8.1.2. Regulatory subunit A subunit (PR65) - PPP2C A or B........................... 86
1.8.1.3. Regulatory B subunits.................................................................................. 86
Table 1.2. Characteristics of B subunits...............................................................86
7
1.8.2. Regulation of PP2A 87
1.8.3. PP2A and CML....................................................................................................87
1.8.4. PP2A inhibitor - SET........................................................................................... 88
Figure 1.13. Model mechanisms by which SET/JAK2 regulates PP2A and BCR- 
ABL1 signalling.....................................................................................................89
1.8.5. PP2A inhibitor - SET binding protein 1 (SETBP1)..........................................90
1.8.6. Cancerous Inhibitor of PP2A (CIP2A)............................................................... 90
1.8.7. Proviral Integrations of Moloney virus (PIM1)..................................................92
1.9.0. AIMS OF THIS THESIS...................................................................................... 94
CHAPTER TWO - Patients and methods...............................    96
2.1.0. PATIENTS.............................................................................................................. 97
2,2.0. DEFINING CLINICAL RESPONSE................................................................ 98
2.3.0. SAMPLE COLLECTION AND PREPARATION.......................................... 99
2.3.1 Total leukocytes.............................................................  99
2.3.2 Mononuclear cells (MNC) preparation................................................................ 99
2.3.3 Preparation of CD34+ cells................................................................................ 100
2.3.4 Plasma preparation..............................................................................................100
2.4.0. GENE EXPRESSION ANALYSIS.................................................................. 101
2.4.1 RNA extraction.................................................................................................... 101
8
2.4.2 cDNA synthesis 101
2.4.3 Identification ofBCR-ABLl transcript type......................................................102
Table 2.1. BCR-ABL1 manual and real-time PCR primer and probe sequences 
............................................................................................................................... 103
2.4.4 Quantification ofBCR-ABLl expression by quantitative real-time PCR (qRT-
PCR)............................................................................................................................... 103
2.4.5 Quality of samples............................................................................................... 105
2.4.6 hOCTl transporter mRNA analysis...................................................................105
2.4.7 Pre-designed TaqMan real time PCR assays..................................................... 106
Table 2.2. Pre-designed TaqMan assays........................................................... 107
2.4.8 CIP2A mRNA expression.................................................................................. 107
2.5.0. CELL CULTURE................................................................................................108
2.5.1 Cell lines...............................................................................................................108
2.5.2 Measurement of cell viability............................................................................. 108
2.5.3 In vitro TKI assay................................................................................................ 109
2.6.0 FLOW CYTOMETRY (FACS)..........................................................................110
2.6.1 ‘In-House5 FACS protocol................................................................................. 110
2.6.2 Caltag FIX & PERM FACS protocol...............................................................110
Table 2.3. FACS antibodies................................................................................ Ill
2.6.3. Triple layer FACS .............................................................................................112
9
2.6.4 Measurement of LTB4 receptor BLT1 112
2.6.5 BCR-ABL1 protein detection flow cytometry protocol................................... 112
2.7.0 WESTERN BLOTTING..................................................................................... 114
2.7.1 Protein Determination..........................................................................................114
2.7.2 Western blotting.................................................................................................. 114
2.7.3 Immunoprecipitation.........................................................................................  115
2.8.0 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA).......................116
2.8.1 pTyr and c-Myc ELISA.......................................................................................116
2.8.2.Leukotriene B4 ELISA........................................................................................117
2.9.0 PP2A ACTIVITY ASSAY................................................................................... 118
2.10.0 CIP2A SMALL INTERFERING RNA (siRNA) TREATMENT............... 119
2.11.0 STATISTICAL ANALYSIS............................................................................. 120
CHAPTER THREE - A population study of imatinib in chronic myeloid 
leukaemia........................................................................................................................... 121
3.1.0. INTRODUCTION................................................................................................ 122
3.2.0. PATIENT COHORT...........................................................................................123
Table 3.1. Summary of patients' characteristics - population study............... 124
3.3.0. RESULTS..............................................................................................................125
3.3.1. Defining the clinical cohort................................................................................ 125
10
3.3.2. Response rates to imatinib treatment (400mg) 125
Figure 3.1. A flow diagram of patients achieving CCRe................................126
3.3.3. Imatinib response in patients assessable at 12 months................................... 127
Table 3.2. CCRe response rate............................................................................128
Figure 3.2. A flow diagram of patients achieving MMR............................... 131
3.3.4. Event free survival is not associated with Sokal score in imatinib treated
patients........................................................................................................................... 132
Figure 3.3. Kaplan-Meier estimates of event free survival............................ 133
3.3.5. Time to achieve CCRe is not associated with Sokal score in imatinib treated
patients........................................................................................................................... 134
Figure 3.4. Kaplan-Meier estimates of time to achieve CCRe..........................135
3.3.6. Continuation of imatinib treatment....................................................................136
Figure 3.5. Patients continuing imatinib treatment......................................... 136
3.4.0. DISCUSSION................................................................................................. 137
Figure 3.6. IRIS 7 year analysis..........................................................................139
11
CHAPTER FOUR - BCR-ABL1 tyrosine kinase activity as determined by the 
pCrkL/CrkL ratio at diagnosis is predictive of treatment outcome in chronic 
myeloid leukaemia..................................................................................................... 141
4.1.0 INTRODUCTION............................................................................................142
4.2.0. RESULTS........................................................................................................144
4.2.1. Detection of pCrkL and CrkL by Flow cytometry......................................... 144
4.2.1.1. Fixation and permeabilisation....................................................................144
Figure 4.1. Detection of pCrkL in K562 cells by FACS using different methods 
af fixation and permeabilisation. (Representative plots are shown)................ 145
Figure 4.2. Comparing two CrkL antibodies..................................................... 147
4.2.1.2. Saturating antibody concentration.............................................................147
4.2.1.3. Triple layer FACS.......................................................................................148
4.2.1.4. Source of fluorophore...............................................................................148
Figure 4.3. Comparison of second layer antibodies for the detection of pCrkL. 
............................................................................................................................... 149
4.2.1.5. Source of control antibody......................................................................... 149
Figure 4.4. Assessment of controls.....................................................................150
4.2.1.6 Fresh and frozen material............................................................................ 151
4.2.2. Endogenous pCrkL.............................................................................................151
Figure 4.5. Endogenous pCrkL...........................................................................152
12
4.2.3. Detection of CrkL and pCrkL by Western Blotting 152
Figure 4.6. Western blotting demonstrating the presence of pCrkL............. 153
Figure 4.7. CrkL crossover experiment............................................................ 154
4.2.4. pCrkL in non-malignant myeloid cells............................................................ 154
Figure 4.8. pCrkL cannot be detected in non-malignant myeloid cells..........154
4.2.5 pCrkL levels in normal blood mononuclear cells (MNC)...............................155
Figure 4.9. pCrkL and CrkL levels in normal blood.......................................156
4.2.5.1 Calculating the pCrkL/CrkL ratio.............................................................. 157
4.2.6. TKI treatment decreases the BCR-ABL1 tyrosine kinase activity................ 157
4.2.6.1 Imatinib treatment........................................................................................157
4.2.6.2 Dasatinib treatment.................................................................................... 157
Figure 4.10. Effects of imatinib, dasatinib and nilotinib treatment on pCrkL 
and CrkL............................................................................................................... 755
4.2.6.3 Nilotinib treatment.......................................................................................158
Figure 4.11. pCrkL/CrkL ratio decreases in K562 cells following ti'eatment 
with TKIs...............................................................................................................160
A.2.1. Efficacy and uptake of the second generation drugs....................................... 161
Figure 4.12. Effect of imatinib, dasatinib and nilotinib on BCR-ABL1 function. 
..............................................................................................................................162
4.3.0. pCrkL, CrkL and pCrkL/CrkL ratio in CML patients................................ 163
13
4.3.1. pCrkL, CrkL and pCrkL/CrkL ratio at diagnosis and clinical outcome, 163
Table 4.1. Summary of patients' characteristics.............................................163
Figure 4.13. Optimisation of pCrkL and CrkL detection in MNC by flow 
cytometry...............................................................................................................164
Figure 4.14. pCrkL/CrkL ratio assessed at diagnosis predicts a cytogenetic 
response................................................................................................................ 165
Figure 4.15. Clinical outcomes of patients in the pCrkL/CrkL study.............166
Table 4.2 pCrkL/CrkL ratios for imatinib and nilotinib treated patients...... 167
Figure 4.16. Time to achieve a CCRe...... ..........................................................168
4.3.2. Measurement of pCrkL/CrkL ratio following in vitro treatment with imatinib 
 169
Figure 4.17. Measurement of pCrkL/CrkL ratio following in vitro imatinib 
treatment and serial monitoring of pCrkL/CrkL ratio...................................... 169
4.3.3. Serial monitoring of pCrkL/CrkL ratio following treatment with imatinib ..170
4.3.4 Tyrosine phosphorylation and clinical outcome................................................170
Figure 4.18. Total tyrosine phosphorylation ELISA..........................................171
4.3.5 Total BCR-ABL1 protein....................................................................................172
Figure 4.19. Total BCR-ABL1 protein............................................................... 172
4.3.6 CrkL mRNA expression......................................................................................173
Figure 4.20. CrkL mRNA expression................................................................. 173
14
4.3.7. Relationship between the pCrkL/CrkL ratio and other prognostic parameters 
...................................................................................................................................... 174
Figure 4.21. The pCrkL/CrkL ratio and other clinical parameters................174
4.4.0. DISCUSSION................................................................................................ 175
CHAPTER FIVE - Chronic myeloid leukaemia patients with the el3a2 ber- 
abll fusion transcript have inferior responses to imatinib than e!4a2 patients
.................................................................................................................................... 178
5.1.0 INTRODUCTION............................................................................................179
5.2.0 PATIENT COHORT.......................................................................................180
Table 5.1. Patient characteristics and response rates.......................................180
5.3.0 RESULTS.........................................................................................................181
5.3.1. Patients expressing el3a2 have inferior responses to imatinib than el4a2
patients............................................................................................................................181
Table 5.2. Patients response rates......................................................................181
Figure 5.1. Kaplan-Meier estimates of time to achieve CCRe, overall survival
and event free survival.......................................................................................182
5.3.2 No correlation between BCR-ABL1 transcript type and the imatinib transporter 
hOCTl.......................................................................................................................... 184
Figure 5.2. hOCTl mRNA for el3a2 and el4a2 patients................................184
Figure 5.3. ABCB1 mRNA for el3a2 and el4a2 patients............................... 185
15
5.3.3 el3a2 transcript type patients have higher BCR-ABL1 kinase activity 186
Figure 5.4. pCrkL/CrkL ratio for el3a2 and el 4a2 patients.........................187
5.3.4 Does the total amount of BCR-ABL1 protein differ according to transcript 
type? 187
Figure 5.5. Analysing BCR-ABL1 protein in different BCR-ABL1 transcript 
types.......................................................................................................................188
5.3.5 The kinetics of response is not different between the two transcript types.... 189 
Figure 5.6. Early changes in BCR-ABL1 mRNA and BCR-ABL1 transcript type
............................................................................................................................... 189
5.3.6 Variant BCR-ABL1 transcripts and clinical outcome..................................... 190
Table 5.3. Variant transcript type patient characteristics.................................190
5.4.0 DISCUSSION........................................................................................................ 192
CHAPTER SIX - The role of ALOX5 in CML..................................................... 196
6.1.0 INTRODUCTION.................................................................................................197
6.2.0. PATIENT COHORT...........................................................................................198
Table 6.1. Patient characteristics.......................................................................198
6.3.0 RESULTS.............................................................................................................. 199
6.3.1 ALOX5 mRNA expression and clinical outcome.............................................199
6.3.2 ALOX5 function - LTB4 levels in CML patients............................................ 202
16
6.3.3 ALOX5 function in chronic phase and blast crisis........................................... 205
6.3.4 LTB4 receptor BLT1.......................................................................................... 206
6.3.5 BLT1 mRNA expression....................................................................................209
6.4.0 DISCUSSION........................................................................................................ 211
CHAPTER SEVEN - The role of PP2A and its inhibitor SET in CML patients 
............................................................................................................................................... 213
7.1.0 INTRODUCTION.................................................................................................214
7.2.0 PATIENT COHORT........................................................................................... 215
Table 7.1. Patient clinical characteristics.........................................................215
7.3.0 RESULTS.............................................................................................................. 216
7.3.1 Optimisation of FACS methodology for the detection of PP2A, pY l07-PP2A
and SET..........................................................................................................................216
Figure 7.1. Optimisation ofPP2A, pY307-PP2A and SET FACS assays.........216
Figure 7.2. Changes in PP2A, pY307-PP2A and SET following imatinib, 
dasatinib and FTY720 treatment in K562 cells................................................. 217
7.3.2 PP2A activity.......................................................................................................218
Figure 7.3. PP2A activity in K562 cells............................................................. 218
7.3.3 Determining the normal level of PP2A, pY307-PP2A and SET...................... 219
7.3.4 PP2A protein is elevated during blast crisis...................................................... 219
17
Figure 7,4. Level of PP2A protein at chronic phase and blast crisis. 220
7.3.5 PP2A protein expression is increased in MNC and CD34+ cells from patients
destined to progress to blast crisis.............................................................................. 220
Figure 7.5. PP2A protein expression is increased in MNC and CD34+ cells 
from patients destined to progress to blast crisis.............................................222
7.3.6 pY307-PP2A status is increased in MNC and CD34+ cells from patients
destined to progress to blast crisis.............................................................................. 223
Figure 7,6, pY307-PP2A at diagnosis and following 12 months of h'eatment or 
at progression, stratified by response............................................................... 224
7.3.7 SET and SET binding protein 1 (SETBP1) levels are not indicative of clinical
outcome.........................................................................................................................224
Figure 7.7. SET and SETBP1 at diagnosis and follow-up...............................226
7.3.8 Inactive PP2A functions to stabilises c-Myc..................................................227
Figure 7.8. Assessing PP2A function - c-Myc is elevated at diagnosis in
patients destined to progress into blast crisis...................................................228
7.4.0 DISCUSSION.................................................................................................229
18
CHAPTER EIGHT - Cancerous inhibitor of PP2A (CIP2A) at diagnosis of 
chronic myeloid leukaemia is a critical determinant of disease progression 232
8.1.0 INTRODUCTION........................................................................................... 233
8.2.0. RESULTS....................................................................................................... 234
8.2.1. CIP2A mRNA expression does not correlate with clinical outcome............ 234
Figure 8.1. CIP2A express io?i levels at diagnosis and follow-up.................... 234
8.2.2 Cancerous inhibitor of PP2A (CIP2A) protein levels predict blast crisis......235
Figure 8.2. CIP2A protein level in MNC and CD34+ at diagnosis is predictive 
of blast crisis.........................................................................................................236
8.2.3 CIP2A protein correlates with high BCR-ABL1 tyrosine kinase activity..... 237
Figure 8.3. BCR-ABL1 tyrosine kinase activity (pCrkL/CrkL ratio) is higher at
diagnosis in patients destined to progress into blast crisis............................. 238
8.2.4 Is CIP2A protein regulated by BCR-ABL1?................................................... 238
Figure 8.4. Is CIP2A protein regulated by BCR-ABL1?.................................239
8.2.5 CIP2A inhibits PP2A function and stabilises c-Myc.......................................239
8.2.6 PIM1, a surrogate marker for PP2A function and activity.............................. 240
Figure 8.5. PIM1..................................................................................................240
Figure 8.6. PIM1 protein and mRNA expression in MNC and CD34+ cells at 
diagnosis............................................................................................................... 241
8.2.7. C1P2A plays a key role in regulating PP2A and BCR-ABL1 tyrosine kinase 
activity in CML cells................................................................................................... 242
19
Figure 8.8. Effect of CIP2A inhibition by siRNA. Inhibition of CIP2A
decreases BCR-ABL1 tyrosine kinase activity...................................................243
Figure 8.9. CIP2A knockdown in LAMA84 cells — confirms the key siRNA data 
presented in figure 8.8......................................................................................... 244
8.2.8 Model mechanisms by which CIP2A regulates PP2A and BCR-ABL1 
signalling proteins......................................................................................................... 244
Figure 8.10. Model mechanisms by which CIP2A regulates PP2A and BCR- 
ABL1 signalling proteins.....................................................................................245
8.3.0 DISCUSSION.................................................................................................. 246
CHAPTER NINE - General discussion......................      250
APPENDIX - Publications arising from this thesis .................................  266
REFERENCES.................................................  293
20
Publications
1. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. 
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is 
a critical determinant of disease progression. Blood. 2011;117(24):6660-6668.
2. Lucas CM, Fagan JL, Carter A, Swale B, Evans C, Clark RE, Harris RJ.
Rapid diagnosis of chronic myeloid leukemia by Bow cytometric detection of 
BCR-ABL1 protein. Haematologica. 2011;96(7): 1077-1078.
3. Lucas CM, Harris RJ, Giannoudis A, Davies A, Clark RE.
SET Binding Protein 1 expression does not predict clinical outcome in chronic 
myeloid leukemia. eBlood. 2010.
4. Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Clark 
RE. Chronic myeloid leukaemia patients with the e!3a2 BCR-ABL fusion 
transcript have inferior responses to imatinib than el4a2 patients. Haematologica. 
2009;94( 10): 1362-1367.
5. Lucas CM, Harris RJ, Giannoudis A, Knight K, Watmough SJ, Clark RE. 
BCR-ABL 1 tyrosine kinase activity at diagnosis, as detennined via the 
pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. 
British Journal of Haematology. 2010;149(3):458-460.
6. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, Dasgupta 
R, Butt NM, Galvani D, Hoyle CF, Seale JRC, Clark RE.
A population study of imatinib in chronic myeloid leukaemia demonstrates lower 
efficacy than in clinical trials. Leukemia. 2008;22(10):1963-1966.
21
Presentations
European Haematology Association annual conference 2011 - London, UK
1. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukaemia 
is a critical determinant of disease progression.
Lucas CM - Oral presentation
2. Cancerous inhibitor of PP2A (CIP2A) inhibits PP2A and stabilises PIM1 and 
c-Myc in CML leading to blast crisis.
Lucas CM - Oral presentation
3. ALOX5 is down-regulated at diagnosis of chronic myeloid leukaemia.
Lucas CM, Harris RJ, McDonald E, Giannoudis A, Holcroft AK, Fowler RC 
Clark RE
European school of Haematology annual CML meeting 2010 - Washington, USA
Cancerous Inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukaemia 
is a critical determinant of disease progression.
Lucas CM - Oral presentation
European Haematology Association annual conference 2010 - Barcelona, Spain
The pre-treatment levels of Protein Phosphatase 2A (PP2A) and its inhibitor SET 
can predict patients destined to progress to blast crisis of CML.
Lucas CM, Harris RJ, Clark RE.
British Society of Haematology annual conference 2010 - Edinburgh, UK
The clinical significance of Protein Phosphatase 2A (PP2A) in CML.
Lucas CM, Harris RJ, Clark RE.
22
European school of Haematology annual CML meeting 2009 - Bordeaux, France
Initial diagnostic BCR-ABL tyrosine kinase activity determined via the 
pCrkL/CrkL ratio is predictive of long term treatment outcome in chronic myeloid 
leukaemia (CML).
Lucas CM, Harris RJ, Giannoudis A, Knight K, Watmough SJ, Clark RE. 
European Haematology Association annual conference 2009 - Berlin, Germany
Chronic myeloid leukaemia patients with the e!3a2 BCR-ABL transcript have 
inferior response to imatinib than el4a2 patients.
Lucas CM, Harris RJ, Wang L, Knight K, Watmough SJ, Clark RE.
British Society of Haematology annual conference 2009 - Brighton, England
FACS assessment of pCrkL/CrkL ratio at initial diagnosis is predictive of long 
term treatment outcome in chronic myeloid leukaemia (CML).
Lucas CM, Harris RJ, Giannoudis A, Knight K, Watmough SJ, Clark RE.
British Society of Haematology annual conference 2008 - Glasgow, Scotland
A population study of imatinib in chronic myeloid leukaemia (CML) 
demonstrates lower efficacy than in clinical trials.
Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH,
Dasgupta R, Butt NM, Galvani D, Hoyle CF, Seale JRC, Clark RE.
23
Abbreviations
Abbreviation
5-HEPTE 5(S)-hydroperoxy-6-trans-8,l 1,14-cis-eicosatetraenoic acid
5-LOX ALOX5 protein
ABCB1 (MDR1) ATP-Binding Cassette Sub-Family B Member 1
ABCC1 ATP-Binding Cassette Sub-Family C Member 1
ABCG2 ATP-Binding Cassette Sub-Family G Member 2
ABL1 The human homologue of the Abelson murine leukaemia virus
AGS Human gastric cancer cell line
ALL Acute Lymphoblastic Leukaemia
ALOX5 Arachidonate 5-lipoxygenase
AML Acute Myeloid Leukaemia
AP Accelerated Phase
Ara-C Cytosine arabinoside
ASH American Society of Hematology
BAD BCL-2-Associated Death Promoter
BALL B-cell Acute Lymphoblastic Leukaemia
BC Blast Crisis
BCR Breakpoint Cluster Region
BD Becton Dickinson
BLT1 LTB4 receptor
cAMP Cyclic Adenosine Mono-Phosphate
CCR Complete Cytogenetic Response
CCRe Complete Cytogenetic Response equivalence
CEBPa CCAAT/enhancer-binding protein-a
24
CHR Complete Haematological Response
CIP2A Cancerous Inhibitor of PP2A
CIVIL Chronic Myeloid Leukaemia
CMML Chronic Myelomonocytic Leukaemia
CMR Complete Molecular Response
CP Chronic Phase
CrkL CT10 regulator of kinase like
DASISION Clinical trial comparing dasatinib and imatinib in newly diagnosed CP patients.
EPS Event Free Survival
EHA European Haematology Association
ELN European Leukaemia Network
ENESTnd Clinical trial comparing nilotinib and imatinib in newly diagnosed CP patients.
EUTOS European Treatment Outcome Study
FBC Full Blood Count
FISH Fluorescent In Situ Hybridisation
FLAP Five Lipoxygenase Activating Protein
hOCTl Human Organic Cation Transporter 1
IFN-a Interferon-a
IKZFI Ikaros gene
IRIS International Randomized Study of Interferon-a and STI571
JAK2 Janus Kinase 2
K562 First human immortalised CML cell line
KCL22 CML cell line
KYOl CML cell line
LAMA84 CML cell line
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LSC Leukaemic Stem Cell
LTA4 Leukotriene A4
LTB4 Leukotriene B4
MARK Mitogen Activated Protein Kinase
M-BCR Major Breakpoint Cluster Region
m-BCR Minor Breakpoint Cluster Region
MF1 Mean Fluorescence Intensity
MMR Major Molecular Response
MNC Mononuclear cells
NICE National Institute of Clinical Excellence
No-CCRe No Complete Cytogenetic Response equivalence
NSCLC Non-Small Cell Lung Cancer
OA Okadaic Acid
OS Overall Survival
pCR Partial Cytogenetic Response
pCrkL Phosphorylated CT10 regulator of kinase like
PDGFR Platelet Derived Growth Factor Receptor
PFS Progression Free Survival
Ph+ Philadelphia positive
PI3K Phosphatidylinositol 3-kinases
PIM1 Proviral Integrations of Moloney virus 1
PKC Protein kinase C
PP1 Protein phosphatase 1
PP2A Protein Phosphatase 2A
PP2Ac Protein Phosphatase 2A catalytic subunit
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p-Tyr Phosphorylated tyrosine
qRT-PCR quantitative Real Time Polymerase Chain Reaction
ROS Reactive Oxygen Species
SCT Stem Cell Transplant
SET PP2A inhibitor
SETBP1 SET binding protein 1
SHI Src Homology domain 1
SH2 Src Homology domain 2
SH3 Src Homology domain 3
siRNA Small interfering RNA
STATS Signal Transducer and Activator of Transcription 5
TK1 Tyrosine kinase inhibitor
WBC White Blood Count
WHO World Health Organisation
Zileuton 5-LOX inhibitor
27
CHAPTER ONE - General introduction
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1.1.0 INTRODUCTION
1.1.1. Chronic myeloid leukaemia - a brief history.
In 1845 the first probable case of what we now recognise as chronic myeloid leukaemia 
(CML) was described by John Hughes Bennett, a doctor from Edinburgh, who initially 
thought the disease was due to an infection.1 A few weeks later Virchow in Vienna 
reported a similar case, hypothesising that it was a non-infectious condition involving 
white blood cells; hence he named the disease “Weisses Blut” to describe the high 
proportion of white blood cells observed in the blood.2 These two reports appeared five 
weeks apart in the literature of the day, and in 1858 Virchow conceded that Bennett was 
first to report the disease. It has since been speculated that the case reported by Bennett 
was indeed chronic myeloid leukaemia, while Virchow's was likely to be chronic 
lymphocytic leukaemia.3,4 In 1870 Neumann, working with Virchow, identified that the 
leukaemic cells originated from the bone marrow,^ and the advent of panoptic staining 
methods in the 1880s by Ehrlich assisted in the classification of leukaemia into various 
types.6 It was now possible to describe the morphological differences between 
granulocytes and lymphocytes, leading to the characterisation of chronic myeloid 
leukaemia (chronic granulocytic leukaemia as it was known at the time) as a distinct 
disorder. It was not for another 80 years until the next major discovery concerning CML 
was reported.
In 1960, in Philadelphia USA, Nowell and Hungerford observed that patients with CML 
had a shortened abnormal chromosome (22q-) which they named the “Philadelphia
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chromosome”.7 The development of chromosome banding techniques identified the 
Philadelphia chromosome as a partial deletion of chromosome 22. The Philadelphia 
chromosome was later identified by Janet Rowley8 to arise from a reciprocal 
translocation between chromosomes 9 and 22 (Figure 1.1.). In the early 1980s the two 
genes disrupted by the translocation were identified. These were the ABL1 gene from 
chromosome 9 (the human homologue of the Abelson murine leukaemia virus),9'10 and its 
translocation partner the ‘‘breakpoint cluster region” (BCR) from chromosome 22.11
Figure 1.1. The Philadelphia chromosome
The Philadelphia chromosome results when the distal parts of the long arms of 
chromosome 9 and 22 break and the resultant fragments switch place. The (9,22) 
translocation forms a short chromosome 22 which is the Philadelphia chromosome (that 
contains the abnormal BCR-ABL1 fusion gene), and a abnormally long long arm of 
chromosome 9.
Before translocation After translocation
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A major advance in the understanding of CML was the demonstration that the BCR- 
ABL1 fusion protein encoded by the BCR-ABL1 fusion gene had deregulated tyrosine 
kinase activity when compared to its normal ABL1 counterpart, and that this was 
correlated with its ability to transform cells to a malignant phenotype.12 In the early 1990s 
it was reported that a CML-like disease could be induced in mice transplanted with BCR- 
ABL1 positive cells.13,14 This strongly supported the notion that BCR-ABL1 was the 
cause of the disease and not just a disease marker. Knowledge of BCR-ABL1 deregulated 
tyrosine kinase activity as the driving force behind the disorder focused attention on 
BCR-ABL1, as a logical specific therapeutic target.
In 1996 the first highly specific inhibitor of ABL1 tyrosine kinase activity was described 
by Druker and colleagues.15 The drug was initially known as CG57148B or STI571 
(Ciba-Geigy/Novartis) but is now commonly known as imatinib (trade name Glivec).16 
Imatinib was first used clinically in June 1998. In the year 2000 a phase III clinical trial, 
IRIS (International Randomized Study of Interferon versus STI571), opened comparing 
imatinib to the accepted treatment of the time — interferon alpha plus cytosine.17,18 
Imatinib has undoubtedly revolutionised the treatment of CML and hence has become 
first-line treatment. However, many patients become resistant to or intolerant of imatinib 
and it is this which concerns both clinicians and scientists and so the history of CML 
continues to be written.
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I.2.O. CML-IN THE CLINIC
1.2.1. Epidemiology
CML has an annual incidence of 1-2 cases per 100,000 of the population.19'21 It is the 
most common myeloproliferative disease - accounting for 15-20% of all leukaemia cases. 
It is more common in men than women and the median age at diagnosis is 60 years.22 
There is no reported geographical or ethnic background which predisposes patients to 
CML." Exposure to ionising radiation is the only known risk factor. There was an 
increased incidence of CML following the atomic bombs at Hiroshima and Nagasaki.24 
Patients exposed to the a-emitter thorotrast, (used as a contrast medium in radiology in 
the 1930s), as well as patients treated with radiation therapy have all demonstrated an 
increased risk of developing CML.2? Furthermore, BCR-ABL1 fusion transcripts can be 
induced in-vitro by high dose ionising radiation.26 In contrast to acute myeloid leukaemia 
(AML) there is currently no evidence linking the incidence of CML with exposure to 
organic solvents such as benzene.27
1.2.2. Pathogenesis
CML is a clonal myeloproliferative disorder of haemopoietic stem cells; characterised by 
the reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome) 
which creates the functional fusion gene BCR-ABL1.8 BCR-ABL1 is a deregulated 
tyrosine kinase known to play a crucial role in the pathogenesis of CML.12 The molecular
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characteristics of BCR-ABL1 and its activity will be discussed in more detail in section 
1.3.0.
1.2.3. Clinical features
Clinically, patients with CML present with a leukocytosis, a left shift in the differential 
count i.e. more immature cells, and splenomegaly. CML is not limited to the myeloid 
compartment since the Philadelphia chromosome can be demonstrated in endothelial cells 
though not in lymphoid cells. High platelet counts are regularly observed but 
erythrocytosis is rarely seen. Many patients are asymptomatic at diagnosis, though some 
may experience vague/mild symptoms such as fatigue, weight loss, anaemia, increased 
susceptibility to infections or joint/bone pain or symptoms attributable to splenomegaly. 
Priapism and other thrombotic problems are rare and serious presentations. Patients are 
often diagnosed by a routine full blood count (FBC) performed for other reasons.28
CML has traditionally been described as a tri-phasic disease. The three phases are known 
as chronic phase (CP), accelerated phase (AP) and blast crisis (BC). During CP there is a 
significant expansion of the myeloid cell compartment - these cells are able to function 
and differentiate reasonably normally. Without clinical intervention the disease typically 
progresses to accelerated phase which is defined as the appearance of one of the 
following: blasts in the blood or bone marrow >15%, or percentage of blasts plus 
promyelocytes in the peripheral blood or bone marrow >30%, or peripheral blood 
basophils >20%. (There are no reliable criteria for accelerated phase based on platelet
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count as it is virtually impossible to distinguish the effects of treatment from the effects 
of accelerating disease). The third phase of the disease is blast crisis where immature 
myeloid blood cells dominate the circulation. Blast crisis is defined as blasts in the blood 
or bone marrow >30%, or appearance of extramedullary involvement (e.g. chloromas), 
except for hepatosplenomegaly. However, in the tyrosine kinase inhibitor (TKI) era this 
may no longer be true, as few patients remain in accelerated phase for any length of time, 
progressing to blast crisis rapidly thus giving the appearance of a biphasic disorder (CP 
and BC).
1.2.4. Diagnosis
Diagnosis of CML is generally straightforward. Initial indication of the disease is usually 
based on the characteristics of a FBC and differential white cell count. Typically the 
WBC is high with an excess of neutrophils and myelocytes. Absolute basophilia and 
eosinophilia are also a characteristic finding. Confirmation of the disease occurs by two 
methods; cytogenetic analysis (G-banding, involving identification of the Philadelphia 
chromosome) and molecular diagnosis, confirming the presence of BCR-ABL1 
transcripts.
Although 95% of CML cases are Philadelphia chromosome (or translocation) positive by 
G-banding cytogenetic analysis, 5% of patients are negative. This is thought to be 
because the patient has a cryptic BCR-ABL1 rearrangement that is only detectable at the
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sub-microscopic level.29 Failure to demonstrate the presence of the Philadelphia 
chromosome is thought to be due to insensitivity of the cytogenetic assay or the quality of 
the blood /bone marrow specimen. In these cases confirmation of diagnosis can be 
achieved by performing FISH (fluorescent in situ hybridisation, using fluorescent probes 
for BCR and ABL1) or molecular techniques for BCR-ABL1 transcripts. The advantage 
of chromosome analysis compared to FISH and molecular techniques is that additional 
chromosome abnormalities can be identified which may offer additional prognostic 
information.30
The presence of the Philadelphia chromosome and/or BCR-ABL1 transcripts confirms a 
diagnosis of CML. However, if negative, the patient may have atypical CML (although 
this cannot be positively distinguished). This is a myeloproliferative disorder which 
presents like CML but with the absence of the Philadelphia chromosome and BCR-ABL1 
transcripts. These patients have a poorer prognosis compared to true CML, and have 
median survival of 18 months.31 The differential diagnosis should also include chronic 
myeiomonocytic leukaemia (CMML), polycythaemia vera, essential thrombocytosis, 
myelofibrosis and a leukaemoid reaction.
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I.3.O. MOLECULAR PATHOGENESIS OF CML
1.3.1. Normal ABL1
The ABL1 gene is the human homologue of the \-abl oncogene carried by the Abelson 
murine leukaemia virus (A-MuLV).9 It encodes a non-receptor tyrosine kinase that is 
expressed in most tissues and is involved in signal transduction, conveying signals from 
cell surface growth factors and adhesion receptors to regulate cytoskeleton structure, 
DNA repair and cell cycle regulation.3233 Several structural domains have been 
identified and are shown in Figure 1.2. Three Src homology domains (SHI, SH2 and 
SH3) are located near the N terminal. SHI is responsible for tyrosine kinase activity 
while SH2 and SH3 allow interactions with other proteins. The proline rich region can 
interact with the SH3 domains of other proteins such as CrkL (CT10 regulator of kinase 
like).34
ABL1 protein can be found in both the cytoplasm and the nucleus of cells and can shuttle 
between the two compartments under the influence of its nuclear localisation signal 
(NLS) and its nuclear export signal domains.3536 Nuclear ABL1 is an essential pro- 
apoptotic protein and even though BCR-ABL1 retains the ABL1 nuclear localisation and 
export signal domains, it is unable to enter the nucleus and therefore exhibits anti- 
apoptotic properties.'7
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Figure 1.2. Structure of the ABL1 protein
Type la isofonn is slightly shorter than type lb, which contains a myristoylation (myr) 
site for attachment to the plasma membrane. Three Src-homology (SH) domains are 
located near the NH2 terminus. Y393 is the major site of autophosphorylation within the 
kinase domain, and phenylalanine 401 (F401) is highly conserved in protein tyrosine 
kinases which contain a SH3 domain. The proline-rich regions (PxxP) are capable of 
binding to SH3 domains, and contain the nuclear localisation signals (NLS). The carboxy 
terminus contains DNA as well as G- and F-actin-binding domains. Sites phosphorylated 
by ATM, cdc2, and PKC are shown. The red arrow indicates the position of the 
breakpoint in the BCR-ABL1 fusion protein. (Adapted from Deininger et aF7)
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1.3.2. Normal BCR
Normal BCR is expressed in many cell types and the gene is known to be evolutionarily 
conserved. Its structure is depicted in Figure 1.3. The first N-terminal exon encodes a 
serine/threonine kinase.39 The coiled-coil domain at the N terminal allows dimerisation to 
occur. The BCR protein also contains dbl-like and pleckstrin homology domains (a 
protein domain of approximately 120 amino acids that occurs in proteins involved in 
intracellular signalling or as constituents of the cytoskeleton) which stimulate GDP-GTP 
exchange on Rho guanidine exchange factors,40 which activate transcription factors such 
as NF-kB.41 The C-terminal has GTPase activity for Rac, a member of the RAS family.
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which functions to activate NADPH oxidase in neutrophils. Neutrophils from BCR 
knockout mice have increased reactive oxygen species (ROS) production when activated. 
Activation also causes an increase in Rac membrane translocation. BCR knockout mice 
are viable and have a normal phenotype;42 this may reflect a degree of redundancy with 
these signalling pathways.37
It has been shown in animal models that the BCR component of BCR-ABL1 determines 
the aggressiveness and lineage of the BCR-ABL1 induced leukaemia.43 Mutations within 
the autophosphorylation site Y177 of BCR-ABL1 have linked BCR signalling with lineage 
determination and disease latency.44 Y177 lies within the GRB2 binding motif in BCR and 
is essential for GRB2/BCR binding.45 Data suggesting the significance of GRB2/BCR 
binding are conflicting and controversial. It has been suggested that phosphorylation of 
BCR-ABL1 at Y177 is essential for RAS activation and BCR-ABL1 transformation45 
although others have suggested that RAS is activated by other means.46
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Figure 1.3. Structure of the BCR protein
At the N-terminal there is a dimerisation domain (DD) and two cyclic adenosine mono­
phosphate (cAMP) domains. Y177 is the autophosphorylation site crucial for binding to 
GRB2. The centre of the protein contains a region homologous to Rho guanidine 
nucleotide exchange factors (Rho-GEF) as well as dbl-like and pleckstrin homology (PH) 
domains. Toward the C-terminus a putative site for calcium-dependent lipid binding 
(CaLB) and a domain with activating function for Rac-GTPase (Rac-GAP) are found. 
Red arrows indicate the position of the breakpoints in the BCR-ABL1 fusion proteins 
(pi90, p210 and p230). (Adapted from Deininger et al37)
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1.3.3. BCR-ABL1
The breakpoints of chromosome 22 cluster within a small (5.8kb) region, spanning exons 
el2-16 (formerly denoted as bl-5) known as the Major Breakpoint Cluster Region (M- 
BCR). Breakpoint locations almost always fall between either exons el3 and el4 or 
between el4 and el5. Although the breakpoints in the ABL1 gene are also variable, 
because of splicing events, the transcribed mRNA usually has either an e!3a2 (b2a2) or 
an el4a2 (b3a2) junction. The e!3a2 and e!4a2 BCR-ABL1 transcript types differ in 
length by 75bp (25 amino acids)/'7 Both BCR-ABLl mRNA molecules encode a 210kDa 
constitutively active protein kinase which is central to the pathogenesis of the disease.47 
Occasionally both major types of BCR-ABLl transcript (el3a2 and el4a2) can be
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detected within the same patient sample and this is thought to be a result of alternative 
splicing.48 In addition to BCR-ABL1 being the hallmark of CML it is also found in 25% 
of patients with B-Cell Acute Lymphoblastic Leukaemia (B-ALL). Two thirds of BCR- 
ABL1 positive B-ALL patients express an alternative BCR-ABL1 splice variant (ela2) 
known as the minor-BCR (m-BCR), which encodes a smaller protein (190kDa). Reports 
suggest that the p!90kDa confers a poorer prognosis than the conventional p210 
isoform.49,50 In rare cases the ela2 transcript is detected in CML (Figure 1.4).51
There is a third breakpoint cluster region known as p-BCR which is rarely observed in
48CML. In extremely rare cases breakpoints have been identified outside these three 
regions. ’ Variant BCR-ABL1 transcripts may confer a poor prognosis in imatinib 
treated patients, although the number of patients reported is small52
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Figure 1.4. Breakpoint cluster region of the BCR-ABL1 fusion gene
Breakpoint cluster region of the BCR-ABL1 fusion gene showing the M-BCR (major) and 
m-BCR (minor) found in CML.
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1.3.4. Does the BCR-ABL1 transcript type offer any additional prognostic 
information in the imatinib era?
Previous reports prior to the introduction of imatinib have in general not identified an 
effect of BCR-ABL1 transcript type on clinical outcome.54"60 In the imatinib era one small 
study of 22 patients at different phases of disease suggested that the e!3a2 BCR-ABL1 
transcript type may be more sensitive to imatinib treatment;61 while a larger study has 
indicated that patients with el4a2 have a better molecular response to imatinib.62 The 
clinical significance of the BCR-ABL1 transcript type in newly diagnosed chronic phase 
CML patients treated with imatinib remains uncertain. In chapter five 1 will assess if 
BCR-ABL1 transcript type correlates with clinical outcome in a population based study in 
a single contiguous geographical locality, investigating the clinical outcome of 78 newly 
diagnosed patients with chronic phase CML treated with imatinib 400mg. In addition, 1
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will evaluate the significance, if any, of having a variant transcript type in the imatinib
era.
1.4.0. BCR-ABL1 TYROSINE KINASE ACTIVITY AND SIGNALLING
PATHWAYS
Under normal cellular circumstances the tyrosine kinase activity of ABL1 is tightly 
regulated. However, when it fuses with BCR to form BCR-ABL1 the BCR part of the 
protein causes it to be constitutively active.36 Two adjacent BCR-ABL1 molecules can 
phosphorylate each other on tyrosine residues in their kinase activation loops.1 BCR- 
ABL1 tyrosine kinase activity drives the leukaemic process through the phosphorylation 
and activation of downstream proteins.48 50 BCR-ABL1 transforms fibroblasts and 
haematopoietic cells in culture6’ and induces leukaemia in mice.13’64,65
1.4.1. Increased proliferation
Evidence of increased proliferation is derived from the many CML cell lines which were 
made from primary blast crisis cells and which rapidly proliferate in culture without the 
need for growth factors. Primary chronic phase cells are able to proliferate rapidly in 
culture, although they are not completely growth factor independent. When compared to 
normal cells these cells are able to grow at much lower cytokine concentrations.66 This 
may explain why the malignant cells can outgrow normal haematopoietic cells.
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BCR-ABL1 can activate the RAS and MAP (Mitogen-Activated Protein) kinase 
pathways. Phosphorylation of BCR-ABL1 at Y177 provides a docking site for the adaptor 
protein GRB2. GRB2 binds to SOS, which then stabilises RAS in its active GTP-bound 
form.45 BCR-ABL1 can also activate the Signal Transducer and Activator of 
Transcription (STAT) pathway. The STAT family of transcription factors is involved in 
signal transduction downstream of multiple cytokines, hormones, and growth factors, and 
is involved in the regulation of cell survival, proliferation, and differentiation.67 STAT5 
has been found to be constitutively active in BCR-ABL1 positive cells, and is associated 
with anti-apoptotic and proliferative abilities of BCR-ABL1 transformed cells via 
interaction with the pro-survival protein Bcl-xL.68 Studies have shown that 
phosphorylation of Y694 within STAT5 is an indicator of BCR-ABL1 activity.69 However, 
STATS is not immediately downstream of BCR-ABLI, and other signalling pathways 
converge on STATS leading to phosphorylation. STATS is therefore not a direct or 
specific marker of BCR-ABLI tyrosine kinase activity.
JAK2 functions to transmit signals generated by interaction of IL-3 with the IL-3 
receptor. BCR-ABLI activates JAK2 and inhibition of JAK2 in BCR-ABLI positive 
cells can overcome imatinib resistance.70 Knockdown of JAK2 causes a decrease in the 
phosphorylation of BCR-ABL1Y177 as well as inhibiting the RAS, P13K and STAT 
pathways.70
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1.4.2. Reduced apoptosis
BCR-ABL1 stimulates survival pathways resulting in decreased apoptosis (programmed 
cell death). Several reports have demonstrated that CML cell lines do not undergo 
apoptosis in response to DNA damage.71,72 BCR-ABL1 can cause a prolonged rest in the 
G2 phase of the cell cycle. This allows cells to extensively undergo DNA repair, resulting 
in survival of the cells which under normal circumstances would have undergone 
apoptosis.71
Another mechanism by which BCR-ABL1 prevents apoptosis is by preventing the release 
of cytochrome c from mitochondria and thus the activity of caspases.73,74 Additionally 
BCR-ABL1 induces the expression of the anti-apoptotic protein BCL-2, through a 
signalling mechanism involving RAS.7? BCR-ABL1 via the AKT/PKB pathways also 
inhibits apoptosis by phosphorylating the pro-apoptotic protein BAD (BCL-2-associated 
death promoter). When phosphorylated BAD becomes an anti-apoptotic protein.76 AKT 
is a serine/threonine kinase involved in the pro-survival pathway.77 AKT is recruited to 
the plasma membrane by binding to phosphatidylinositol 3-kinases (PI3K), and is 
activated by phosphorylation at Thr308.69 Activation of AKT is required for BCR-ABL1 
transformation of both myeloid and lymphoid lineage cells.78 AKT activation is mediated 
in part by the adaptor protein CrkL.69 CrkL is an adaptor protein, immediately 
downstream of BCR-ABL1, which mediates BCR-ABL1 signal transduction.79'81 The 
role of CrkL as a marker of BCR-ABL1 activity will be discussed in more detail in 
section 1.6.8.
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1.4.3. Genomic instability and DNA repair
Mechanisms responsible for surveying genomic damage and repairing these lesions are 
compromised in CML, as well as other cancers.BCR-ABL1 induces mutations in genes 
responsible for maintaining genomic integrity. Chromosome abnormalities such as 
trisomy 8,83 trisomy 19,84 trisomy 21,83 additional Philadelphia chromosome,84,85 
isochromosome 17,86 loss of Y chromosome8'84 and monosomy 7 have all been described 
in patients progressing to blast crisis;84 these changes are considered markers of disease 
progression and an indication of genomic instability. BCR-ABL1 has been shown to 
induce ROS which results in oxidative DNA damage and double-strand breaks (DSBs) in 
S and G2/M cell cycle phases which leads to unfaithful homologous recombination repair 
(HRR) and nonhomologous end-joining (NHEJ) repair.87 The ROS generated by BCR- 
ABL1 can cause kinase domain mutations. Mutations in the BCR-ABL1 kinase domain 
can cause resistance to imatinib. Inhibition of ROS in leukaemic cells by antioxidants can 
decrease the frequency of mutations. The combination of imatinib and an antioxidant 
(pyrrolidine dithiocarbamate (PDTC), N-acetylcysteine (NAC), and vitamin E) reduces 
the mutagenic frequency in mice.88 The role of BCR-ABL1 kinase domain mutations will 
be discussed in more detail in section 1.6.7.
c-Myc is an oncogenic transcription factor which directly or indirectly regulates about 
1,000 genes.89,90 c-Myc regulates cell proliferation, differentiation and stem cell renewal 
and has been reported to be deregulated in many malignancies including CML.91'95 
Genomic instability is a hallmark of many cancers and c-Myc can cause genomic 
instability via the induction of ROS and by promoting whole chromosome instability
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leading to tetraploidy and aneuploidy.96 It is known that c-Myc contributes to disease 
progression in CML, mediated through aneuploidy.96’97 c-Myc is essential for BCR- 
ABL1 mediated cellular transformation98 and has been shown to be over-expressed 
during blastic transformation.99 Recently Albajar et af5 demonstrated that c-Myc 
induces aberrant DNA synthesis in CML cells which are under “imatinib stress.” c-Myc 
mRNA expression levels at diagnosis correlated with treatment response. Furthermore, 
no correlation between BCR-ABL1 and c-Myc mRNA expression was observed. The role 
of c-Myc in predicting clinical outcome will be addressed in chapters seven and eight.
The purpose of genomic surveillance is to protect the integrity of the genome. ATM 
(ataxia telangiectasia mutated) and ATR (ataxia telangiectasia and RADS-related) nuclear 
protein kinases function as DNA damage ‘sensors’. ATR signalling is inhibited in 
CML.100 Following exposure to genotoxic agents or genomic insult BCR-ABL1 
translocates to the nucleus, where it binds to both ATM and ATR. ATM is unaffected by 
BCR-ABL1 binding, as one of its substrates CHK2 (checkpoint kinase 2) can still be 
phosphorylated.100 Conversely, ATR is inhibited by BCR-ABL1 binding; evidence for 
this inhibition is provided by one of its substrates CHK1 (checkpoint kinase 1) which is 
not phosphorylated and has reduced activity. CHK1 is essential for the activation of the 
intra-S-phase cell cycle check point.101 Inhibition of ATR causes 
inappropriate/uncontrolled DNA replication, despite the presence of DNA damage.102 
Impaired ATR signalling predisposes leukaemic cells to an increased frequency of 
deletions, mutations and translocations.103
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1.4.4. Altered adhesion properties
BCR-ABL1 positive progenitor cells exhibit decreased adhesion to bone marrow stroma 
cells and extracellular matrix.104 The bone marrow stroma regulates proliferation, and P- 
integrins are responsible for the interaction between the stroma and progenitor cells. 
CML cells express a variant of pi integrin, which has anti-adhesion properties.Kb BCR- 
ABL1 has also been reported to up-regulate the expression of the a6 integrin.106 Murine 
models have demonstrated that mice lacking the adhesion molecules P-selectin and 
ICAM1 (intercellular adhesion molecule 1) develop a CML-like leukaemia at a 
significantly faster rate than do wild-type mice. Additionally the authors demonstrated 
that the lack of P-selectin resulted in early release of BCR-ABL1 expressing myeloid 
progenitors from bone marrow, appearing to alter the biologic properties of leukaemic 
cells rather than their growth rate.107
1.4.5. Arrest of differentiation
CML progression to blast crisis is characterised by disruption of differentiation. BCR- 
ABL1 modulates the activity of many transcription factors which regulate genes involved 
in differentiation. CEBPa (CCAAT/enhancer-binding protein-a) is essential for normal 
granulocyte differentiation and although present in chronic phase it is lost as patients 
progress into blast crisis.108 CEBPa down-regulation is mediated by BCR-ABL1 at the 
translational level through the stabilisation of the hnRNP E2 (poly(rC)-binding protein 
heterogeneous nuclear ribonucleoprotein E2). Expression of hnRNP E2 is low in chronic 
phase but becomes elevated at blast crisis.108 Ikaros (IKZF1) is essential for early 
lymphoid lineage commitment.
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Deletions in the IKZF1 gene have been associated with disease progression to lymphoid
• • 109blast crisis. B lymphocytes from mice engineered to express low levels of Ikaros arrest 
at the pro-B cell stage.110
1.5.0. TREATMENT
Several standardised ‘milestones’ of clinical response have been defined somewhat 
arbitrarily, to allow comparisons across clinical studies and provide goals for patient 
responses.111
1.5.1. Defining clinical response 
Haematological
1. Complete Haematological Response (CHR) is defined as the normalisation of 
the peripheral circulating blood count and resolution of splenomegaly.
Cytogenetic
This is conventionally assessed by G-banded metaphase analysis of at least 20 
metaphases from the bone marrow.111
• Minimal Cytogenetic Response (minCR) = 66-95% Ph+ metaphases.
• Minor Cytogenetic Response (mCR) = 36-65% Ph+ metaphases.
• Partial Cytogenetic Response (pCR) = 1-35% Ph+ metaphases.
• Complete Cytogenetic Response (CCR) = 0% Ph+ metaphases.
48
Molecular monitoring is easier and more acceptable to patients than conventional 
cytogenetics (which requires a bone marrow sample). The correlation between 
cytogenetically defined CCR and the equivalent BCR-ABL 1/ABL1 transcript ratio has 
been explored by several groups. In our laboratory, no samples with a BCR-ABL1/ABL1 
ratio of >10% was ever in CCR, but all samples with a ratio <1% were in CCR.112 A 
ratio of 1% or less can therefore be taken as CCR equivalence (CCRe)21 and this 
concept can be useful where only molecular data are available.
Molecular
1. Major Molecular Response (MMR) is defined as a BCR-ABL1/ABL ratio of 
0.1% or less. This is sometimes described as a 3 log reduction from baseline/ 
diagnosis, though this is misleading, since it refers to reduction compared to an 
arbitrary pool of 30 samples used as a standard for the IRIS (International 
Randomised Study of Interferon versus STI571) study.113
2. Complete Molecular Response (CMR). Currently there is no universally agreed 
definition; however CMR4, CMR4.5 and CMR5 have been suggested referring to 
4, 4.5 and 5 log reduction in BCR-ABL1 transcript ratios respectively.
1.5.2. Treatment in the pre-imatinib era
Arsenic was the first compound used to treat CML in the late 1800s but with the 
development of radiotherapy arsenic was replaced by splenic irradiation in the 1920s. 
Although relieving symptoms, this treatment did not increase survival.23 In the 1950s, the
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first synthetic compound used in the treatment of CML was busulphan, an alkylating 
agent. Busulphan is toxic to stem cells and this may explain the observed increase in 
survival.114 Busulphan was replaced in the 1980s by hydroxycarbamide. This was 
assessed formally as part of a clinical trial which demonstrated a greater overall survival 
when compared to busulphan.114 Figure 1.5 shows a time line for the development of 
treatment for CML.
Figure 1.5. Development of treatment for chronic myeloid leukaemia
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Hydroxycarbamide
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Dasatinib, Nilotinib, Bosutinib
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Interferon was introduced in 1983, and was standard therapy for CML patients prior to 
the advent of imatinib. The precise mechanism of action is unknown, however it is 
thought that interferon may function by selectively targeting the leukaemic cell, 
enhancing the immune response and regulating haematopoiesis in the bone marrow.115 
Interferon was the first drug to produce cytogenetic responses, varying degrees of which 
are seen in about one third of patients. Several clinical trials showed that responses to 
interferon are superior to busulphan or hydroxycarbamide.114’116,117
1.5.3. Stem cell transplantation
Stem cell transplantation (SCT) remains the only proven curative therapy for CML/3,118' 
The guidelines from the American Society of Hematology reported that about 50% of 
CP CML patients who received a SCT from a matched related donor were alive and 
leukaemia free at 5 years.Several subsequent reports confirmed these data and 
extended the follow-up to 10 years, with an overall survival (OS) of 60% and an event- 
free survival (EPS) of 50%.33,122,123 Survival after a SCT is dependent on seven risk 
factors - age, disease phase, transplantation from an unrelated donor, female donor, male 
recipient, CMV status and time from diagnosis to transplantation.121,124
Hehlmann and colleagues1-0 compared transplantation to current drug therapy. The study 
included 621 CP patients. Three hundred and fifty four patients were eligible for 
transplantation, of which only 123 patients received a transplant due to suitability of
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available donors. The 10 year estimated survival for the transplanted group of patients 
was 53%. Patients who did not have a transplant received interferon treatment until 
imatinib became available later. The 10 year estimated survival for this group of patients 
was 52%. Although there was no difference in overall survival at 10 years between the 
two cohorts, statistical analysis demonstrated that the drug treated group had a superior 
OS (p=0.049); this is due to the high mortality observed early on in the transplantation 
cohort. The authors conclude that OS was greater in the drug (interferon/ imatinib) 
treated cohort and thus drug treatment should be offered as first-line therapy instead of 
transplantation.120
1.5.4. BCR-ABL1 targeted therapy
Since BCR-ABL1 drives the leukaemic process, it is an obvious choice as a therapeutic 
target. ’ ’ Initial work focused on inhibition of the tyrosine kinase activity with 
compounds known as tyrphostins.12'' Tyrphostins compete with ATP and bind to a site 
outside the active site, affecting BCR-ABL1 activity by a conformational change.125,126 
Although these tyrphostins inhibit growth of the K562 cell line via the inhibition of 
BCR-ABL1 tyrosine kinase activity, these compounds were not developed for clinical 
use as these were very toxic.126
Another compound which demonstrated activity against BCR-ABL1 is the antibiotic 
herbimycin A. Herbimycin A acts by accelerating the degradation of the BCR-ABL1
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protein but has no effect on the BCR-ABL1 tyrosine kinase activity.127 Like tyrphostins, 
herbimycin A was also very toxic and therefore was not developed further for clinical 
use.
1.5.5. Imatinib
In the late 1980s scientists working for Ciba Geigy, (now part of Novartis) embarked on a 
project to identify novel PKC (protein kinase C) inhibitors. A 2-phenylaminopyrimidine 
was identified as the best compound.'‘s Although it had low specificity inhibiting both 
serine/threonine and tyrosine kinases, more specific derivates were synthesised from it. 
The substitution of a side chain of an aniline phenyl ring with a methyl group enhanced 
the specificity towards tyrosine kinases and the addition of a benzamide group improved 
the drug activity towards platelet derived growth factor receptor (PDGFR).129 Screening 
of these compounds showed that they also inhibited ABL1.15,130 The best compound 
synthesised was CG57148B, later STI571, now known as imatinib, trade name 
Glivec.15,128-130
Imatinib is a tyrosine kinase inhibitor which acts by competing with ATP at the ATP 
binding site within BCR-ABL1 (Figure 1.6), leading to a decrease in the phosphorylation 
of proteins downstream of BCR-ABL1 which, in turn, results in several behavioural 
changes including inhibition of proliferation and enhanced apoptosis as discussed in 
section 1.4.0.131
53
Clinical evaluation of imatinib began in June 1998, when a phase 1 clinical trial was 
opened at three centres in the United States. Patients who were resistant or intolerant of 
interferon were included in this study. The starting dose was 25mg daily; however 
haematological responses were only seen at doses above 85mg. At a dose of 300mg daily 
complete haematological responses were seen in 98% of patients, and 31% achieved a 
major cytogenetic response and 13% achieved a complete cytogenetic response. The 
observed responses were durable and only 4% of patients lost their response.132
Several phase II trials began in 1999 at multiple international centres. These ran in CML 
patients in myeloid blast crisis, accelerated phase, those who had failed interferon and 
relapsed Ph+ acute lymphoblastic leukaemia (ALL). The encouraging early data from the
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phase I and II trials in chronic phase patients led to the phase III IRIS trial in newly 
diagnosed chronic phase patients. This opened in the year 2000, comparing imatinib 
against interferon plus cytosine arabinoside (Ara-C) which at the time was the best 
available therapy.133 The trial primary endpoint was time to progression, which was 
defined as death from any cause during treatment, progression to accelerated phase or 
blast crisis, extramedullary involvement, loss of CHR or loss of a major cytogenetic 
response. The secondary endpoints were the rate of complete haematological response, 
the rate of major and partial cytogenetic response, safety and tolerability.17 Five hundred 
and fifty three patients were randomised into each study arm and crossovers were 
permitted (though tightly policed), if the patient failed to respond to treatment, lost a 
response, had an increase hi the WBC, was intolerant of treatment or had an adverse 
effect that was considered immediately life-threatening (Figure 1.7).17
55
Figure 1.7. IRIS study design.
Newly diagnosed chronic phase CML patients were assigned to the imatinib or interferon 
plus Ara-C arm of the trial. Crossover was permitted due to intolerance or failure to 
respond to treatment. After 5 years of treatment 69% of patients remained on imatinib 
treatment compared to 3% on interferon + Ara-C.
After five years of treatment 69% of patients assigned to the imatinib arm continued to 
receive the drug, while only 3% of the patients assigned interferon plus Ara-C remained 
on treatment. Sixty-five percent of patients originally assigned to receive interferon plus 
Ara-C switched to imatinib treatment while only 3% of imatinib patients crossed over to 
receive interferon plus Ara-C.18 By 18 months of the trial, it was clear that the response 
rates in the imatinib arm were superior,17 and it was unethical to continue further follow­
up in the interferon plus Ara-C arm. The emphasis of the study therefore changed to 
become a long-term follow-up study of patients who received imatinib as first-line 
therapy.
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After five years of imatinib treatment the estimated cumulative rate of CHR was 98%. 
Estimated cumulative CCR rate was 69% at 12 months which increased to 87% at 5 
years.17,18 There was a significant difference in CCR rate according to Sokal score; 89%, 
82% and 69% for low, intermediate and high risk groups respectively. The estimated EPS 
was 83%. Events were defined by the first occurrence of any of the following: death from 
any cause during treatment, progression to the accelerated phase or blast crisis of CML, 
or loss of a CHR or MCR.18 Disease progression to either accelerated phase or blast crisis 
was estimated to be 6%, which was concentrated in the first 2-3 years of treatment.18 As a 
result of the IRIS trial data imatinib 400mg daily became the new standard first-line 
therapy for newly diagnosed CML patients, approved by the National Institute of Clinical 
Excellence (NICE) in late 2003.
Imatinib is well tolerated with side effects and toxicity only being reported in a small 
percentage of patients. Common side effects include oedema, muscle cramps, diarrhoea, 
nausea, rash and other skin problems, abdominal pain, fatigue, joint pain, and headache. 
Side effects are generally mild and rarely reach World Health Organisation (WHO) grade 
3 or 4 toxicity criteria.17,18 In the IRIS study haematological toxicity (neutropenia, 
thrombocytopenia and anaemia) was the most common adverse event.123 In 2006, in 
vitro imatinib was reported to damage cardiac myocytes and an association was made 
with clinical cardiac failure.134 However, a large number of subsequent studies 
investigating the relationship between imatinib treatment and congestive heart failure 
have reported no correlation.135,136
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The IRIS clinical trial results are impressive. However is it important to establish if the 
IRIS trial results can be reproduced in a more general, unselected, CML population in 
order to determine the degree of imatinib failure. This will be addressed in chapter three.
1.5.6. Imatinib dose escalation
Dose escalation of imatinib from the standard 400mg daily to 600mg or 800mg daily is a 
possible treatment option to overcome resistance.137 The rationale behind this came from 
cell line work on the overexpression of BCR-ABL1.1,7 Treatment with a higher dose of 
imatinib can induce CHR in 65% of patients who were in haematological relapse and 
MCR in 56% of patients.117 The Australian TIDEL (Therapeutic Intensification in DE- 
novo Leukaemia) trial tested an initial imatinib dose of 600mg daily with a dose 
escalation to 800mg for sub-optimal responders. For patients receiving 600mg of imatinib 
the MMR rates were 55% and 77% at 12 and 24 months compared to 32% and 53% for 
patients receiving less than 600mg.138
Recently, the French Spirit trial (STI571 Prospective Randomized Trial) demonstrated 
that imatinib 600mg is better than 400mg at 12 months, with a CCR rate of 65% versus 
58% and an MMR rate of 49% versus 38% for the 600mg and 400mg doses respectively. 
This trial also showed that the combination of imatinib 400mg and interferon gave even 
better CCR and MMR rates at 12 months (66% and 57% respectively).1 9 However, the 
German CML IV trial demonstrated a higher rate of MMR at 12 months in patients 
treated with imatinib 800mg (59% compared to 44% for imatinib 400mg), while showing
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no benefit of adding interferon.140 The British SPIRIT 1 trial also compared these 
treatments, and has yet to report.
1.5.7. ELN recommendations
In 2006 the European LeukemiaNet (ELN) reviewed all available data in respect to 
treatment and monitoring of CML patients.3’ The aim was to update definitions of 
responses and to provide recommendations for the clinical management of CML patients. 
These recommendations were updated in 2009.1,1 These suggest frequent initial 
monitoring to detect a haematological response e.g. every 15 days. Bone marrow 
specimens should be sent for cytogenetic analysis at diagnosis, at 3 and 6 months, then 
every 6 months until a CCR has been achieved, and then every 12 months if robust 
molecular monitoring is not assured. Whilst these are recommendations and not 
guidelines, the practicality of performing a bone marrow cytogenetic analysis frequently 
may be difficult to perform. Cytogenetic analysis certainly should be performed at 
diagnosis to confirm the presence of the Philadelphia chromosome, as well as to identify 
additional chromosome abnormalities. It should again be perfonued at 12 months and 
when there is an indication of disease progression/ loss of response.111 Molecular 
monitoring of BCR-ABLl transcripts should be performed every three months as this 
technique is more accurate and sensitive than cytogenetic analysis in patients with low 
level disease. Once an MMR has been achieved the ELN recommendations are for 
monitoring to be performed every 6 months.111 However, frequent monitoring of patients 
will allow poor responders/ loss of response to be identified as early as possible.141
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A summary of ELN criteria for identification of optimal response, sub-optimal response.
failure and additional warning signs is shown in Table l.l.m
Table 1.1. Evaluation of response to imatinib treatment.
Time Optimal Suboptima! Failure Warning signs
High risk Sokal score.
Diagnosis N/A N/A N/A Additional clonal abnormalities in PIT 
cells
3 Months CHR and mCR (Ph+ < 65%)
No cytogenetic 
response 
(Ph+ >95%)
Less than CHR N/A
6 Months pCR(Ph+ < 35%)
Less than PCR 
(Ph+ > 35%)
No cytogenetic 
response 
(Ph+ >95%)
N/A
12 Months CCR pCR(Ph+ > 35%)
Less than pCR 
(Ph+ > 35%) Less than MMR
18 Months MMR Less than MMR Less than CCR N/A
Stable or 
improving
MMR
Loss of CHR.
Loss of CCR Any rise in transcript level
Additional clonal 
abnormalities in Ph* 
cells
At any 
time
Loss of MMR 
Mutation
Mutation
Additional clonal 
abnormalities in Ph 
cells
Abbreviations
N/A= Not applicable, CHR = Complete Haematological Response. mCR = Minor Cytogenetic Response, 
pCR =partial Cytogenetic Response, CCR = Complete Cytogenetic Response, MMR = Major Molecular 
response
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1.5.8. Dasatinib
Dasatinib is a second generation, oral, multi-target inhibitor of BCR-ABL1 and SRC 
family kinases, licensed by Bristol-Myers Squibb for the treatment of newly diagnosed 
and imatinib resistant and intolerant CML. The chemical structure of dasatinib is shown 
in Figure 1.8. In vitro, the drug has over 300-fold greater potency than imatinib, and is 
effective against many BCR-ABL1 kinase domain (KD) mutations that confer imatinib 
resistance, excluding T315I.14“ Unlike imatinib, dasatinib is able to bind to both the 
active and inactive conformations of BCR-ABL1.14, In a phase I study, haematological 
and cytogenetic responses were observed in both chronic and advanced phase imatinib 
resistant patients.144 In a phase II study of imatinib-resistant or intolerant chronic-phase 
CML patients, 90% achieved CHR and 52% achieved a major cytogenetic response 
following eight months of treatment with dasatinib. Importantly responses were observed 
in patients with KD mutations that confer resistance to imatinib.145
The phase III DASISION study compares the effectiveness of dasatinib lOOmg against 
imatinib 400mg. At 12 months the CCR rate for dasatinib was 77% while for imatinib it 
was 66%. The rate of MMR was higher with dasatinib than with imatinib at 46% and 
28% respectively. This suggests that dasatinib is a superior drug when compared with 
standard imatinib,146 although it is not yet known whether these superior response rates 
for dasatinib are maintained at years two and beyond.
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Our laboratory has shown that dasatinib transport is independent of human organic cation 
transporter 1 (hOCTl) unlike imatinib147 and therefore it may be more effective at 
suppressing BCR-ABL1 tyrosine kinase activity in patients with low hOCTl 
expression/activity.147 hOCTl will be discussed in more detail in section 1.6.5.
Figure 1.8. Imatinib, dasatinib and nilotinib chemical structure.
Imatinib
(Novartis)
Dasatinib
(Bristol-Myers Squibb)
Nilotinib
(Novartis)
Chemical structure taken from PubChem.
1.5.9. Nilotinib
Nilotinib is a selective inhibitor of BCR-ABL1, and was designed by Novartis using the 
chemical structure of imatinib as a template. Like imatinib, nilotinib binds to the ATP 
binding site within BCR-ABL1 suppressing its tyrosine kinase activity.148 Nilotinib binds 
to the BCR-ABL1 inactive conformation with a higher affinity than imatinib due to its
62
enhanced topologic fit to the protein. It is effective against the majority of BCR-ABL1 
KD mutations which result in imatinib resistance, again with the exception of T3151.148 
Phase II clinical trials have been encouraging with the added observation that patients 
treated with nilotinib exhibit less side effects than those observed with imatinib 
treatment.149 After 24 months of treatment 44% of imatinib resistant and 51% of imatinib 
intolerant patients achieved a CCR with nilotinib treatment.150 Overall the rate of MMR 
was 32% and 39% at 12 and 18 months respectively.150 Progression-free survival (PFS) at 
24 months was 64% and overall survival (OS) was 87%.150
The phase III ENESTnd trial randomised patients into one of three arms; imatinib 400mg 
once daily, nilotinib 300mg twice daily or 400mg twice daily. The rates of CCR by 12 
months were significantly higher for nilotinib (80% for the 300mg dose and 78% for the 
400mg dose) than for imatinib (65%). At 12 months, the rates of MMR for nilotinib were 
44% for the 300mg dose and 43% for the 400mg dose and 22% for imatinib. At 24 
months the rates of MMR for nilotinib were 71% for the 300mg dose and 67% for the 
400mg dose compared with 44% for imatinib.151 These data suggest that nilotinib is a 
superior drug when compared with standard dose imatinib.152
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1.6.0. CLINICAL LABORATORY PROGNOSTIC FEATURES
Identification of prognostic features at diagnosis is important for the clinical management 
of patients. The aim of my thesis is to identify new biomarkers predictive of clinical 
outcome in CML. In this section I will review the current prognostic indicators and 
outline those parameters/ biomarkers which 1 will investigate in more detail within this 
thesis.
Disease stage at presentation is an important prognostic marker, with patients presenting 
in chronic phase having a better prognosis than patients who present in accelerated phase 
or blast crisis.153,154
1.6.1. Prognostic scoring methods - pre-imatinib era 
1.6.1.1 Sokol score
In the pre-imatinib era Sokal and colleagues155 developed a prognostic scoring 
calculation. The Sokal score was derived by studying the clinical outcome of 813 
patients, most of whom had received busulphan. It is based on the platelet count, 
percentage of blast cells, age, and spleen size at diagnosis. The Sokal score stratifies 
patients into three risk groups; low, intermediate and high. Using the calculation Sokal 
demonstrated that the 4 year survival was 62%, 43% and 33% for the low, intermediate 
and high risk group respectively. Sokal later reported that both gender and the 
haematocrit levels were additional prognostic markers in patients younger than 45
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years.156 Sokal also identified that additional chromosome abnormalities conferred a poor 
prognosis. ' Although the Sokal score was a valuable prognostic tool in the pre-imatinib 
era its ability to reliably predict the clinical outcome of patients treated with a tyrosine 
kinase inhibitor may be more limited. This will be examined in a population study 
presented in chapter three.
1.6.1.2. Hasford/Euro score
The Hasford/Euro score is another prognostic scoring method. This was derived from 
over 1500 CML patients treated with interferon at 12 institutions.158 As well as the 
components of the Sokal score, the Hasford score additionally incorporates the 
percentage of eosinophils and basophils. Using the Hasford score the 5 year survival was 
76%, 55% and 25% for the low, intennediate and high risk group respectively.
1.6.2. Prognostic scoring method - imatinib era
1.6.2.1. EUTOS (European Treatment and Outcome Study for CML) score 
Both the Sokal and Hasford/Euro score were developed in the pre-imatinib era and so 
there is a requirement to revisit these baseline scoring methods in the imatinib/TKI era. 
The ELN established a European registry of CML patients receiving imatinib based 
therapy. A total of 2060 patients, biased for patients faring poorly, was eligible for 
treatment response assessment. Of these 1261 (61%) patients progressed within 36 
months. This is extremely high and does not represent the normal rate of progression
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observed with imatinib treatment (which has previously been reported at 6%).18,159 The 
authors used CCR at 18 months to stratify patients as responders and non-responders; 
however the ELN guidelines state that at 18 months patients who are in CCR and not 
MMR are sub-optimal responders.111
In this study neither the Sokal or Euro score had a significant ability to predict the 
clinical response of patients which is consistent with the data 1 present in chapter three.21 
The authors suggest a new simplified scoring method known as the EUTOS score which 
only includes the basophil count and spleen size at diagnosis.160
EUTOS score =7 x Basophils + 4 x Spleen size 
> 87 = high risk, < 87 low risk
1.6.3. Chromosome 9 deletion
Deletions of the derivative chromosome 9, especially proximal to breakpoint, occur in 
10-15% of patients and it has been suggested that these confer a poorer prognosis for 
interferon and hydroxycarbamide treated patients.161 Patients with a deletion in 
chromosome 9 had a short OS and an increased risk of disease progression, which was 
shown to be independent of the patient’s Sokal or Hasford/Euro score.8:1 However, in the 
imatinib era this may be less significant; the previously reported difference in OS was not
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observed in imatinib treated patients,16- although time to disease progression remains 
shorter in patients with a deletion in chromosome 9.162
1.6.4. Timing of response
The prognostic significance of achieving an early molecular response following first-line 
imatinib treatment was first reported by our laboratory in 2003.163 After 4 weeks of 
imatinib treatment patients with a BCR-ABL1/ABL1 transcript ratio level less than 50% 
and following 3 months of treatment less than 10%, had a significantly higher probability 
of achieving a major cytogenetic response at 6 months and a better PFS.163
The prognostic value of an early molecular response was also investigated as part of the 
IRIS trial.164 Patients with a BCR-ABLl/ABLl transcript ratio less than 10% at 6 months 
and less than 1% at 12 months had a superior EPS and lower probability of disease 
progression. The study also demonstrated that patients who achieved an MMR by 18 
months would not progress to accelerated phase or blast crisis over a five year period.164 
Patients who achieve an MMR by 18 months have a 3% probability of losing their 
response compared to 26% for patients who had only achieved a CCR.164 These studies 
suggest that an early molecular response is a good prognostic indicator.
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1.6.5. Drug transporters
Our laboratory has previously shown that imatinib is a substrate for the uptake transporter 
hOCTl.165 In more recent work using clinical samples, our group has shown that low 
hOCTl expression may be an important mechanism of imatinib resistance and that 
patients with higher levels of hOCTl had a greater probability of achieving a CCR, as 
well as superior PFS and OS.166 Regression analysis of hOCTl expression in relation to 
other parameters such as white blood cell count, platelet count, spleen size at original 
diagnosis, age, haemoglobin concentration, and phase of disease at commencement of 
imatinib, together with time since diagnosis until commencement of imatinib were 
investigated and hOCTl expression at diagnosis was found to be superior in predicting 
CCR.166 However, White et a/167 reported that hOCTl mRNA expression in their cohort 
of patients did not correlate with CCR. Instead the authors reported that hOCTl activity 
(determined by assessing the amount of uptake of C14 labelled imatinib that is blocked by 
prazosin, an inhibitor of hOCTl) did correlate with the clinical outcome of patients, and 
also correlated with the degree of in vitro kinase inhibition (pCrkL/CrkL ratio).167 
Patients with high hOCTl activity had an 85% chance of achieving a MMR at 24 months 
compared to 45% of patients with low hOCTl activity. Low hOCTl activity can be 
overcome to a certain extent by using high doses of imatinib thus hOCTl activity may be 
useful in identifying patients who may benefit from a higher dose of imatinib or an 
alternative TKI. Since higher doses of imatinib can overcome low hOCTl activity, these 
data may suggest that imatinib is transported by other transporters in addition to hOCTl. 
hOCTl activity was found to correlate with PFS and OS, and was not correlated with 
either the Sokal or Hasford scores.164,167
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The current literature suggests that hOCTl is the dominant transporter controlling 
intracellular imatinib concentration. However, some of the pharmacological transporter 
inhibitors used147,167 can affect other transporters and thus other transporters may be 
important in affecting the intracellular concentration of imatinib.
P-glycoprotein is an efflux transporter which has been shown to confer resistance to 
treatment in a variety of cancers, by effluxing many chemotherapy agents.168'170 It is 
encoded by the ABCB1 (MDR1) gene. High expression of the ABCB1 gene may be 
associated with imatinib resistance in CML cell lines,170 and silencing of ABCB1 
expression increases the intracellular concentration of imatinib.171 In contrast, the pre­
treatment expression level of the efflux transporters ABCB1, ABCC1 (MRP-1) and 
ABCG2 has been shown to be unrelated to clinical outcome, though this is 
controversial.172
1.6.6. Plasma imatinib monitoring
Drug compliance, metabolism, and interactions with other drugs are all factors which 
could influence a patient’s response to imatinib treatment. These factors will all affect the 
intracellular concentration of the drug. Measuring the plasma level of imatinib may 
provide additional clinical information, especially for patients responding sub-optimally 
or who have failed imatinib treatment. Picard et al17* reported that a trough plasma level 
of 1002ng/ml or higher following 12 months of treatment was associated with
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achievement of CCR.173 Plasma monitoring was also performed as part of the IRIS trial, 
finding that plasma levels of imatinib at day 29 were linked to achievement of CCR. 
Patients with a trough plasma level of 1009ng/ml or greater had a significantly higher 
probability of achieving CCR and MMR at 12 months.174 Additionally patients with 
higher trough plasma levels had superior EPS. The authors of both studies suggest that 
plasma monitoring in suboptimal responders could be used to determine compliance to 
therapy or suspicion of drug-drug interaction, and knowledge of the plasma level may 
improve the chance of treatment success.173,174 Conversely, two independent studies 
carried out in our laboratory17> and in Canada176 found no correlation between plasma 
levels of imatinib and clinical outcome. Plasma monitoring may not therefore be a good 
deterministic biomarker of clinical outcome in an individual patient, as it is dependent on 
the timing of the imatinib dose prior to sampling and can be altered by co-medications. 
Caution is therefore needed when interpreting imatinib plasma level data.
1.6.7. Imatinib resistance and BCR-ABL1 kinase domain mutations 
With increasing clinical experience it is becoming clear that there are distinct subgroups 
of patients who are either primarily resistant or acquire secondary resistance to 
imatinib. Many cases of acquired imatinib resistance are associated with the emergence 
of mutations within the BCR-ABL1 KD.33,178 These are less common in primary imatinib 
resistance. However, some patients may acquire resistance without KD mutations, whilst 
others develop KD mutations without developing imatinib resistance,179 suggesting that 
additional factors are required to produce a fully drug resistant phenotype.
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Currently over 100 BCR-ABL1 KD mutations have been identified. Some mutations 
remain sensitive to imatinib while others confer resistance (the degree of resistance can 
also vary between each mutation).180 Some but not all mutations within the BCR-ABL1 
KD impair drug binding to BCR-ABL1 and hence impair the suppression of BCR-ABL1 
tyrosine kinase activity.181,182
Mutations can be classed into three groups. Firstly, there are those which involve 
important drug contact sites such as T315I. The second group of mutations are located 
within the ATP binding loop and confer resistance by preventing ABL1 from adopting 
the specific conformation required for high-affinity imatinib binding. The third group of 
mutations are located within the activation loop. These can prevent BCR-ABL1 from 
adopting the inactive conformation and hence inhibit both imatinib and nilotinib binding. 
However, dasatinib is able to bind to both the active and inactive conformation and so 
may still be effective in this subgroup of patients.183 Common resistant mutations 
include: for imatinib T315I, M244V, L248, G250E, Y252F,184 and E255K/V, for 
dasatinib T315I and F317L185 and for nilotinib T315I, E255K/V and Y253H.111,148
In an Argentinean multi-centre study, mutations were detected in 23% of patients with 
who failed or lost a response on imatinib treatment. Detection of mutations correlated 
significantly with accelerated phase, lack of molecular response, and lower cytogenetic 
and haematological responses, while no difference in OS was observed.186
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Branford et al187 reported that a 2-fold or greater rise in BCR-ABL1 transcript ratio was 
suggestive of a mutation. However, in 2006 our laboratory reported that two consecutive 
rises in BCR-ABL1/GUS transcript ratio could identify patients likely to have a BCR- 
ABL1 KD mutation and that a single 2-fold or greater rise in BCR-ABL1/ABL1 transcript 
did not predict a mutation.188 These differences are likely to be due to variation in the 
methodology for measuring the BCR-ABL1 transcript ratio between different labs, e.g. 
the choice of control gene. Early detection of mutations may be clinically beneficial by 
allowing early intervention such as switching to a second generation TK1. Many of the 
data on sensitivity of a specific mutation to TKIs are based on w vitro and not in vivo 
data; thus caution is required when interpreting mutation data.183
1.6.8. CrkL a surrogate marker of BCR-ABL1 tyrosine kinase activity 
It is difficult to accurately assess BCR-ABL1 tyrosine kinase activity directly in primary 
CML cells due to granulocytic activity which degrades the BCR-ABL1 protein upon 
lysis.189 CrkL (CT10, regulator of kinase-like) is an adaptor protein.190 The normal 
cellular function of CrkL is to mediate signal transduction through membrane-bound 
receptors for extracellular matrix, growth factors, and cytokines.81 CrkL is immediately 
downstream of BCR-ABL1 and functions to mediate BCR-ABL1 signal transduction.79'81 
CrkL is located centromeric to the BCR gene on chromosome 22 and encodes a 39kDa 
protein.191 CrkL consists only of one SH2 and two SH3 domains.192 The direct interaction 
of CrkL and BCR-ABL1 is, at least in part, mediated by a proline-rich region in the C- 
terminal tail of the ABL1 kinase which is localised near the nuclear localisation signal of 
the ABL1 sequence and binds to the first SH3 domain of CrkL.81 Studies have shown
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that overexpression of CrkL alone allows cellular transformation to occur.193'195 
Overexpression of CrkL in transgenic mice expressing the pi90 BCR-ABL1 protein 
resulted in the more rapid development of leukaemia.196 BCR-ABL1 mutants lacking the 
SH3 binding domain still have the ability to transform myeloid cells suggesting that CrkL 
remains associated with BCR-ABL1 via its interactions with other proteins.
Phosphorylation of CrkL occurs in the cells of CML patients as a direct consequence of 
BCR-ABL1, and levels of phosphorylated CrkL correlate with BCR-ABL1 protein 
levels.197,198 CrkL phosphorylation status has therefore been identified as a surrogate 
marker for BCR-ABL1 tyrosine kinase activity (Figure 1.9).197,199
Immunohistochemistry has demonstrated that pCrkL levels are elevated in the following 
malignancies;200 breast cancer (49%)s lung carcinomas (55%), skin cancer (67%), ovarian 
cancer (50%) and colon carcinomas (63%). Recently CrkL mRNA was found to be over­
expressed in Non-Small Cell Lung Cancer (NSCLC). Knockdown of CrkL in lung cancer 
cell lines led to significantly decreased cell proliferation, cell cycle progression, cell 
survival, invasion and cell motility, suggesting a significant role for CrkL in NSCLC.201
Deletion of the CrkL gene on chromosome 22 causes DiGeorge syndrome, a condition 
with a variety of clinical features including congenital heart disease, facial disfiguration, 
hypoparathyroidism and increased risk of schizophrenia.202
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Figure 1.9. BCR-ABL1 and CrkL signalling pathway.
1.6.8.1. Current approaches for detecting and assessing CrkL phosphorylation 
status.
White et a?97 investigated the imatinib induced in vitro inhibition of pCrkL and CrkL 
levels by Western blotting in 60 patients. Using Western blotting and densitometry of 
pCrkL and CrkL protein bands they produced a ratio, which was then expressed as a
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percentage against normalised values. They reported that imatinib IC50 (defined as the 
imatinib concentration that reduces the pCrkL/CrkL ratio by 50%) was predictive of 
subsequent clinical outcome of imatinib treated newly diagnosed CP patients. However, 
this is of limited practical use since Western blotting can be time consuming and also 
requires a large number of cells (>106) which may be difficult to obtain from CML 
patient samples, especially once treatment has begun. In a subsequent paper White et a/198 
measured pCrkL/CrkL levels following two or three weeks of in vivo imatinib treatment 
and found that this ratio also correlated with clinical outcome.
In 2006 Hamilton et al199 developed a method for the detection of pCrkL by flow 
cytometry. Flow cytometry has the advantage that it requires fewer patient cells (~ 103 
cells), produces quantitative values, and results can be obtained rapidly. They 
demonstrated that flow cytometry results were comparable to those produced by Western 
blotting. Unphosphorylated CrkL was not assessed, so it was not possible to calculate a 
pCrkL/CrkL ratio as suggested by White et al}91 Furthermore, their study was limited to 
previously frozen CD34+ cells and the relationship with clinical outcome was not 
investigated. More recently Kliorashad et al203 investigated the relationship between 
pCrkL levels and clinical outcome using previously frozen CD34+ cells from 36 newly 
diagnosed CML patients and found no correlation with clinical outcome.
The first biomarker to be investigated in this thesis is pCrkL and CrkL as a surrogate 
marker for BCR-ABL1 tyrosine kinase activity. This involves optimising reported
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techniques and developing a FACS based assay for rapid screening of clinical samples to 
investigate the predictive value of pCrkL and CrkL in newly diagnosed CML patients. 
These data will be presented in chapter four.
1.6.9. Predicting disease progression
Mechanisms underlying the evolution of blast crisis are poorly understood. It is thought 
that disease progression is a multi-factorial process initiated by both BCR-ABL1 
dependent and independent mechanisms.204 Genetic lesions such as additional 
chromosomes, deletions, insertions or mutations of genes (including BCR-ABL1 itself 
e.g. T3151) occur as patients progress to blast crisis.
Currently there are no biomarkers which can predict at diagnosis those patients who will 
progress into blast crisis. This will be explored in more detail in chapters seven and eight.
1.6.9.1. Microarray analysis
Gene expression profiles may be helpful in patient prognostication. However, most 
methodologies are time consuming and result in a large list of candidate genes and, most 
importantly, these techniques cannot be easily adapted for routine clinical use. Using the 
Bayesian model averaging (BMA) method on a large microarray data set Radich et al205 
identified six genes (NOB1, DDX47, IGSF2, BLT1 and SCARB1 and SLC25A3) that
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discriminate between early chronic phase, late chronic phase, accelerated phase and blast
crisis.
Yong at al206 performed a gene expression profiling study using diagnostic CD34+ cells 
from patients who either progressed to blast crisis or remained well in CP. A multivariate 
Cox regression model identified the combination of low CD7 expression with high 
expression of proteinase 3 or elastase as associated with longer survival. The potential 
application for this assay would be to identify at diagnosis those patients at a greater risk 
of disease progression. However, this approach has yet to be tested prospectively.
Certain genes have been identified as being altered depending on whether the patient has 
lymphoid or myeloid blast crisis. Myeloid blast crisis is associated with changes in both 
p53.207=208 and the transcription factor RUNX1.83 p53 is a tumour suppressor and is 
inactive in 30% of solid tumours. During progression to blast crisis deletions and 
rearrangements of the p53 gene have been identified.209 The transcription factor Ikaros210 
and CDKN2A/B211 (Cyclin-dependent kinase inhibitor 2A/B) are associated with 
lymphoid blast crisis. EVI-1 and WT1 have also been reported to play a role in blast 
crisis. These genetic changes occur as patients progress into blast crisis but although they 
are associated with disease progression, they offer no prospective prognostic information. 
The EVI-1 oncogene has been reported to be up-regulated during blast crisis. Detection 
of EVI-1 mRNA in imatinib failure patients correlates with a poorer EPS, PFS and OS 
when the patients are treated with a second generation TKI. Screening for EVI-1
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expression at the time of imatinib failure may predict for response to second generation 
TKI.212
BCR-ABL1 via its tyrosine kinase activity can also cause post-translational modifications 
of the following proteins altering their activity; c-Myc94,214’215 JAK2,216 Lyn,216,217 
hnRNP-E2,218 STAT5,68,168 ~19 BMI-1,220 and BCL-2, all of which are altered at disease
204progression.
1.6.9.2. TWIST1
TWIST1 is a transcription factor involved in embryogenesis, cell proliferation and cell 
survival.221'223 A small study of CML patients reported that TWIST 1 mRNA expression 
was up-regulated in CD34+ cells from imatinib resistant patients as well as during 
disease progression. Furthermore, TWIST1 was found to be over-expressed in CML 
diagnostic samples of patients who later developed resistance to imatinib.223 TWIST1 
may be a biomarker of imatinib resistance, although this needs to be confirmed on a 
larger cohort of patients.
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1.7.0. LEUKAEMIC STEM CELLS AND ALOX5
Most malignancies are initiated by a small population of cells known as cancer stem 
cells; thus these are the ultimate therapeutic target. Leukaemic stem cells (LSC) are 
believed to be a population of cells required for the initiation and maintenance of the 
disease.“4 226 Therapeutically the difficulty lies in the identification of differences 
between normal and leukaemic stem cells, in order to ensure that the leukaemic stem cells 
are selectively targeted. Genes such as Wnt/p- catenin,227'229 Hedgehog,230 Notch,231 
Biml1-7 and p53‘09 have been identified as playing an important role in cancer 
development; however all these genes also play an active role in normal stem cells.
1.7.1. ALOX5
The ALOX5 (Arachidonate 5-lipoxygenase) gene encodes a member of the lipoxygenase 
gene family and plays a role in the synthesis of leukotrienes from arachidonic acid. The 
encoded protein is expressed specifically in bone marrow-derived cells, and catalyses the 
conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,l 1,14-cis-eicosatetraenoic 
acid (5-HEPTE), and further to the allylic epoxide 5(S)-trans-7,9-trans-l 1,14-cis- 
eicosatetraenoic acid (leukotriene A4/LTA4). LTA4 is unstable and is converted to 
LTB4 which is more stable. 5-HEPTE and LTA4 negatively regulate ALOX5 expression; 
positive regulation of ALOX5 occurs when LTB4 binds to its receptor BLT1 (Figure
j j q) 226,232-236
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Figure 1.10. Arachidonic acid metabolism pathway.
5-LOX is encoded by the ALOX5 gene and is activated by the enzyme FLAP. 
Arachidonic acid is converted to 5-HEPTE by 5-LOX which is further converted to 
LTA4 by 5-LOX. Both 5-HEPTE and LTA4 negatively regulate ALOX5 expression. 
LTA4 is unstable and is further converted to LTB4. The binding of LTB4 to its receptor 
BLT1 positively regulates ^110X5 expression.
1.7.2. Leukotriene B4 (LTB4)
Leukotrienes are a family of pro-inflamatory lipid mediators which play an important role 
in inflammation. Leukotrienes are generated in leukocytes through the metabolism of 
arachidonic acid via the 5-lipooxygenase pathway.237 LTB4 activates leukocytes on the
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endothelium allowing them to migrate into tissues. In neutrophils, LTB4 is a chemo­
attractant and can induce the formation of ROS.238
1.7.3. LTB4 receptor - BLT1
LTB4 has two G protein coupled receptors, BLT1 and BLT2. BLT1 is a high affinity 
receptor for LTB4 and is only expressed on leukocytes, while BLT2 is a low affinity 
receptor expressed on leukocytes, spleen, liver and ovarian tissue.239 The classical 
function of BLT1 is to mediate LTB4 induced neutrophil and macrophage migration to 
sites of inflammation via chemotaxis and up-regulation of adhesion molecules.240 BLT1 
is up-regulated in rheumatoid arthritis and chronic obstructive pulmonary disease, thus 
BLT1 antagonists are currently being explored as therapeutic options in these 
conditions.241 LTB4 must bind to BLT1 to mediate its positive feedback on ALOX5.
1.7.4. The role of ALOX5 role in asthma and coronary heart disease
Leukotrienes are known to cause symptoms in asthma, causing smooth muscle 
contraction, impairing mucociliary clearance, enhancing mucus secretion and attracting 
eosinophils to the airways.234 242 243 Zileuton, an ALOX5 inhibitor, has been developed for 
the treatment of asthma as an alternative to low-dose inhaled glucocorticosteroids.244 
ALOX5 is also a target for pharmaceutical intervention in coronary heart disease. 
Mutations in the promoter region of this gene lead to a diminished response to anti-
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leukotriene drugs used in the treatment of asthma and may also be associated with
atherosclerosis 235,243,245
1.7.5. ALOX5 and Cancer
Alterations in the ALOX5 pathway can result in increased cellular proliferation, survival, 
and suppression of apoptosis in human cells. It thereby plays a significant role in human 
carcinogenesis. ALOX5 protein and mRNA expression were found to be elevated in 79% 
of oesophageal cancer tissue compared to normal oesophageal mucosa.236 The ALOX5 
gene is up-regulated in pancreatic cancer.246 247 Furthermore, the ALOX5 metabolite 5(S)- 
HEPTE has been shown to stimulate cellular proliferation via the activation of the 
mitogenic intracellular tyrosine kinases MEK/ERK and PI3 kinase/AKT. In colorectal 
cancer, exposure to cigarette smoke extract has been shown to enhance ALOX5 protein 
expression in inflammation-associated colonic adenomas. This effect is mediated in part 
by deregulated ALOX5 DNA demethylation, and up-regulation of matrix 
metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF), all key 
angiogenic factors for tumourigenesis. These effects can be reversed by treating colon 
cancer cells with dual ALOX5 and COX-2 inhibitors.“48 In patients with ovarian cancer 
ALOX5 expression correlated with OS, and single nucleotide polymorphisms (SNPs) in 
the ALOX5 gene were identified in patients with a poorer outcome.240
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1.7.6. AL0X5 and CML
CML leukaemic stein cells are not sensitive to imatinib or second generation tyrosine 
kinase inhibitors which are the current treatment option for CML patients.250'252 Chen el 
al investigated changes in mouse leukaemia stem cells (LSC) genes pre and post 
imatinib treatment using DNA microarray analysis. ALOX5 was up-regulated in LSC, and 
the up-regulation was not inhibited by imatinib treatment. Furthermore, mice transplanted 
with BCR-ABL1 positive bone marrow which was ALOX5 deficient were resistant to the 
induction of CML. Additionally, ALOX5 deficiency had no effect on the growth of BCR- 
ABL1 negative cells, suggesting that ALOX5 is important for malignant LSC but not for 
normal haematopoietic stem cells. These data suggest that ALOX5 is essential for the 
development of CML.253 ALOX5 can be inhibited by the 5-lipoxygenase inhibitor 
zileuton, and knocking down of ALOX5 results in decreased P-catenin expression.253 
ALOX5 function can be assessed by measuring the concentration of the stable leukotriene 
LTB4 in plasma."51 LTB4, the product of the 5-LO pathway, was found to be elevated in 
a mouse model of CML.
In summary, ALOX5 expression and function are associated with prognosis in solid 
tumours and the Chen et al paper253 suggests that ALOX5 is essential for the 
development of CML in mice. The aim of chapter six in the current thesis is therefore to 
investigate the role of ALOX5 in clinical CML samples, and to determine if the level of 
ALOX5 can predict a patient’s clinical outcome.
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1.8.0. THE ROLE OF PROTEIN PHOSPHATASE 2A (PP2A) IN CML
1.8.1. PP2A structure and biology
Many cells utilise reversible phosphorylation as a mechanism of post-translational 
modification for activating and deactivating key regulatory molecules involved in cell 
signalling.2^4 Deregulation of reversible phosphorylation can have a significant impact 
on cellular behaviour. Alterations in the action of kinases and phosphatases give rise to 
many fonns of cancer.12 255
A major cellular serine/threonine phosphatase working in opposition to kinases is the 
tumour suppressor Protein Phosphatase 2A (PPIA).2^4 PP2A plays an important role in 
regulating cell proliferation, differentiation and survival. Loss of PP2A function has been 
associated with cellular transformation; thus it is also known as a tumour suppressor.2^ 
PP2A is highly conserved from yeast to humans and accounts for 1% of total cellular 
proteins. Along with PP1 (Protein Phosphatase 1), PP2A accounts for 90% of the 
serine/threonine phosphatase activity in a cell (Figure 1.12).
1.8.1.1. Catalytic subunit - PP2Ac
The PP2A catalytic subunit (PP2Ac) targets phosphate groups on either serine or 
threonine residues. Two mammalian isoforms of PP2Ac have been identified, named a 
and p, which are 97% identical in primary sequence but are encoded by different genes.
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PP2Aca is expressed 10 fold more than (3 and the PP2Aca promoter is 7-10 times more 
active than p. Expression of PP2Ac is tightly controlled to ensure a constant level of 
PP2A. Activity of PP2A is controlled by post-translation modification. Loss of PP2Aca is 
lethal in yeast, demonstrating the importance of maintaining cellular homeostasis.2^7
Figure 1.12. PP2A protein structure.
Diagram of the PP2A trimeric complex, illustrating the scaffolding subunit A binding to 
the catalytic subunit C to mediate the binding of the B subunits. B subunits interact via 
the same or overlapping sites within subunit A of the core dimer to form an active PP2A 
protein. (Adapted from Eichhorn et al2>1).
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I.8.I.2. Regulatory subunit A subunit (PR65) - PPP2CA or B 
The scaffolding subunit A (PR65) binds to the catalytic subunit C to mediate the binding 
of the B subunits. Two isoforms of the scaffolding subunit A have been identified, named 
PR65a and PR65p. Both isoforms are ubiquitously expressed, though PR65a is expressed 
at a higher level than PR65p. PR65P has been identified as a tumour suppressor, as 
mutations in PR65P are associated with lung and colon cancer.2M
1.8.1.3. Regulatory B subunits
B subunits determine tissue specificity and sub-cellular localisation of the PP2A protein. 
Details about the different B subunits can be found in Table 1.2.
Table 1.2. Characteristics of B subunits.
B subunits determine tissue specificity and sub-cellular localisation of the protein.
B Subunits
B or PR55 family - PPP2R2 A-D
B’ or PR61 family (PPP2R5 A-E)
B” or PR72 family - (PPP2R3 A-C)
B”’ or PR93/PR110 family
Details
55kDa encoded by 4 genes PR55 o,p,y.S (A-D). 
Expression is tissue specific, 
a 8 are widespread, p,y limited to brain, 
encoded by 5 genes PR61 a,p,y,8 e. 
human B’ p has two isoforms - pi and P2.
B' y has three isoforms - yl, y2 and y3.
All B' isoforms are 80% identical.
Mainly found in heart and skeletal muscle.
Found in all tissues but at higher concentration in heart 
and skeletal muscle.
Function as scaffolding proteins.
Involved in Ca~’ dependent signaling.
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1.8.2. Regulation of PP2A
PP2A is regulated by post-translational modifications such as methylation and 
phosphorylation. Phosphorylation occurs on tyrosine 307, which is located in the 
conserved C-terminal part of PP2Ac, and prevents the recruitment of B subunits, 
resulting in inactivation of the enzyme.2 4 Phosphorylation can also occur on threonine 
304; however the functional significance of phosphorylation at this site is unclear.2^7 
PP2A can rapidly re-activate itself in an auto-dephosphorylation reaction. Tyrosine 
phosphorylation of PP2Ac is enhanced in the presence of the phosphatase inhibitor 
okadaic acid (OA).2^4
Methylation of PP2Ac varies during the cell cycle. The mechanism and the physiological 
consequences of this oscillating methylation are unknown. Conflicting data exist with 
regard to the effect of PP2Ac methylation on its catalytic activity, with one group 
observing a moderate increase,2>8 another seeing no effect,259 and a third observing a 
decrease in phosphatase activity.“6<) Methylation of the C terminal tail by leucine carboxyl 
transferase 1 (LCMT1) is required for the binding of the PR55 B subunit but not the 
other B subunits and this can be reversed by phosphatase methylesterase (PME-1).261
1.8.3. PP2A and CML
PP2A is inactive or mutated in many solid tumours93,262’263 and haematological 
malignancies.264265 In CML cells PP2A is a key target of BCR-ABL1 signalling; this
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protein becomes inactivated in these cells because BCR-ABL1 prevents the auto­
dephosphorylation at tyrosine 307.264 266 Maintenance of pYj07-PP2A levels in CML cells 
feeds back to BCR-ABL1 and facilitates increased and sustained kinase activity. 
Inhibition of BCR-ABL1 by imatinib results in reactivation of PP2A, inducing both 
suppression of growth and enhanced apoptosis of the leukaemic cells.264 However, it is 
unknown whether Y307 in PP2A is a direct substrate of BCR-ABL1, and the mechanism 
regulating phosphorylation of PP2A at this site is not clearly defined.
BCR-ABL1 might regulate PP2A activity in CML cells via the PP2A inhibitor protein 
SET. In CML cell lines, increased expression of BCR-ABL1 increases expression of SET 
through a process that is mediated by active JAK2 (Figure 1.13).216264 Furthermore, 
Neviani et al264 also observed that SET levels rose at evolution of blast crisis in two cases 
of paired chronic phase and blast crisis primary CML samples, and that incubation with 
imatinib decreased SET levels in primary CML cells from a single patient undergoing 
blast crisis.
1.8.4. PP2A inhibitor - SET
The SET gene is located on chromosome 9q34.11, centromeric to c-abl267 and gives rise 
to a putative 39kDa protein that shuttles between the nucleus and cytoplasm under the 
influence of hnRNP Al.268 It has also been reported to be over-expressed in solid tumours
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as well as leukaemia.264,269,270 The normal physiological function of SET is not fully 
understood.271
Figure 1.13. Model mechanisms by which SET/JAK2 regulates PP2A and BCR- 
ABL1 signalling.
Possible mechanism of PP2A inhibition in CML. BCR-ABL1 up-regulates JAK2 which 
in turn increases the expression of the SET leading to the inhibition of PP2A. Imatinib 
can reactivate PP2A by decreasing both JAK2 and SET.
Kev
Activation
Inhibition
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1.8.5. PP2A inhibitor - SET binding protein 1 (SETBP1)
SET binding protein (SETBP1) protects SET from protease cleavage leading to an 
increase in the levels of full-length SET and formation of a SETBP1-SET-PP2A 
complex, which in turn results in the inhibition of PP2A phosphatase activity. Recently 
Cristobal et al265 reported that overexpression of SETBP1 mRNA predicts adverse 
outcome in elderly patients with acute myeloid leukaemia (AML) and SETBP1 promotes 
the proliferation and expansion of leukaemic cells.265 However, the role of SETBP1 in 
CML is unknown and warrants further investigation since SET has been reported to 
inhibit PP2A CML.
The role and predictive value of measuring PP2A, inactive PP2A and its two inhibitors 
will be addressed in chapters seven.
1.8.6. Cancerous Inhibitor of PP2 A (CIP2 A)
Cancerous Inhibitor of PP2A (CIP2A, also known as “constans interacting protein 2A” 
and KIAA1524) has recently been described as a novel inhibitor of PP2A.271 In a cancer 
setting CIP2A functions by preventing PP2A driven dephosphorylation of pS62-c-Myc, 
which results in greater stabilisation of c-Myc protein as demonstrated by a longer half- 
life, as well as reduced proteolytic degradation. c-Myc can mediate genetic instability 
resulting in tetraploidy and aneuploidy.96'97 CIP2A has no normal cellular function; it is
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not essential for cell cycle progression or cell viability but functions to propagate
malignant cell growth via its stabilisation of c-Myc.271
In gastric cancer, CIP2A mRNA was found to be over-expressed in 87% of tumour 
samples. Immunohistochemical analysis revealed that CIP2A protein was readily 
detectable in malignant samples but not in normal gastric mucosa. CIP2A depletion in the 
AGS gastric cancer cell line resulted in inhibition of growth and clonogenic capabilities 
as well as reduced stability and expression of c-Myc protein.91,272 Furthermore, CIP2A 
protein was associated with a poorer OS in patients with tumours less than 5cm, with the 
10 year overall survival for CEP2A positive patients being 8.1% compared to 37.6% in 
the CIP2A-negative group. CIP2A may therefore be an adverse prognostic feature in 
gastric cancer.91
Similarly in breast cancer, CIP2A mRNA was found to be over-expressed in 39% of 
samples and was associated with the aggressiveness of the disease as well as promoting 
the in vitro malignant growth of breast cancer cells. 93
CIP2A depletion triggered partial differentiation of the acute promyelocytic leukaemia 
cell line HL60272 and decreased growth of gastric91 and breast cancer cells.93 In mouse 
neural progenitor cells, overexpression of CIP2A increases progenitor cell self-renewal 
and proliferation, and both c-Myc and C1P2A enhance each others expression.273 At the
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time of conducting this work no studies had investigated the role of CIP2A in any 
haematological malignancy. This novel PP2A inhibitor therefore warrants investigation 
in CML; this will be addressed in chapter eight.
1.8.7. Proviral Integrations of Moloney virus (PIM1)
PIM1 (Proviral Integrations of Moloney virus 1) is a constitutively active serine/threonine 
kinase, thus its activity is dependent on the absolute amount of protein.274 P1M kinases 
are mediators of cytokine signalling pathways in haemopoietic cells and contribute to the 
progression of certain types of leukaemia and solid tumour.274 Overexpression of P1M1 
in transgenic mice resulted in lymphoma, leading to PIM1 being classified as a proto- 
oncogene. ’ Co-expression of PIM1 and c-Myc in transgenic mice is embryonically 
lethal due to the formation of lymphomas in utero.92 These data suggest that although 
P1M1 is a proto-oncogene in its own right, its effects are mild. However, when expressed 
with the oncogene c-Myc, a lethal synergistic transformation effect can occur.42 PI Ml 
can phosphorylate and stabilise c-Myc. PP2A can inactivate PIM1 and target it for 
degradation, thus levels of P1M1 are indicative of PP2A activity and function.276
In prostate cancer both c-Myc and PIM1 are over-expressed, and PIM1 overexpression 
increases the tumourigenicity of prostate cancer cell lines.42 274 277 The exact molecular 
mechanism involving P1M1 and c-Myc interaction is not fully understood. It is thought 
that PIM1 may phosphorylate c-Myc, thus preventing it from being degraded.
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PIM1 is important for the survival of BCR-ABL1 positive cell lines and it is thought that 
PIM1 may play an anti-apoptotic role, as well as mediating proliferation.278 PIM1 protein 
is up-regulated in a BCR-ABL1 kinase-dependent manner in CD34+ cells when 
comparing CP with BC samples. This up-regulation is associated with expression of 
microRNA miR328.218
A previous report91 regarding CIP2A has suggested that it functions by inhibiting the 
destruction of c-Myc, and this in part can be mediated via PIM1. While investigating the 
role of CIP2A in CML, the role of c-Myc and PIM1 will also be explored, in chapter 
eight.
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1.9.0. AIMS OF THIS THESIS
Although imatinib has dramatically altered the outlook for CML, a minority of patients 
still fare badly. The prime aim of this thesis is to investigate whether patients destined to 
respond poorly to imatinib can be identified prospectively. This would be clinically 
useful as they might then be candidates for alternative treatment strategies, such as early 
SCT or a second generation TKI from initial diagnosis.
The aims of this work are:
1. To establish if IRIS and other clinical trial data can be extrapolated to an 
unselected CML population. This will be done by determining ‘real’ rates of CCR 
and MMR, and thus the rate of imatinib failure, for patients treated within our 
region.
2. To evaluate recently reported biomarkers for CML outcome for their significance 
in detennining outcome of modern CML therapy:
a. Whether BCR-ABL1 tyrosine kinase activity can predict outcome.
b. Whether the BCR-ABL1 transcript type affects outcome.
3. To investigate new biomarkers for their predictive value on outcome.
a. Investigate the role of ALOX5 in human CML for the first time.
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b. Investigate the role of PP2A and its inhibitory proteins (SET, SETBP1 
and CIP2A) in CML cells and ascertain whether any /all are predictive of 
clinical outcome.
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CHAPTER TWO - Patients and methods
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2.1.0. PATIENTS
In our area of the North West of England, the adjacent North Wales coastal strip and the 
Isle of Man (total population 2 million), all services for adults with haematological cancer 
are located at 12 hospitals. Molecular diagnosis of CML and monitoring for BCR-ABL1 
transcripts are carried out at a single centre (Royal Liverpool University Hospital) for all 
CML patients in this geographical area. The clinical outcome and molecular data of all 
patients in our area are documented at our centre. Similarly, conventional G-banded 
metaphase analysis for t(9,22) and additional chromosome lesions, and fluorescent in situ 
hybridisation (FISH) in our geographical area are carried out at one of three regional 
laboratories (Liverpool, Manchester and Cardiff). Where required, metaphase and FISH 
data at appropriate time points were obtained from these laboratories.
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2.2.0. DEFINING CLINICAL RESPONSE
Patients were stratified into three clinical outcomes:
• CCRe - complete cytogenetic response after 12 months of imatinib treatment. 
This group corresponds to “optimal responders” as defined in the ELN 2009 
guidelines.111
• No-CCRe - Patients who had achieved a complete haematological response 
but not a complete cytogenetic response after 12 months of imatinib treatment, 
and who had not progressed. This group corresponds to “sub-optimal 
responders / failures” as defined in the ELN 2009 guidelines.111
• Blast crisis (BC) - patients who presented in chronic phase but who 
subsequently progressed into blast crisis, irrespective of their response at 12 
months.
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2.3.0. SAMPLE COLLECTION AND PREPARATION
At diagnosis and after 1, 2, 3, 6, 9 and 12 months of imatinib treatment, 20-30mls of 
peripheral blood was collected into EDTA. The blood was processed according to the 
requirements of each study.
2.3.1 Total leukocytes
Erythrocytes were depleted using red cell lysis buffer (0.1M ammonium chloride, lOmM 
sodium bicarbonate and 1.3mM EDTA (Sigma-Aldrich, Dorset, UK). Blood was mixed 
with lysis buffer for 5 minutes then centrifuged at 770g for 10 minutes, washed with PBS 
(phosphate buffered saline), centrifuged for a further 5 minutes and then the cells were 
pelleted. For RNA extraction total leukocytes were resuspended in RET buffer (Qiagen, 
West Sussex, UK) containing 1% P-mercaptoethanol (Sigma-Aldrich) and stored at -20°C 
for extraction at a later time point. Alternatively total leukocytes were used fresh as 
required.
2.3.2 Mononuclear cells (MNC) preparation
Mononuclear cells (MNC) were prepared from 20-30mls of peripheral blood. MNC were 
separated by density-dependent centrifugation (Lymphoprep Axis-Shield, Cambridge, 
UK), washed in RPMI (Roswell Park Memorial Institute) 1640, and resuspended in 
RPMI 1640 containing 10% dimethyl sulphoxide (DMSO) (Sigma-Aldrich) and 10% 
foetal calf serum (FCS; BioSera, Ringmer, UK) at 4°C and cryopreserved in liquid
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nitrogen. When required, cells were thawed at 37°C and the DMSO was diluted to <1% 
over a period of 30 minutes via dropwise addition of 10% FCS/RPMI. After washing, 
cells were re-suspended at 2 x 106 /ml in ‘culture medium’ (RPMI 1640 containing 10% 
PCS, 1% L-glutamine and 2% penicillin / streptomycin; Invitrogen, Paisley, UK), seeded 
into 6-well tissue culture plates (Becton Dickinson (BD), Oxford, UK) and cultured under 
standard tissue culture conditions (5% CO2 in air, 37°C, 100% humidity) overnight. 
MNC from normal healthy volunteers were used fresh.
2.3.3 Preparation of CD34+ cells
Samples were enriched for CD34+ cells using the CliniMACS kit (Miltenyi Biotec, 
California, USA) according to the manufacturer's instructions, then resuspended in 10% 
DMSO/10% FCS/RPMI at 4°C and cryopreserved in liquid nitrogen. All CD34+ cells 
were collected at diagnosis and then grouped according to the patients’ subsequent 
clinical outcome as defined in section 2.2: CCRe (n=3), No-CCRe (n=4) or BC (n=3). In 
some experiments were purified CD34+ cell samples were not available, MNC were co­
stained with a CD34 antibody (BD), and FACS analysis was performed gated on CD34+ 
cells.
2.3.4 Plasma preparation
5ml of peripheral blood was centrifuged at 770g for 15 minutes. Plasma was collected 
from samples, aliquoted and stored at -20°C prior to use.
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2.4.0. GENE EXPRESSION ANALYSIS
2.4.1 RNA extraction
RNA was extracted using RNeasy mini kit (Qiagen). Samples (as prepared in section 
2.3.1) were thawed and transferred to a QIA shredder column sitting in a 2ml collection 
tube, and centrifuged at 14,000g for 2 minutes in a bench-top microcentrifuge. 600(il of 
70% ethanol was added and mixed well with the flow through in the 2ml collection tube. 
600jil of sample was added to a RNeasy mini spin column sitting in a 2ml collection tube 
and centrifuged for 15 seconds at 14,000g. The flow through was discarded. 700|il of 
RW1 buffer was added to the RNeasy column and left at room temperature for 5 minutes, 
followed by centrifugation at 14,000g for 5 minutes, then the flow through was discarded. 
The RNeasy spin column was transferred to a new RNeasy collection tube. The RNeasy 
spin column was washed twice with 500pl RPE buffer and centrifuged at 14,000g for 15 
seconds. The RNeasy spin column was transferred into a new 1.5ml collection tube, and 
then 40|il of RNase free water was added directly onto an RNeasy membrane and left at 
room temperature for 5 minutes. RNA was eluted by centrifuging for 2 minutes at 
14,000g. RNA was stored at -70°C.
2.4.2 cDNA synthesis
cDNA was synthesised using RNA prepared above. 30pl RNA was incubated with 2pl 
(500ng/fil) of random hexamers (Promega, Southampton, UK) at 70°C for 10 minutes, 
then cooled on ice for 3 minutes. 16)il 5xRT buffer, 8pl of 0.1 M DTT (DL-Dithiothreitol) 
and 4pl of lOmM dNTP (Superscript III Reverse Transcriptase kit, Invitrogen) was
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added to the sample and incubated for 5 minutes at 25°C. Ipl of 200u/pl Superscript II 
reverse transcriptase was added to the sample and heated at 25°C for 10 minutes, then at 
42°C for 60 minutes and finally at 70°C for 15 minutes to stop the reaction. cDNA was 
stored at -20°C.
2.4.3 Identification of BCR-ABL1 transcript type.
The BCR-ABL1 transcript type was identified manually by amplifying cDNA and 
performing a PCR reaction. Each PCR reaction consisted of 2pl cDNA, 1.5mM Mg2Cl, 
200|iM of each dNTP, 0.5pM of each primer (MWG Biotech, Milton Keynes, UK) and 1 
unit of GoTaq Flexi DNA polymerase (Promega). Primer sequences are given in Table 
2.1. PCR conditions were: 95°C for 10 minutes, then 32 PCR cycles consisting of a 
denaturation step at 95°C for 1 minute followed by an annealing step at 62°C for 30 
seconds and an extension step at 72°C for 1 minute. A final extension step was carried 
out at 72°C for 10 minutes.
To determine the size of the PCR product, 15pl of PCR product was mixed with 3pl 6x 
loading buffer and loaded onto a 1% agarose gel and run in 0.5M Tris-Borate-EDTA 
buffer (Sigma-Aldrich) at 120 volts for 90 minutes. The agarose gel was stained with 
0.5mg/inl ethidium bromide buffer for 15 minutes. A photograph was taken under UV 
light. Three sets of primers (EK158 with EK159, NA4 with B2A, and E1F with NA4) 
were used to amplify BCR-ABL1 2iq and the primers NA4 and A2N were used to amplify
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ABL1 (Table 2.1). KCL22 and LAMA84 cells lines along with an ela2 plasmid were 
used as positive controls.
Table 2.1. BCR-ABL1 manual and real-time PCR primer and probe sequences
Primer name Sequence
A2N 5'-CCC AAC CTT TTC GTT GCA CTG T-3’
B2A 5'-TTC AGA AGC TTC TCC CTG ACA T-3’
EK158 5’-CAC GTT CCT GAT CTC CTC TGA C-3'
EK159 5'-TCC AAC GAG CGG CTT CAC TCA G-3'
NA4 5'-CGG CTC TCG GAG GAG ACG TAG A-3'
E1F 5 ’ AGA TCT GGC CCA ACG ATG G
BAHP1 5’ TGA AAA GCT CCG CTT AGG CTA TAA TCA-Fluoresence
BAHP2 5’LC Red 640-A AT GGG GAA TGG TGT GAA GCC CAA A-P
2.4.4 Quantification of BCR-ABL1 expression by quantitative real-time PCR 
(qRT-PCR).
qRT-PCR was performed on a LightCycler (Roche Diagnostics, East Sussex, UK). The 
LightCycler uses two fluorophore-labelled probes that hybridise to adjacent sequences in 
the target DNA. An external light source excites a donor fluorophore at the 3' end of the
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first probe. This then passes its excitation energy on to the second probe, if adjacent, via 
fluorescence resonance energy transfer (FRET). The 5' end of the second probe is 
coupled with the acceptor fluorophore which, when activated by FRET, emits measurable 
light. The intensity of the emission light is proportional to the DNA formed during the 
ongoing PCR.163
dpi of cDNA was added to 2j.il of mastermix (LightCycler FastStart DNA master plus, 
Roche), and made up to 20j.il by the addition of 3mM MgCI2, 0.2pM of each 3’ and 5’ 
hybridisation probes (TIB MOLBIOL Syntheselabor, Berlin, Germany) and 1 pM of each 
3’ and 5* primers (MWG Biotech). Primers for BCR-ABL1 and ABL1 transcript 
amplification were B2A with NA4 and A2N with NA4 respectively, and the FRET 
fluorophore probes were BAHP1 and BAHP2 (Table 2.1). The mixture was firstly 
incubated at 95°C for 10 minutes. Then 40 PCR cycles were carried out, denaturation at 
95°C for 10 seconds, annealing at 58°C for 15 seconds and then extension at 72°C for 27 
seconds.
The absolute copy numbers of BCR—ABL1 and ABL1 transcripts (as an internal control) 
were calculated by reference to a series of dilution standards ranging from 5x105 to 1x102 
copies of linearised plasmids containing a BCR-ABL1 el3a2 or el4a2 insert. The 
plasmids were used to generate a standard curve using the LightCycler software. The 
location of both primers for ABL1 is within the insert of each of these plasmids, and it 
was therefore possible to use the same plasmid DNA to generate a standard curve for
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ABL1 transcript expression as well. The copy number of ABL1 transcripts represents 
both BCR-ABL1 and wild-type ABL1 transcripts.
To calculate the BCR-ABL1/ABL1 ratio, the following formula was used:
BCR-ABL1/ABL1 ratio = ^Abcr-abli / (NTotal/ifiz./ -N bcr-abu)
where Nbcr-abu and Ntotai abli were absolute copy numbers of BCR-ABL1 and ABL1 
transcripts, calculated from the respective standard curves.112
2.4.5 Quality of samples.
The quality of a sample is dependent on the sample volume, transportation time and 
conditions of storage, and is reflected in the control gene ABLI transcript number. At our 
institution the minimum acceptable ABLI transcript copy number for clinical reporting is 
10,000. Any sample with less than 10,000 copies of ABLI is not clinically reported, and 
therefore was not included in this study.
2.4.6 hOCTl transporter mRNA analysis
hOCTl (SLC22A1) mRNA expression levels were determined using diagnostic cDNA on 
all suitable samples as previously described.166 This work was carried out by Dr Athina 
Giannoudis.
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2.4.7 Pre-designed TaqMan real time PCR assays
Pre-designed TaqMan® Gene Expression Assays were used in a 384-well assay plate. 
Each assay consists of a forward and reverse primer at a final concentration of 900nM 
and a 6-FAM dye-labelled TaqMan probe at a final concentration of 250nM. Table 2.2 
lists the TaqMan assays used. This work was kindly performed by Dr Athina Giannoudis.
The concentration of cDNA was determined using the Nanodrop2000 (ThermoScientific, 
Leicestershire, UK). lOOng of cDNA was used per 20pl reaction consisting of 20x 
TaqMan gene expression assay and 2x TaqMan gene expression master mix. Each sample 
was run in triplicate. After loading the reaction mixture, the plate was sealed with an 
appropriate cover and briefly centrifuged. The real time PCR amplifications were 
undertaken using an ABI Prism 7900HT System with the following conditions: 50°C for 
2 min, 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 15 secs and 
annealing/extension at 60°C for 1 min. The relative expression level of a particular gene 
of a given sample was calculated by the comparative Ct method.280 The comparative Ct 
method uses the 2'AACl formula to achieve results for relative quantification, where AACt 
is the normalised signal level in a sample relative to the normalised signal level in the 
calibrator sample. A pool of cDNA from 4 normal individuals was used as calibrator and 
all the samples were normalised to GAPDH as an endogenous control. The RQ Manager 
software supported by the ABI Prism 7900HT System was used for the analysis.
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Table 2.2. Pre-designed TaqMan assays
Assay ID number
AloxS Hs0l095330_ml
BLTI Hs019388704_sl
CrkL Hs00l78304_ml
GAPDH Hs99999905_m 1
PP2A (catalytic subunit) Hs00427259 ml
SET Hs00853870 gl
P1MI Hs00270514 ml
SETBP1 Hs00210209 ml
2.4.8 CIP2A mRNA expression
The expression of CIP2A was measured using qRT-PCR on a LightCycler 1.5 using 
LightCycler FastStart DNA MasterPlus SYBR Green 1 (Roche). CIP2A primers and PCR 
conditions used were as previously described by Come et al93 (forward primer 5'- 
GAACAGATAAGAAAAGAGTTGAGCATT-3' and reverse primer 5'- 
CGACCTTCTAATTGTGCCTTTT-3'). GAPDH gene expression in each sample was 
used as the internal control. PCR conditions were: 50°C for 2 min and a denaturation 
step at 95°C for 10 min followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 
min. The quantification was based on the standard curve method using the BCR-ABL1 
positive cell line K562.
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2.5.0. CELL CULTURE
2.5.1 Cell lines
Four human BCR-ABL1 positive CML cell lines, KCL22,281 KY01, LAMA84 and 
K562“ “ were used as a cell line model of CML and a positive control in some 
experiments, donated by Prof Junia Melo at the LRF Leukaemia Unit, Ffammersmith 
Hospital, London, UK. The human acute monocytic leukaemia cell line U937283 was 
used as a BCR-ABL1 negative control. The gastric cancer cell line AGS was used as a 
CIP2A positive control. Cell lines were cultured under standard tissue culture conditions 
(37°C, 5% CO2 in air, 100% humidity) at approximately 3xl05/ml in ‘complete culture 
medium' (RPMI, 10% FCS, 1% L-glutamine and 2% penicillin and streptomycin). 
Twenty-four hours prior to use the cell lines were resuspended in fresh medium to ensure 
optimal exponential growth prior to use.
For effects of hOCTl expression on TKI uptake two stable cell lines were generated, 
expressing high and low (but not absent) levels of hOCTl as previously described.147 
This work was carried out by Dr Athina Giannoudis. All control cell lines were cultured 
and maintained according to instructions supplied by the European Collection of Cell 
Cultures (ECACC).272
2.5.2 Measurement of cell viability
DiOC6/PI (3, 3'-dihexyloxacarbocyanine iodide/ propidium iodide, Sigma-Aldrich) was 
used to measure cellular viability. DiOC6 is selectively taken up by the charged
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mitochondria of living cells but not by the depolarised mitochondria of apoptotic cells. PI 
stains DNA and is used to differentiate necrotic, apoptotic and normal cells as it cannot 
permeate the membrane of viable cells. 50pl of cells were gently resuspended in 150|il 
DiOC6 (40nM in PBS). Following incubation for 15 minutes at 37°C, 200pl of PI 
(lOpg/ml in PBS) was added and the cells were chilled on ice for 30 minutes. Viability 
was analysed by flow cytometry (FACScalibur), 10,000 events were counted. Live cells 
are DiOC6 bright / PI dim, early apoptotic cells are DiOC6 dim / PI dim and late 
apoptotic cells are DiOC6 dim / PI bright.284
2.5.3 In vitro TKI assay
In some experiments, the effect of tyrosine kinase inhibitors was examined. MNC at a 
density of 2 x 106/ml were cultured either untreated or with 5jiM imatinib or 150nM 
dasatinib or 5|iM nilotinib for 24 hours. Imatinib and nilotinib were kind gifts from 
Novartis (Basel, Switzerland) and dasatinib was a kind gift from Bristol-Myers Squibb 
(New York, USA).
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2.6.0 FLOW CYTOMETRY (FACS)
2.6.1 'In-House' FACS protocol
Cells (~5xl0 ) were fixed by resuspending in 500pl of 2% paraformaldehyde at pH 7.2 
(VWR, Lutterworth, United Kingdom) for 10 minutes at 37°C. Cells were then chilled on 
ice for 1 minute and centrifuged at 770g for 3 minutes. 500pl of 90% methanol (Fisher 
Scientific, Leicestershire, United Kingdom) was added to the cell pellet and the cells 
were vortexed and then incubated on ice for 30 minutes. Cells were then washed 
(throughout with 1ml incubation buffer containing PBS and 0.5% bovine serum albumin 
(BSA) (Sigma-Aldrich)), and centrifuged at 770g for 3 minutes. Cells were resuspended 
in 25pl incubation buffer and left at room temperature for 10 minutes. Appropriate 
antibody was added (Table 2.3). Cells were vortexed and incubated at room temperature 
for 40 minutes. Cells were then washed twice and resuspended in 100j.il incubation buffer 
containing lOjig/ml goat anti rabbit/mouse second Alexa Fluor 488 antibody (Invitrogen), 
incubated at room temperature in the dark for 30 minutes, then washed twice and 
analysed using flow cytometry (FACScalibur), with Cellquest Pro software (BD) for data 
analysis.
2.6.2 Caltag FIX & PERM FACS protocol
The Caltag FIX & PERM® (Caltag, Buckingham, UK) reagents firstly fix cells in 
suspension and then permeabilise them. The nature of the reagents is not disclosed by the 
manufacturer. This procedure gives antibodies access to intracellular structures but leaves 
intact the morphological scatter characteristics of the cell. According to the
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manufacturer’s literature, the ‘unique formulation’ of FIX & PERM® reagents reduces 
background staining and allows simultaneous addition of permeabilisation medium and 
fluorochrome labelled antibodies.
Cells (~5xl05) were fixed using lOOpl of reagent A and permeabilised using 25pl of 
reagent B (Caltag FIX & PERM® reagents). The cells were then washed in PBS 
containing 0.5% BSA and 0.1% sodium azide (Sigma-Aldrich). Appropriate antibodies 
were added as given in Table 2.3.
Table 2.3. FACS antibodies
Assay Control Primary antibody Seconday antibody
CIP2A Mouse lgG2b C1P2A Anti mouse Alex fluor 488
(BD) (Santa Cruz biotecnology) (Invitrogen)
CrkL Normal Rabbit IgG CrkL Anti rabbit Alex fluor 488
(R&D systems) (Santa Cruz biotecnology) (Invitrogen)
pCrkL Normal Rabbit IgG pCrkL Anti rabbit Alex fluor 488
(R&D systems) (Cell Signalling Technology ) (Invitrogen)
PIM1 Normal Rabbit IgG PIM1 Anti rabbit Alex fluor 488
(R&D systems)) (Abeam) (Invitrogen)
PP2A Mouse IgG2a PP2A Anti mouse Alex fluor 488
(BD) (Millipore) (Invitrogen)
SET Normal Rabbit IgG 12PP2A Anti rabbit Alex fluor 488
Y307PP2A
(R&D systems) (Santa Cruz biotecnology) (Invitrogen)
Normal Rabbit IgG PP2A Y307 Anti rabbit Alex fluor 488
(R&D systems) (Epitomics) (Invitrogen)
R&D systems, Abingdon. UK. Santa Cruz, California, USA. Abeam. Cambridge UK. Millipore, Watford, 
UK. Epitomics, California, U.S.A.
2.6.3. Triple layer FACS
Cells were fixed, permeabilised and incubated with the appropriate primary antibody as 
shown in Table 2.3. Cells were then incubated with 5pl of biotinylated anti-rabbit 
second-layer antibody (Vector Laboratories, Peterborough, UK) for 30 minutes, washed, 
and incubated at room temperature in the dark for 30 minutes with a third layer antibody, 
15pl anti-phycoerythrin streptavidin (SA PE) antibody (BD). Cells were washed twice 
and analysed with 10,000 events being collected.
2.6.4 Measurement of LTB4 receptor BLT1
5ml of peripheral blood was collected into EDTA. Erythrocytes were depleted using red 
cell lysis buffer as described in section 2.3.1. Total leukocytes were then incubated with 
Leukotriene B4 Receptor 1 (BLT1/LTB4R1) (R&D systems) and anti mouse IgGl 
antibody (BD) as control antibody, in the dark for 30 minutes with shaking. Cells were 
then washed in PBS containing 0.5% BSA and analysed by FACS.
2.6.5 BCR-ABL1 protein detection flow cytometry protocol 
Using the BCR-ABL1 protein detection kit (kind gift from BD) the manufacturer’s 
protocol was followed. IxlO7 cells were washed in PBS containing 5% ECS, pelleted, 
and resuspended in 250pl of pre-treatment reagent and incubated on ice for 10 minutes. 
Cells were centrifuged at 500g for 5 minutes at 4°C, washed in PBS and centrifuged 
again. The supernatant was discarded and lOOpl of BD lysing solution was added to the
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cell pellet and incubated on ice for 15 minutes, followed by centrifugation at 20,000g for 
10 minutes at 4°C. 50pl of supernatant was incubated with 50pl of capture beads and 
50pl detector reagent in the dark for 2 hours, then washed with 1ml BD CBA wash buffer 
and centrifuged at 770g for 5 minutes. Beads were resuspended in 300pl BD CBA wash 
buffer and data acquired and analysed using a FACSCanto II.
The reported BCR-ABL1 MFI (mean fluorescence intensity) for a sample was 
determined as the MFI for the sample, minus the MFI value of the negative control plus 
two standard deviations.
The BCR-ABL1 protein FACS assay was performed in collaboration with Miss Jemma 
Fagan.
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2.7.0 WESTERN BLOTTING
2.7.1 Protein Determination
200|il of 1% SDS lysis buffer containing 1% SDS, 50mM Tris, 5mM EDTA, 10% 
glycerol, chymostatin, leupeptin, aprotinin, pepstatin A and antipain 1 mg/ml (Sigma- 
Aldrich) was added to the cell pellet and sonicated. The lysates were then heated at 95°C 
for 10 minutes then placed on ice to cool. Protein detennination was performed using the 
BioRad DC protein assay (BioRad, Hertfordshire, UK). Protein standards of 0-3pg were 
made using BSA diluted in 1% SDS lysis buffer (1% SDS, 50mM Tris, 5mM EDTA, 
10% glycerol). 5pl of protein standards and samples were added into a 96 well flat 
bottom plate (Fisher Scientific), using a positive displacement pipette and tips. 20pl of 
reagent S was added to 1ml of reagent A. 25pl of reagent A/S mixture was added to each 
well followed by 200pl of reagent B (Reagents A, B and S were provided in the BioRad 
DC protein assay kit). The plate was incubated at room temperature for 15 minutes and 
then the plate was read using a spectrophotometer at 750nm.
2.7.2 Western blotting
Lysates were prepared using SDS lysis buffer and boiled for 10 minutes. Samples were 
loaded by either cell number or protein concentration (20pg) and electrophoresed in 15% 
polyacryamide gels in Tris/glycine running buffer285 using Bio-Rad protean II xi cell 
electrophoresis system. Following electrophoresis, proteins were transferred for Western 
blotting to Immobilon-P membranes (Millipore). Membranes were blocked with 5% w/v 
skimmed milk (Tesco) or 5% BSA (Sigma-Aldrich) in Tris buffered saline (TBS- T)
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(lOmM Tris pH 7.4, 150mM NaCl, and 0.1% Tween-20) and incubated with primary 
antibody overnight at 4°C with shaking. Membranes were then washed thoroughly with 
TBS-T and incubated with secondary antibody for 30 minutes at room temperature. 
Membranes were again washed thoroughly and blots were developed using ECL 
(enhanced chemiluminescence) (Millipore). Digital images were obtained using the LAS- 
1000 imaging system and analysed using Aida Image Analyser software (Raytest, 
Straubenhardt, Germany).
2.7.3 Immunoprecipitation
IxlO7 cells were lysed in 500pl R1PA buffer (Tris 50mM, NaCl 150mM, SDS 0.1 %, Na 
deoxycholate 0.5 %, NP40 1%, sodium vanadate 1 mg/ml and PMSF
(phenylmethylsulfonyl fluoride 1 mg/ml)), incubated on ice for 20 minutes, and then 
centrifuged at 12,000g for 30 minutes at 4°C. The supernatant was transferred into a new 
1.5ml Eppendorf tube. 20pl of protein A and G beads (Sigma-Aldrich) were washed 
twice in RIPA buffer and then added to the cell lysate, and agitated for 1 hour at 4°C. The 
lysates were centrifuged at 12,000g for 2 minutes and then transferred into a new 1.5ml 
Eppendorf tube. The appropriate antibody was added to the cell lysate (1 pg per 107 cells) 
and incubated for 2 hours at 4°C (rotating). 20pl of protein A and G beads were washed 
twice in RIPA buffer and then added to the cell lysate and incubated overnight at 4°C 
(rotating). Beads and antibody alone were used as a control. Samples were pelleted, 
washed in TBS-T and resuspended in 20pl of Double strength sample (DSSB) buffer (4% 
SDS, 20% glycerol, 10% 2-mercaptoethanol (Sigma-Aldrich), 0.004% bromophenol blue
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(Sigma-Aldrich) and 0.125M Tris HCL (Sigma-Aldrich)). Western blotting was 
performed as described above.
2.8.0 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
ELISA assays protocols were developed for the detection of tyrosine kinase activity, c- 
Myc total protein and pS6~c-Myc. For the detection of LTB4 a commercially available 
assay was used.
2.8.1 pTyr and c-Myc ELISA
Whole-cell lysates were prepared in NP-40 lysis buffer (1% NP40, 150 mM NaCl, 50 
mM Tris-HCl, 1 mM EDTA, and 1% protease inhibitor, pH 8.0, Sigma-Aldrich). Lysates 
were diluted in 50mM carbonate-bicarbonate coating buffer (Sigma-Aldrich), added to 
each well of an Immulon 4 HB 96-well flat-bottom ELISA plate (Fisher Scientific) in 
triplicate (5pg protein in lOOpI carbonate-bicarbonate buffer/well) and plates were then 
incubated overnight at room temperature with shaking. Following incubation, plates were 
washed with TBS-T four times; surfaces were blocked with lOOpl 5% BSA in TBS-T 
(except those wells reserved for chromagen blanks) and plates incubated for 1 hour at 
room temperature with shaking. Plates were then washed as previously. Plates were 
incubated with lOOpl of TBS-T containing primary antibody and 5% BSA, for 2 hours at 
room temperature on a shaker. Plates were washed with TBS-T four times and incubated 
with lOOpl per well of 1:1000 anti-mouse or rabbit IgG-horseradish peroxidase 
secondary antibody (New England Biolabs, Hitchin, UK) for 1 hour at room temperature
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on a shaker. Plates were then washed four times with TBS-T, and then 1 OO^l chromagen 
substrate (tetrainethylbenzidine, Sigma-Aldrich) was added to each well and plates 
incubated for 20 minutes in the dark. The reaction was stopped by adding 50pl 2M HC1 
and plates were then read at 460 nm absorbance. Negative control wells were included in 
the assay (lysate only and antibody only) and these values were subtracted as background 
from each relevant test well.
For tyrosine kinase activity the primary antibody was 4G10 mouse anti-phosphotyrosine 
(P-Tyr) antibody (Upstate Biotechnology, New York, USA).
For assaying c-Myc and pS62c-Myc status, Myc antibody (New England Biolabs) and 
pS6“c-Myc antibody9" (Abeam) were used respectively.
2.8.2.Leukotriene B4 ELISA
LTB4 standards (3000, 750, 188, 46.9 and 11.7pg/ml) were prepared and the assay was 
performed according to the manufacturer’s protocol (Cambridge Biosciences, Cambridge, 
UK). lOOpl of the specific standard, sample or assay buffer was added in duplicate to 
appropriate wells of a 96-well plate and a further 50j.il of assay buffer to the negative 
control wells. 50jil of LTB4 conjugate and 50pl of LTB4 antibody, supplied in the kit, 
were added to the appropriate wells. The plate was incubated at room temperature, with 
shaking, for 2 hours. Following incubation the plate was washed three times with wash
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solution (provided in the kit). 5f.il of conjugate was added to the total activity wells, 
followed by 200pl of pNpp substrate solution to every well. The plate was incubated 
again, at 37°C with shaking, for a further 2 hours. 50pl of stop solution (2M HC1) was 
then added to all wells. The absorbance was immediately read at 405nm using a BioTeK 
pQuant plate reader. The mean optical density of the negative control wells was 
subtracted from the optical density reading of all wells, to eliminate “background noise” 
of each well.
2.9.0 PP2A ACTIVITY ASSAY
PP2A phosphatase assays were carried out using the PP2A IP phosphatase assay kit 
(Millipore). The manufacturers protocol for this assay was optimised by Professor Danilo 
Perrotti’s laboratory. Cells were pelleted and washed in 1ml of lOmM HEPES buffer and 
then resuspended in lOOpl of hypertonic buffer (lOmM HEPES, 1% NP-40, 0.5 M NaCl, 
10% Glycerol, ImM PMSF, 5mM Benzamidine and protease inhibitors cocktail) and left 
on ice. Cell lysates were subjected to four freeze thaw cycles, consisting of 30 seconds in 
ethanol and dry ice and then heated to 37°C. Lysates were then sonicated and kept on ice 
for 20 minutes, followed by centrifugation at 14,000g for 20 minutes at 4°C. Protein 
concentration was determined as described in section 2.7.1. 25|ul protein A beads were 
washed in pNPP ser/thr assay buffer (50mM Tris-HCl, pH 7.0 and lOOmM CaCl2) and 
resuspended in 400pl pNPP Ser/Thr assay buffer. 5pg anti-PP2A, c subunit, clone 1D6 
(as provided in the kit) and lOOpg of cell lysate were added to the beads, and then 
samples were agitated for 2 hours at 4°C. Samples were centrifuged at 14,000g for 3 
minutes at 4°C and the supernatant was discarded. Beads were washed three times in TBS
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and once in 1ml of pNPP Ser/Thr assay buffer and resuspended in 25pl pNPP Ser/Thr 
assay buffer. 60pl of phosphopeptide was added to the washed immunoprecipitated 
beads. Lysates were agitated for 10 minutes at 30 °C, then centrifuged at 14,000g for 3 
minutes and the supernatant was transferred to a new 1.5ml Eppendorf tube. 25pl of the 
supernatant was added to a 96 well plate in triplicate. pNPP ser/thr assay buffer was used 
as an assay negative control. Phosphate standards provided with the kit were also added 
to the plate. The Malachite phosphate detection solution was prepared by adding lOOOpl 
of solution A to lOpl of solution B and 300pl Malachite phosphate detection solution was 
added to every well. The plate was incubated at room temperature for 10 minutes and 
plates were then read at 650nm absorbance. The standard curve was used to determine 
the pico moles of phosphates released from phosphopeptide by PP2A activity 
(absorbance depends on PP2A activity of the samples).
2.10.0 CIP2A SMALL INTERFERING RNA (siRNA) TREATMENT
K562 and LAMA84 cells were washed three times in PBS. 1x106 cells were resuspended 
in lOOpl solution V Nucleofector Kit V (Lonza, Verviers, Belgium) and lOOnM siRNA 
was added to solution V (CIP2A siRNA and control siRNA, Santa Cruz) or CIP2A 
siRNA (Integrated DNA technologies, Leuven, Belgium). Samples were transferred to an 
Amaxa vial, and nucleofected using the Amaxa instrument pre-set programme T16. 
After nucleofection the cells were immediately transferred into pre-warmed culture 
medium, and cultured for 72 hours in a 24 well plate prior to analysis.
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2.11.0 STATISTICAL ANALYSIS
Statistical analysis and comparisons were performed using the statistical programme 
SPSS 16.0 (SPSS Inc. Chicago, USA). Fishers and Mann-Whitney tests were used to test 
if the data were significant; details are given where appropriate with each experiment. 
SPSS was also used to draw box and whisker plots as well as Kaplan-Meier plots.
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CHAPTER THREE - A population study of 
imatinib in chronic myeloid leukaemia
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3.1.0. INTRODUCTION
Imatinib has undoubtedly saved and improved the quality of lives of many thousands of 
patients with CML and it has become the treatment of choice for newly diagnosed 
chronic phase patients. A recent report suggests that modern drug treatment may produce 
superior outcomes compared to allogeneic stem cell transplantation (SCT).120 However, 
SCT remains the only proven curative therapy, but is only an option for about 25% of 
patients and carries substantial risks.20
At the time of conducting this study the only data available on the efficacy of imatinib for 
newly diagnosed CML patients were from a single trial, IRIS, which was carried out 
under the supervision of the imatinib manufacturer Novartis. The development of 
imatinib and the IRIS clinical trial results have been discussed in the general introduction 
section 1.5.5. Briefly the IRIS trial reported a five year cumulative CCR rate of 87% and 
an estimated OS of 89%. However, 30% of patients were excluded from the five year 
assessment for various reasons. EPS and disease progression rates were therefore only 
calculated on those patients still continuing imatinib treatment at five years and not those 
who had switched treatment because of treatment failure or for other reasons.
As for any clinical trial, patients who enrolled in the IRIS clinical trial differ from the 
general population - for example patients over the age of 70 were excluded, together with 
those with conditions such as diabetes mellitus, angina, or a history of another
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malignancy within the past five years. However, such patients are seen in CML clinics on 
a regular basis. It was therefore important to establish if the IRIS trial outcome data could 
be reproduced in a more general, unselected CML population. The work contained within 
this chapter is the outcome of the analysis undertaken to assess the clinical outcome of all 
newly diagnosed CML CP patients receiving imatinib 400mg daily in our healthcare area.
3.2.0. PATIENT COHORT
All patients aged 16 or over with CML newly diagnosed between January 1st 2003 and 
June 30th 2006 were included in this study. Patients diagnosed before this period were 
excluded since the timing of imatinib approval by primary care trusts in 2002 varied 
across our geographical area. Younger patients were excluded as imatinib usage in 
children is not universal, and molecular monitoring in paediatric patients was not 
performed routinely at that time. Patients were included in the assessment of imatinib 
efficacy if they received imatinib 400mg daily from original diagnosis (preceded only by 
up to six weeks of hydroxycarbamide).
Considerable effort was made to include all CML cases, firstly from the records at the 
molecular diagnostic centre, secondly by contact with local haematologists and thirdly by 
cross-checking against Philadelphia translocation positive (Ph+) results at the Liverpool, 
Manchester and Cardiff regional cytogenetics centres which cover our geographical area.
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For each case, local haematologists verified that each case had never received prior 
interferon-a or alternative chemotherapy. Patient characteristics are shown in Table 3.1.
Table 3.1. Summary of patients' characteristics - population study
Total
Number of patients 88
Mean age, (range years) 53 (18-87)
Sex (M/F) 41/47
Sokal score High 28
Intermediate 29
Low 20
No data 11
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3.3.0. RESULTS
3.3.1. Defining the clinical cohort.
Over the 42 months of the study, 88 new cases of CML were seen, giving an annual 
incidence of 1.2 cases per 100,000 population per annum. These comprised 41 men and 
47 women, and their median age at diagnosis was 53.4 years (range 18.6 - 86.8 years). Of 
these, four presented in blast crisis and were treated with chemotherapy prior to imatinib 
and then stem cell transplant (SCT), and therefore were excluded from further study. Of 
the 84 presenting in chronic phase, 16 cases were not assessable for the effect of imatinib 
as they first received interferon-a (seven cases) or an elective SCT (one case), or because 
insufficient follow-up data were available (eight cases). Analysis was therefore carried 
out on all 68 assessable cases that presented in chronic phase and received imatinib from 
initial diagnosis.
3.3.2. Response rates to imatinib treatment (400mg)
A flow diagram of patient outcome is shown in Figure 3.1. During the first 12 months of 
treatment, three patients progressed to blast crisis, of whom two died and one achieved a 
second chronic phase during which they underwent a SCT. Two patients had serious side 
effects attributable to imatinib treatment, one Stevens-Johnson syndrome - a serious 
exfoliative skin disease affecting the skin and mucous membranes that is usually the 
result a drug reaction,286 and one case of hepatotoxicity, both of whom were successfully 
treated with an alternative TK1. One further patient lost an initial CHR, and proceeded to
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SCT. Six cases therefore failed imatinib before 12 months, leaving 62 cases assessable at 
12 months.
Figure 3.1. A flow diagram of patients achieving CCRe.
88 Newly diagnosed patients
4 presented in blast crisis
84 Newly diagnosed chronic phase patients
I' 16 cases did not receive imatinib first line
68 Patients received imatinib 400mg
^ 6 failed before 12 months
62 assessable at 12 months
3 Disease progression 
2 Intolerant 
1 Loss ofCHR
12 months
5 Ongoingfollow-up
CCRe
28
No CCRe j
34 I
1 2 Disease progression3 Loss ofCHRr
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3.3.3. Imatinib response in patients assessable at 12 months.
Of the 62 cases that were assessable for response at 12 months, 28 (41%) had achieved a 
complete cytogenetic response (CCRe). Twenty-three of these 28 cytogenetic responders 
were assessable at 18 months and 22 remained in CCRe; the remaining case developed 
central nervous system (CNS) blast crisis. Of the 34 cases who had not achieved CCRe at 
12 months, eight patients went on to achieve a CCRe at 18 months. Twelve of the 
original 68 imatinib treated patients were not assessable at 18 months (three cases lost 
their CHR and proceeded to SCT, two died of disease progression and seven cases had 
not reached the 18 month assessment point).
By 24 months, a total of six (9%) of the original 68 imatinib treated patients had 
progressed to advanced phase, and 10 further cases remained in chronic phase but had 
received SCT or switched to an alternative TKI because of intolerance (three cases) or 
failure to achieve/maintain CCRe. The overall CCRe rates were 41% (28 of 68 patients) 
at 12 months, 49% (30 of 61 assessable cases) at 18 months, and 51% (28 of 55 
assessable cases) at 24 months (Table 3.2).
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Table 3.2. CCRe response rate. 
Panel A: All 88 patients and B: 
diagnosis.
the 68 patients who received imatinib from initial
A.
All patients
Total 12 months 18 Months 24 months
Number of cases assessable 88 83 81 80
LowSokal score 20 55% (11/20) 53% (10/53) 42% (8/19)
Intermediate Sokal score 29 24% (6/25) 36% (9/25) 36% (9/25)
High Sokal score 28 48% (13/27) 41% (11/27) 41% (11/27)
No data 1! 27% (3/11) 40% (4/10) 44% (4/9)
Overall CCRe 88 40% (33/83) 42% (34/81) 40% (32/80)
B.
Patients receiving imatinib from initial diagnosis
Total 12 months 18 Months 24 months
Number of cases assessable 68 68 61 55
LowSokal score 18 50% (9/18) 52% (9/17) 43% (7/16)
Intermediate Sokal score 22 27% (6/22) 38% (6/21) 42% (8/19)
High Sokal score 23 52% (12/23) 61% (11/18) 68% (11/16)
No data 5 20% (1/5) 40% (2/5) 50% (2/4)
Overall CCRe 68 41% (28/68) 49% (30/61) 51% (28/55)
CCRe was used as a conservative and confirmed predictor of treatment success or failure 
at 12, 18 and 24 months.111,160 At 24 months, 49% (27 of 55 assessable cases) had failed 
imatinib because of either progression to blast crisis (six cases, all fatal), failure to 
achieve/maintain CCRe (19 cases, of which four lost CHR as well) or intolerance (two
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cases). Fourteen of the 15 failures who remain in CHR and without disease progression 
have achieved and remain in CCRe at latest follow-up, following either SCT or an 
alternative tyrosine kinase inhibitor (TKI).
The CCRe rates were stratified by the patients’ Sokal score. The purpose of this was to 
demonstrate that there was an even distribution of patients between each Sokal risk 
group. Patients were stratified as follows: 26% low, 32% intermediate and 34% high risk; 
thus patients were considered to be evenly distributed. The lower CCRe rates observed 
cannot therefore be attributed to a bias of high Sokal scoring patients within this study. A 
similar Sokal score range was observed in a single centre study from the Hammersmith 
Hospital, London.287 The distribution of patients within the IRIS study was 52.5% low, 
29% intermediate and 18.5% high risk.17 Given that the IRIS study censored patients 
when they discontinued treatment it is plausible that the ‘missing’ patients from IRIS 
were predominately high risk Sokal score patients. Superior IRIS response rates 
compared to the present study might therefore be attributed to the bias in the patient 
cohort for low risk Sokal score patients.
The IRIS study reported 12 month CCR rates of 79% low, 67% intermediate and 49% 
high risk. At 18 months the CCR rate was reported for the high risk group as 56.3%, 
which is comparable with 61% at 18 months in this population study. While the IRIS 
study demonstrated that a patient’s Sokal score correlated with achievement of CCR, in 
the present population based study this was not the case (Table 3.2). Patients with high
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risk Sokal scores had a higher rate of CCRe at all time points compared to low and 
intermediate risk groups. It is possible that the number of patients in this study is too low 
for an association between CCR and Sokal score to be observed. Alternatively the follow 
up period may not be long enough.
In the present study, MMR rates were 22% at 12 months, 26% at 18 months and 31% at 
24 months. Five patients (8%) lost MMR during the study. Three patients had a transient 
loss of MMR but regained MMR at a later time point while still on imatinib treatment. 
One patient developed the T315I BCR-ABL1 kinase domain mutation and subsequently 
died. The remaining patient lost both CCRe and MMR and switched to nilotinib 
treatment. At latest follow up she remains in CMR (Figure 3.2).
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Figure 3.2. A flow diagram of patients achieving MMR.
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3.3.4. Event free survival is not associated with Sokal score in imatinib treated
patients.
In the IRIS study and the present study, event free survival (EPS) was defined as death 
from any cause, progression to blast crisis or accelerated phase, loss of haematological 
response or loss of cytogenetic response.17 Patients who presented in blast crisis are not 
eligible for a disease progression event since they presented in blast crisis.
Figure 3.3 shows that in the present study, the EPS for all patients was 95% at 12 months 
and 80% at 24 months, with no difference in EPS between all 88 patients and the 68 
entered into the study (Panel A). EPS was also stratified by Sokal score, and no 
statistically significant difference was observed between the Sokal score risk group and 
EPS for all 88 patients (Figure 3.3B) or the 68 who entered the study (Figure 3.3C). 
These data suggest that Sokal score may not be an appropriate calculation of disease risk 
for imatinib treated patients given that it was developed in the pre-imatinib era.155 A 
recent study perfonued by the European LeukaemiaNet on 2060 newly diagnosed CML 
patients treated with imatinib at initial diagnosis reported that the Sokal score 
discrimination was only statistically significant for high risk patients. The authors 
developed a new scoring calculation known as the ‘EUTOS score’ which they suggest is 
more accurate at stratifying imatinib treated patients into risk groups.160 Unfortunately the 
parameters required to perform the new calculation were not available for this cohort of 
patients therefore it could not be tested.
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Figure 3.3. Kaplan-Meier estimates of event free survival.
Panel A: Comparison between all 88 patients and the 68 patients who received imatinib 
from initial diagnosis. Panel B: Outcome according to Sokal score for all 88 patients. 
Panel C: The 68 imatinib treated patients. No statistically significant differences were 
observed for either group (SPSS statistical package - Mantel-Cox log rank test).
Time (months)
- All newly diagnosed patients 
• 68 receiving imatinib at initial diagnosis
Time (months)
Sokal risk score
--------  Low
...........  Intermediate
------- High
c
Time (months)
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3.3.5. Time to achieve CCRe is not associated with Sokal score in imatinib treated
patients.
No statistically significant difference in time to achieve a CCRe was observed between all 88 
patients and the 68 patients whom entered the study (Figure 3.4A). However, this Kaplan- 
Meier graph is a cumulative estimate of time to achieve CCRe and does not take into account 
loss of response. When the patient cohort was stratified by Sokal score no statistically 
significant difference in time to response was observed (Figure 3.4B and C). These data 
further confirm the idea that Sokal score cannot predict achievement of CCRe or EFS in 
imatinib treated patients.
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Figure 3.4. Kaplan-Meier estimates of time to achieve CCRe.
Panel A: Comparison between all 88 patients and the 68 patients who received imatinib from 
initial diagnosis. Panel B: Outcome according to Sokal score for all 88 patients. Panel C: 
The 68 imatinib treated patients. No statistically significant differences were observed for 
either group (SPSS statistical package - Mantel-Cox log rank test).
Time (months)
■ All newly diagnosed patients
■ 68 receiving imatinib at initial diagnosis
B
Time (months)
Sokal risk score
.......... . Intermediate
— — High
c
Time (months)
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3.3.6. Continuation of imatinib treatment.
After two years follow-up 80% of patients who received imatinib at initial diagnosis continue 
to receive imatinib 400mg daily as treatment for CML. Failure to respond to treatment in this 
study is defined as not achieving CCRe.160 Although 49% of patients had failed imatinib 
therapy at 24 months (Figure 3.5), the fact that a high percentage of patients remain on 
imatinib treatment reflects the lack of alternative treatment options for chronic phase CML 
patients at the time of study, which was limited to SCT or imatinib since second generation 
TKIs were not available.
Figure 3.5. Patients continuing imatinib treatment.
Kaplan Meier curve showing the percentage of patients continuing to receive imatinib 400mg 
daily.
I 80-
£ 60-
Time (months)
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3.4.0. DISCUSSION
At the time of conducting this study there were several hundred publications on various 
clinical aspects of imatinib, but only three independent series describing clinical outcome in 
previously untreated chronic phase CML patients; the IRIS trial, and studies from the MD 
Anderson Hospital, Texas, USA and the Hammersmith Hospital in London.18 287 288 In a 
single centre study of 279 newly diagnosed patients presenting to the MD Anderson Hospital 
87% achieved a CCR, with an estimated three year survival rate of 96%.288 A single centre 
study conducted at Hammersmith Hospital evaluated the response to imatinib first-line in 204 
newly diagnosed CML patients.287 The five year cumulative CCR and MMR rates were 82.5 
and 50.1% respectively. Patients who achieved a CCR by 12 months had a significantly better 
PFS and OS compared to those patients who did not, and achievement of MMR had no 
additional benefit in this cohort, which contrasts with the reported data by the IRIS 
investigators.164 By five years 25% of patients had discontinued imatinib and cumulative 
incidence of loss of CCR at 48 months was 17%. The study concluded that a third of patients 
need better treatment. The above studies provide insight into the efficacy of imatinib in CP 
CML patients, though none of these three studies were population based.
The present data indicate that within our geographical area, following 24 months of imatinib 
treatment, the CCRe rate is only 51%, meaning that nearly half of all patients will fail 
treatment at two years. This differs from the response rates seen within the IRIS study, which 
demonstrated that after five years of imatinib therapy, 83% of patients are alive and remain in 
chronic phase.18 The cumulative rates of CCR among the patients receiving 400mg of 
imatinib were reported as 69%, 76%, and 87% at 12, 18 and 60 months respectively.18 In 
this population study evaluation of the patients’ Sokal score revealed an even distribution
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between the risk groups’ ruling out the hypothesis that there were more high risk patients 
presenting within the North-West explaining our lower rates of CCRe and MMR.
Exclusion criteria were applicable for inclusion within the IRIS trial including: an age limit 
(> 18 and < 70 years of age), patients who have received other investigational agents, patients 
who received prior chemotherapy and patients with uncontrolled medical disease such as 
diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection or angina. In 
addition to the exclusion criteria there was a geographical bias for patients entering the IRIS 
study, since only large specialist centres offered the IRIS trial. Patients being treated at 
smaller district general hospitals were often not entered due to the time and cost implications 
of travelling frequently to the larger hospital.
A further major issue within the IRIS data is the censoring of ‘failed’ patients. Unlike the 
present analysis which includes all patients in the final analysis, the IRIS trial censored 
patients who had failed to stay on imatinib treatment, at the point of imatinib discontinuation. 
Thus as time evolves, the IRIS dataset is increasingly selected for patients who have done 
well.
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Figure 3.6. IRIS 7 year analysis.
Still receiving study imatinib 
(n = 332; 60%)
Discontinued study imatinib 
(n = 221; 40%)
All randomized to imatinib 
(n= 553; 100%)
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(n = 17; (n = 26; I (n = 52; (n=30; (n*81; (n = lS;
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♦Patients may have continued imatinib off study. 
♦♦Including primary discontinuation
At the American Society of Hematology (ASH) annual meeting in 2008 the IRIS data were 
re-analysed to include these previously excluded patients (Figure 3.6). After seven years of 
follow up over 40% of patients initially entered into the trial had been excluded from 
analysis.-8; Of the 40% of patients who discontinued treatment 8% were due to safety, 15% 
due to lack of efficacy which included progression to AP or BC, loss of response, and 
unsatisfactory therapeutic effect, and 17% other reasons including SCT, withdrawn consent 
and lost to follow-up.
The findings of this present population study were recently substantiated by an abstract 
presented at the European Haematology Association (EHA) annual meeting 2010.290 A 
population study examining a more recent cohort of patients in the West of Scotland and
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Lothian reported that only 46.2% of patients initially treated with imatinib remain on 
treatment (median time to discontinuation of imatinib treatment 13.2 months). These data 
together with the present findings indicate that caution is needed in extrapolating clinical trial 
data to the general CML population.
With increasing clinical experience, it is becoming apparent that some patients can become 
resistant to imatinib. ’ Imatinib resistance is multifactoral, including BCR-ABL1 kinase 
domain mutations, BCR-ABL1 gene amplification, or changes in drug transporter expression 
such as hOCTl and ABCB133,291,292 Second generation TKIs dasatinib and nilotinib are now 
licensed for first-line therapy based on data from ongoing phase III clinical trials (DASISION 
and ENESTnd). These trials suggest that both dasatinib and nilotinib are superior drugs when 
compared with standard dose imatinib,146 although whether these superior response rates are 
maintained in years two and beyond remains unknown.146,152 It will be interesting to see if the 
clinical trial findings from these second generation TKIs can be replicated in the more 
general CML population. A population study of second generation TKI treatment within our 
area is at present being conducted.
Currently it is impossible to prospectively identify patients who will respond to imatinib 
treatment at diagnosis. Clinical decisions would be greatly facilitated if it was possible to 
accurately predict patients who are unlikely to achieve cytogenetic and/or molecular response 
prior to commencing treatment, and this would facilitate the individualisation of therapy. 
Therefore the aim of this thesis is to try and identify biomarkers which may predict eventual 
clinical outcome in newly diagnosed CML patients.
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CHAPTER FOUR - BCR-ABL1 tyrosine kinase 
activity as determined by the pCrkL/CrkL ratio 
at diagnosis is predictive of treatment outcome 
in chronic myeloid leukaemia.
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4.1.0 INTRODUCTION
Prognostic scoring methods based on simple haematological parameters that were devised in 
the pre-imatinib era (i.e. Sokal score1:o) may still distinguish cohorts of patients with 
different outcomes on imatinib treatment.18 Similarly the level and activity of the imatinib 
uptake transporter hOCTl may also correlate with clinical outcome.166293 However, none of 
these parameters are sufficiently powerful to prospectively predict patients destined to fare 
poorly on imatinib treatment. Clinical decisions would be greatly facilitated if it were 
possible, prior to commencing imatinib treatment, to accurately predict patients who are 
unlikely to achieve a cytogenetic response, as these patients could then be offered alternative 
treatments such as SCT or a second generation TKI.
A rational approach to treatment optimisation would be to use an assay which measures the 
degree of BCR-ABL1 tyrosine kinase activity and then how imatinib modifies this either in 
vivo or in vitro. BCR-ABL1 tyrosine kinase activity has previously been assessed by Western 
blotting.197,198 However it is known that CML MNC release a proteolytic degradative activity 
upon lysis which rapidly and selectively degrades the BCR-ABL1 protein leading to an under 
estimation of its activity.189,199294 Thus, direct assessment of BCR-ABL1 tyrosine kinase 
activity in CML primary cells is experimentally problematic. As discussed in the general 
introduction (section 1.6.8), White et r//197 investigated imatinib induced in vitro inhibition 
of the pCrkL and CrkL levels by Western blotting and produced a ratio. The authors reported 
that the imatinib IC50 (defined as the imatinib concentration that reduces the pCrkL/CrkL 
ratio by 50%) was predictive of subsequent clinical outcome. Western blotting can be time 
consuming and also requires a large number of cells (>106) which may be difficult to obtain 
from CML patient samples especially once treatment has begun. A pCrkL FACS method was
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subsequently developed by Hamilton et alm Flow cytometry results were comparable to 
those produced by Western blotting. Flow cytometry has the advantage that it requires fewer 
patient cells (~ 103 cells), produces quantitative values and results can be obtained rapidly. 
However, unphosphorylated CrkL was not assessed, so it was not possible to calculate a 
pCrkL/CrkL ratio as suggested by White et aL191
The aim of this chapter was to optimise and further develop techniques for the detection of 
both pCrkL and CrkL. At the time of commencing this work pCrkL and CrkL could only be 
detected by Western blotting,197’199 and during the project the detection of pCrkL was 
reported by flow cytometry.199 The main focus of this chapter was to investigate the 
predictive value of pCrkL and CrkL in newly diagnosed CP CML patients.
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4.2.0. RESULTS
4.2.1. Detection of pCrkL and CrkL by Flow cytometry
The initial aim of this work was to develop a FACS assay for the detection of pCrkL and 
CrkL which would be clinically more favourable and easier to use as a diagnostic tool than 
Western blotting. A considerable amount of time was spent optimising the FACS assay. The 
following parameters were investigated as likely to affect the final result:
• Cellular fixation and permeabilisation - comparison of ‘Caltag fix and perm kit’ 
and the ‘in house’ protocol of paraformaldehyde and methanol fixation.
• Saturating antibody concentration.
• Signal detection - double or triple layer signal amplification.
• Nature of second layer fluorophores.
• Source of control antibody /non-specific binding.
• Reproducibility (sensitivity).
• Cell source - fresh or frozen.
4.2.1.1. Fixation and permeabilisation
Various methods have been published for the fixation and permeabilisation of cells for FACS 
analysis. Hamilton et al199 used a commercially available kit from Caltag to fix and 
permeabilise cells in order to assess the CrkL phosphorylation status in CD34+ cells. This 
section addresses whether the findings of Hamilton et a/199 are reproducible in our laboratory, 
and whether our ‘in-house’ fixation and permeabilisation protocol (using paraformaldehyde 
and methanol) offers any further improvement.
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Figure 4.1. Detection of pCrkL in K562 cells by FACS using different methods of 
fixation and permeabilisation. (Representative plots are shown).
Panel A: Caltag FIX & PERM® kit. Panel B: 2% paraformaldehyde to fix and 90% 
methanol to permeabilise.
A B
Cells with second layer only 
pCrkL
The outcome of different fixation and permeabilisation methods for the detection of pCrkL in 
K.562 cells is shown in Figure 4.1. Fixation and permeabilisation were done using either the 
Caltag fix and perm kit following manufacturers instruction (panel A) or by our *in house 
protocol' (panel B). Comparison of the resultant mean fluorescent intensity (MFI) shows that 
when the cells are fixed using the Caltag kit the change in MFI was 3.10. This increased to 
12.21 MFI when the cells were prepared using the ‘in-house’ protocol. These data suggest 
that our ‘in house’ protocol using paraformaldehyde and methanol produces a greater degree 
of detection compared to the Caltag kit this was therefore chosen as the method for fixation 
and permeabilisation and was used in all subsequent experiments.
At the time of commencing this work, there was no FACS based assay reported in the 
literature for the detection of CrkL. None of the available antibodies had been shown to
145
detect CrkL by FACS, therefore antibodies previously shown to detect CrkL via Western 
blotting were used in these experiments. The next set of experiments was performed to 
investigate if CrkL could be detected by flow cytometry, as the detection of both pCrkL and 
CrkL by FACS would allow the pCrkL/CrkL ratio to be explored in a quick, reliable and 
quantitative manner which would be ideal for clinical samples. To investigate whether CrkL 
could be detected by FACS the BCR-ABL1 positive K562 and BCR-ABL1 negative U937 
cell lines were used. The cells were fixed and permeabilised as described in section 2.6.1 and 
then labelled with either Cell Signalling Technology or Santa Cruz CrkL antibodies. FACS 
analysis revealed that CrkL could be detected in both the BCR-ABL1 positive K562 cell line 
(Figure 4.2) and the BCR-ABL1 negative cell line U937 (data not shown). This was the first 
time that CrkL detection has been demonstrated using FACS. Both antibodies detected CrkL; 
however the Santa Cruz CrkL antibody gave a better peak shift compared to the Cell 
Signalling Technology antibody (296.37 MFI and 18.8 MFI respectively). The Santa Cruz 
antibody was therefore chosen for the detection of CrkL by FACS and was used in all 
subsequent experiments.
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Figure 4.2. Comparing two CrkL antibodies
Panel A: CrkL antibody (Cell signalling) Panel B: CrkL (Santa Cruz).
A B
Control ----------- Control
CrkL (Cell SignallingTechnology) ----------- CrkL (Santa Cruz)
4.2.I.2. Saturating antibody concentration
An important part of the optimisation process was to determine the saturating concentration 
for the pCrkL and CrkL antibodies. To assess the amount of pCrkL antibody required to 
saturate the cells a range of concentrations were used from 7 - 56|ig/ml on K562 and U937 
cell lines. The saturating pCrkL antibody concentration was determined as 28pg/ml, as at 
concentrations greater than this no further increase in peak shift (MFI) was observed. This 
correlates with the concentration suggested by Hamilton et al.199 The saturating 
concentration for the CrkL antibody was investigated over a range of concentrations from 7- 
56|ig/ml. The saturating concentration was coincidentally determined to be 28pg/ml (data not 
shown).
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4.2.1.3. Triple layer FACS
Triple layer FACS techniques have been reported to enhance sensitivity by lowering the 
detection limit,293 thereby enhancing the detection of molecules present at low levels. In an 
attempt to separate further the control and test peak, comparison was made using a triple 
layer FACS technique compared to the standard dual layer method. Results (not shown), 
indicated that there was no further increase in peak shift (determined by an increase in MFI) 
using a triple layer technique as compared to that observed with the dual layer technique.
4.2.1.4. Source offluorophore
While this work was being undertaken Alexa Fluor dyes (Invitrogen) became commercially 
available. These fluorophores were marketed as being less labile, more photostable, pH- 
insensitive and with a superior fluorescence compared to more conventional fluorophores. In 
order to increase the peak shift further and hence the detection range of both pCrkL and 
CrkL, the use of Alexa Fluor fluorophores was investigated. Comparison was made between 
FITC conjugated antibody (BD) and their Alexa Fluor 488 counterparts. For the detection of 
pCrkL Alexa Fluor 488 was compared with a FITC conjugated antibody which was the 
antibody used by Hamilton et al199 for the detection of pCrkL in CD34+ cells. Figure 4.3A 
shows the results achieved with the FITC conjugated antibody, demonstrating an MFI peak 
shift of 12.41. The peak shift observed for the Alexa Fluor 488 was 85.50, which was 
superior to that observed with the conventional FITC antibody (Figure 4.3B). For the 
detection of CrkL Alexa Fluor 488 was compared to a FITC antibody. The results were 
similar to those seen for the detection of pCrkL, with Alexa Fluor 488 enhancing the 
detection of CrkL by increasing the peak shift (data not shown). As a consequence the Alexa 
Fluor antibody was used as second layer for all subsequent experiments.
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Figure 4.3. Comparison of second layer antibodies for the detection of pCrkL.
Panel A: pCrkL in K562 cells using a FITC conjugated antibody as second layer fluorophore. 
Panel B: pCrkL in K562 cells using Alexa Fluor 488 as fluorophore.
A B
4.2.1.5. Source of control antibody
The pCrkL antibody is a polyclonal antibody which detects endogenous levels of CrkL only 
when it is phosphorylated at tyrosine 207. Hamilton et al'99 used cells plus the second layer 
antibody alone as their control for measuring pCrkL. The reasoning for this is that the pCrkL 
antibody is a polyclonal antibody and unlike monoclonal antibodies, it is not possible to use a 
class matched control. An improvement on the current published methodology might be to 
use a species specific total IgG or whole rabbit serum as a control. As part of the optimisation 
process two normal rabbit IgGs (R & D Systems and Santa Cruz) and two rabbit serums 
(Sigma and Abeam, Cambridge, UK) were investigated as controls. The aim was to compare 
different controls as a way of enhancing peak separation between the control and test peaks, 
and eliminating any false positivity due to non-specific binding. The controls were used at the 
same protein concentration as the pCrkL antibody (28|ig/ml). All controls were tested on 
both the BCR-ABL1 positive (K562) and BCR-ABL1 negative cell lines (U937). The 
concentration matched normal rabbit IgG (Santa Cruz) control experiment revealed that this
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reagent binds non-specifically, since the MFI value for the control is greater than that of the 
test antibody. The normal rabbit serum (Abeam), normal rabbit serum (Sigma-Aldrich) and 
normal rabbit IgG (R&D) gave MFI peak change values of 100.98, 109.74 and 103.04 
respectively. These considerable peak shifts between the control and the pCrkL peak would 
allow a greater range of pCrkL to be detected; any of these three controls would be 
appropriate to use. Normal rabbit IgG (R&D) was selected for use in all future experiments; 
this was simply based on cost. Although Hamilton et al199 failed to use an appropriate 
control, coincidently their ‘second antibody only’ control gave similar results in the present 
experiments to the more appropriate control (normal rabbit IgG) (Figure 4.4). This suggests 
that their results are still valid; however the technique developed in this chapter is more 
appropriate, has greater sensitivity and would thus allow a greater range of pCrkL to be 
detected.
Figure 4.4. Assessment of controls
Detection of pCrkL in BCR-ABL1 positive K562 cells in comparison to two control 
strategies; using normal rabbit IgGs (purple) and cells plus second layer antibody alone 
(pink).
E i P>+ii
FL1-H
Control - Normal rabbit IgG R&D 
pCrkL
Cells plus second layerantibody
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4.2.1.6 Fresh and frozen material
All the optimisation experiments were carried out using cell lines which have been 
continually growing in culture. Primary cells from our CML biobank containing frozen MNC 
were then assessed to see whether the results obtained from cultured cell lines were 
reproducible on frozen cells. Firstly, the pCrkL and CrkL levels measured in frozen material 
did not reflect those observed in the same sample if studied when freshly isolated. Secondly, 
levels of both pCrkL and CrkL varied and were not reproducible on different aliquots of the 
same frozen sample. It was therefore decided that all patient samples should be analysed 
using freshly isolated cells. Finally, it was determined that the minimum number of cells 
required to detect both pCrkL and CrkL in this protocol is 8 x 1 O’ (data not shown).
4.2.2. Endogenous pCrkL
The BCR-ABL1 negative cell line U937 expresses low endogenous levels of pCrkL. To 
confirm that the endogenous pCrkL is not due to non-specific binding, both BCR-ABL1 
positive and negative cells were pre-incubated with rabbit serum in order to block any non­
specific binding sites. The pCrkL antibody was also pre-absorbed. The results from these 
experiments show that there is a small degree of non-specific binding but this is not 
responsible for the amount of pCrkL detected, hence confirming that endogenous pCrkL is 
present (Figure 4.5). The BCR-ABL1 positive cell lines KCL22 and K562 express high levels 
of pCrkL. It is therefore possible that CML cells express both endogenous and BCR-ABL1 
mediated pCrkL. It is plausible that the BCR-ABL1 driven pCrkL responds to BCR-ABL1 
targeted tyrosine kinase inhibitors but the endogenous pCrkL does not. The effects of TKIs 
on pCrkL will be discussed in section 4.2.6.
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Figure 4.5. Endogenous pCrkL
Panel A: U937 BCR-ABL1 negative cells and Panel B: K562 cells, were pre-incubated with 
rabbit serum to prevent any non specific binding of the pCrkL antibody. This demonstrates 
that any pCrkL detected in BCR-ABL1 negative cells is due to endogenous pCrkL and not 
due to non specific binding of the antibody.
A B
Control - Normalrabbit IgG R&D 
pCrKL
pCrKLblocked with rabbit serum
4.2.3. Detection of CrkL and pCrkL by Western Blotting
White et r//1 >7 investigated the level of pCrkL in peripheral blood samples from patients with 
CML by Western blotting. Although this method is time consuming and requires a large 
number of cells it is useful for independently confirming the FACS results. A series of 
experiments were undertaken to establish a robust method for the detection of both pCrkL 
and CrkL in order to allow confirmation of the FACS results. Initially sample loading by 
protein concentration and cell number were compared. Western blotting was performed using 
a standard protocol, using pCrkL, CrkL antibodies (Cell Signalling Technology), and CrkL 
antibody (Santa Cruz). Figure 4.6 demonstrates the presence of pCrkL in the K.562 cell line. 
pCrkL can be detected when either 1x106 cells or lOpg of protein were loaded. pCrkL could 
not be detected when 5 pg of protein was loaded. CrkL could be detected at all concentrations 
loaded.
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Figure 4.6. Western blotting demonstrating the presence of pCrkL
Western blot demonstrating the presence of pCrkL in K562 cells. Comparing loading by cell 
number to protein concentration. pCrkL cannot be detected in the sample loaded with 5pg of 
protein suggesting this concentration is too low.
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Antibody specificity was confirmed by Western blotting by performing cross-over 
experiments. Briefly, two membranes were probed with different CrkL antibodies and then 
stripped and re-probed with the alternative antibody. The results confirmed that both 
antibodies were detecting proteins at the same molecular weight (Figure 4.7A and B). The 
same results were observed when the cross over experiment was performed using the 
antibodies in reverse order. The same experiment was also performed using the pCrkL 
antibody. CrkL was immunoprecipitated using the polyclonal CrkL antibody (Santa Cruz) 
and Western blotting was performed, probing the membrane using the monoclonal CrkL 
antibody (Cell signalling technology) (Figure 4.7C).
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Figure 4.7. CrkL crossover experiment.
A: Western blot probed with monoclonal CrkL antibody (NEB). B: Membrane A stripped and 
re-probed with polyclonal CrkL antibody (Santa Cruz). C: CrkL immunoprecipitation.
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4.2.4. pCrkL in non-malignant myeloid cells
CrkL has been identified as the most phosphorylated protein in neutrophils from patients with
296CML.“ Hence it is important to determine if pCrkL can be detected in non-malignant 
myeloid cells. To achieve this, a neutrophilic blood sample was obtained (WBC 12.2 and 
neutrophils 9.2) from a patient who did not have CML. The results show that pCrkL could 
not be detected in non-malignant myeloid cells by Western blotting (Figure 4.8).
Figure 4.8. pCrkL cannot be detected in non-malignant myeloid cells.
1 2
1.K562
pCrkL
2. Non-malignant myeloid cells
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4.2.5 pCrkL levels in normal blood mononuclear cells (MNC)
To ascertain the level of pCrkL and CrkL in normal blood, five healthy volunteers donated 
20mls of peripheral blood from which MNC were collected. Western blotting and FACS 
were performed using the methodology given in section 2.6.1 and 2.7.0. No pCrkL could be 
detected in any of the five normal blood samples tested. CrkL could be detected in all 
samples (Figure 4.9A). FACS analysis demonstrated low levels of pCrkL in normal blood 
confirming that the FACS technique was more sensitive than Western blotting. FACS 
analysis of CrkL confirmed the Western blotting data with variable CrkL levels being 
detected. FACS analysis of normal samples dual labelled with pCrkL and CD3 (a lymphocyte 
marker; Figure 4.9B) demonstrated that the pCrkL signal observed was not attributable to the 
lymphocytes. CD 14 co-staining showed that the pCrkL detected in normal MNC was largely 
within the monocyte (CD 14 positive) cell population (Figure 4.9C).
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Figure 4.9. pCrkL and CrkL levels in normal blood
Panel A: Western blot showing that pCrkL cannot be detected in MNC from five normal 
blood samples. CrkL protein is variable between samples. Panel B: FACS derived dot plots 
showing pCrkL levels in normal blood. The majority of CD3+ cells are pCrkL negative. 
Panel C: Illustrates that in normal blood monocytes are pCrkL positive.
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4.2.5.1 Calculating the pCrkL/CrkL ratio
The pCrkL/CrkL ratio of a sample was determined thus:
pCrkL/CrkL ratio = pCrkL- Control x 100 
CrkL -Control
4.2.6. TKI treatment decreases the BCR-ABL1 tyrosine kinase activity.
4.2.6.1 Imatinib treatment
To assess the inhibitory effects of imatinib treatment on CrkL phosphorylation, and the 
degree to which such changes are related to effects on BCR-ABL1 tyrosine kinase activity, 
K562 cells were incubated with varying concentrations of imatinib (1,2 and 5pM) for 24 
hours. Figure 4.10A shows that following imatinib treatment the K562 cells exhibit a dose 
dependent decrease in pCrkL levels. 5pM imatinib reduces pCrkL levels to 51.4% of the 
untreated drug control, with no effects on CrkL (Figure 4.1 OB). These results were confirmed 
via Western blotting (Figure 4.10C). Following imatinib treatment cell viability was assessed 
by flow cytometry using PI, indicating that 95% of the K562 cells were still viable.
4.2.6.2 Dasatinib treatment
In order to determine the effects of dasatinib treatment on pCrkL and CrkL, K562 cells were 
cultured for 24 hours with varying concentrations of dasatinib 50, 100 and 150nM (Figure 
4.10D). The data suggest that dasatinib is more effective in suppressing CrkL 
phosphorylation compared to imatinib.
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Figure 4.10. Effects of imatinib, dasatinib and nilotinib treatment on pCrkL and 
CrkL.
Panel A, D and G: pCrkL FACS plots. Panel B, E and H: CrkL FACS plots. Panel C, F 
and I: Western blots for pCrkL and CrkL for imatinib, dasatinib and nilotinib respectively.
A
■■ Control
■ ' Untreated
““™* luMunatinib 
2uM imatinib 
5uM imatinib
D
E
— Control
----- Untreated
50nM dasatinib 
1 lOOnM dasatinib 
150nM dasatinib
H
— Control
--------- Untreated
”™“™’ IpMnilotkiib
' 2nMnik>tinib
" 5^M nilotinib
C
•c s 'C
pCrkL
CrkL
4.2.6.3 Nilotinib treatment
K562 cells were treated with nilotinib at varying concentrations (1, 2 and 5pM) and the 
results show that nilotinib decreases pCrkL levels in a dose dependent manner, similar to that 
observed with imatinib. However, Figure 4.10G suggests that nilotinib is more effective at 
reducing CrkL phosphorylation compared to imatinib (89.9% and 48.6% reduction
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respectively). Dasatinib and nilotinib have comparable effects in suppressing pCrkL and 
hence BCR-ABL1 tyrosine kinase activity.
The drug concentrations used in the dose response curves are all pharmacologically 
achievable. For future experiments, the maximum pharmacologically achievable 
concentration of each drug was used (imatinib 5|iM, dasatinib 150nM and nilotinib 5gM). 
Figure 4.11 compares the degree of BCR-ABL1 tyrosine kinase inhibition for imatinib, 
dasatinib and nilotinib by measuring changes in the pCrkL/CrkL ratio (n=9). Dasatinib and 
nilotinib both inhibit the pCrkL/CrkL ratio to virtually the same extent, with the % 
pCrkL/CrkL inhibition being 73.7% and 77.7% respectively. The pCrkL/CrkL ratio was 
inhibited by imatinib but to a lesser extent (58.8%). These results suggest that at typical 
concentrations achievable in patients, the second generation tyrosine kinase inhibitors are 
more effective than imatinib at inhibiting BCR-ABL1 tyrosine kinase activity. The 
suppression of pCrkL/CrkL ratio was statistically significant for all treatments compared to 
the untreated control (p^O.OOl).
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Figure 4.11. pCrkL/CrkL ratio decreases in K562 cells following treatment with 
TKIs
Panel A: Effects of imatinib (n=14), dasatinib (n=l 1) and nilotinib (n=10) on pCrkL, CrkL 
and pCrkL/CrkL ratio. Panel B: p values for changes in pCrkL and CrkL compared to 
untreated control.
A
400.00
Untreated 5n imatinib 150nM dasatinib 5|iM nilotinib
B
pCrkL pCrkL/CrkL ratio
Imatinib p=0.074 p=<0.001
Dasatinib p=0.015 p=<0.001
Nilotinib p=0.027 p=<0.001
160
4.2.7. Efficacy and uptake of the second generation drugs
Our group has previously shown that imatinib is actively transported into CML cells via the 
influx transporter hOCTl,165 and that the expression of hOCTl is associated with clinical 
outcome following imatinib treatment.166 To assess the efficacy and uptake of the second 
generation TKIs, their effects on BCR-ABL1 tyrosine kinase activity (pCrkL) were assessed 
by flow cytometry. The CML cell line KCL22 was selected for these experiments, since it 
expresses low basal levels of hOCTl.297 KCL22 cells were transfected with hOCTl to give a 
high hOCTl cell line; mock transfected KCL22 were used as a control. These were produced 
by Dr Athina Giannoudis in our laboratory.
Dasatinib produced a significant decrease in pCrkL expression for both cell lines, with a 
reduction of pCrkL to 49.9% (p=0.011) in mock-transfected KCL22 cells and 40.3% 
(p=0.003) in high hOCTl-expressing cells, both in relation to untreated cells. Nilotinib also 
produced a significant decrease in pCrkL in both the hOCTl high expressing and mock 
transfected cell lines (to 36.81% (p=0.001) and 37.35% (p=0.001) respectively; Figure 4.12). 
In contrast, imatinib reduced pCrkL to 39.7% of the control in high hOCTl-expressing cells 
(p=0.001), with no significant effect in mock-transfected cells. Comparison of hOCTl and 
mock-transfected cells showed that the degree of pCrkL suppression by imatinib was greater 
in high hOCTl-expressing cells than in mock-transfected cells (p=0.03). These data are 
consistent with the view that hOCTl transport is more important for imatinib than dasatinib 
or nilotinib.147’298
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Figure 4.12. Effect of imatinib, dasatinib and nilotinib on BCR-ABL1 function.
Effect of imatinib, dasatinib and nilotinib on pCrkL levels in mock-transfected KCL22 cells 
(blue bars) and KCL22 cells with high hOCTl expression (red bars). Data are expressed as 
relative to untreated cells.
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4.3.0. pCrkL, CrkL and pCrkL/CrkL ratio in CML patients
Having optimised and validated the pCrkL/CrkL assay as in sections 4.2.1 to 4.2.7, this was 
applied to investigate if the pCrkL/CrkL ratio at diagnosis was predictive of a patient’s 
clinical response to imatinib treatment.
4.3.1. pCrkL, CrkL and pCrkL/CrkL ratio at diagnosis and clinical outcome.
The 20 patients included in this study were all newly diagnosed chronic phase CML patients 
being treated at the Royal Liverpool University Hospital. All were 18 or more years of age at 
diagnosis, and were followed-up for a minimum of twelve months. Fourteen patients received 
imatinib 400mg daily and six patients received nilotinib 400mg daily as first line treatment. 
Patient characteristics are shown in Table 4.1.
Table 4.1. Summary of patients' characteristics
Total Imatinib treated Nilotinib treated
Number of patients 20 14 6
Age in years (range) 48 (19-72) 46(19-72) 54 (44-67)
Sex (M/F) 9/11 7/7 2/4
Sokalscore High 8 5 3
Intermediate 6 3 3
Low 6 6 0
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MNC were analysed by flow cytometry for levels of pCrkL, CrkL and the pCrkL/CrkL ratio 
at diagnosis prior to receiving any treatment. Figure 4.13 shows representative FACS plots 
for pCrkL and CrkL pre and post in vitro imatinib treatment. These data show a suppression 
of BCR-ABL1 tyrosine kinase activity (pCrkL MFI) with only small changes in CrkL MFI.
Figure 4.13. Optimisation of pCrkL and CrkL detection in MNC by flow cytometry.
Representative FACS plot showing pCrkL (upper plot) and CrkL (lower plot) in a newly 
diagnosed CML patient and changes following in vitro treatment with 5pM imatinib for 24 
hours
pCrkL
Control
pCrkL untreated 
pCrkL 5uM Imatinib
Control
CrkL untreated
CrkLSuM Imatinib
pCrkL and the pCrkL/CrkL ratio were assessed at diagnosis prior to any treatment, and were 
then stratified by the patients’ clinical outcome after 12 months of imatinib treatment (Figure 
4.14). Levels of pCrkL alone (Figure 4.14A) do not correlate with clinical outcome, while the 
pCrkL/CrkL ratio assessed at diagnosis strongly correlates with the achievement of CCRe at 
12 months (p^O.0003). Patients with a pCrkL/CrkL MFI ratio less than 25 prior to 
commencing treatment have a 75% chance of achieving a CCRe following 6 months of 
imatinib treatment, increasing to 100% at 12 months of imatinib treatment. In contrast, no
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patient with a pCrkL/CrkL MFI ratio greater than 25 achieved a CCRe following 12 months 
of imatinib treatment (Figure 4.14B).
Figure 4.14. pCrkL/CrkL ratio assessed at diagnosis predicts a cytogenetic 
response.
Panel A: FACS assessment of pCrkL and Panel B: pCrkL/CrkL ratio in untreated newly 
diagnosed CML patients, stratified by clinical outcome following 12 months of imatinib 
treatment (n=14).
A pCrkL g pCrkL/CrkL
p=0.0003
Clinical outcome Clinical outcomo
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Figure 4.15. Clinical outcomes of patients in the pCrkL/CrkL study.
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Six out of 14 imatinib treated patients investigated in this study failed to achieve a CCRe 
following 12 months of treatment, of whom two patients progressed to advanced phase 
disease. The clinical outcome of each patient is shown in Figure 4.15. Four of the six patients 
in the No-CCRe group switched to nilotinib treatment and three of these subsequently 
achieved a MMR or CMR. The single patient who failed to achieve a CCRe following 
nilotinib treatment also failed to achieve a response with dasatinib or chemotherapy and 
rapidly progressed into blast crisis which was fatal. The remaining two patients within the 
No-CCRe group continued on imatinib treatment but with dose modifications, and both 
subsequently achieved a MMR. No BCR-ABL1 kinase domain mutations were detected in 
these patients. The remaining eight patients, with a diagnostic pCrkL/CrkL ratio below 25 
and a minimum follow-up of four years, all continue to respond well to treatment (one CCRe, 
three MMR and four CMR).
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All patients with high pCrkL/CrkL ratios failed to achieve a CCRe following imatinib 
treatment, but following second line treatment with nilotinib, 75% of these went on to 
achieve a MMR or CMR. This suggests that the pCrkL/CrkL ratio in newly diagnosed 
chronic phase patients receiving nilotinib as first-line therapy. All six such patients treated 
with nilotinib achieved a CCRe (n=3) or MMR (n=3) following 12 months of treatment. With 
a minimum follow up of 30 months, 83% of patients have achieved a CMR. It is therefore not 
possible to show a comparison box-whisker plot for pCrkL and pCrkL/CrkL ratio for these 
patients since no patient failed nilotinib. Table 4.2 addresses this omission by tabulating the 
pCrkL/CrkL ratio for all patients in the study.
Table 4.2 pCrkL/CrkL ratios for imatinib and nilotinib treated patients.
pCrkL/CrkL ratios for imatinib and nilotinib treated patients along with their clinical outcome 
at 12 months. Patients with an MFI below 25 will all respond to imatinib treatment.
TK.I treatment pCrkL/CrkL ratio CCRe at 12 months
Imatinib 4.13 Yes
Imatinib 6.05 Yes
Imatinib 7.01 Yes
Imatinib 11.67 Yes
Imatinib 14.77 Yes
Imatinib 16.19 Yes
Imatinib 24.5 Yes
Imatinib 24.74 Yes
Imatinib 26.68 No
Imatinib 29.13 No
Imatinib 35.29 No
Imatinib 39.57 No
Imatinib 48.62 No
Imatinib 65.70 No
Nilotinib 7.49 Yes
Nilotinib 12.31 Yes
Nilotinib 13.78 Yes
Nilotinib 18.71 Yes
Nilotinib 34.72 Yes
Nilotinib 47.3 Yes
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Patients with a pCrkL/CrkL ratio greater than 25 who were treated with nilotinib achieved a 
CCRe compared to 0% of imatinib treated patients (p=0.03). This is most likely due to 
nilotinib being a more potent BCR-ABL1 tyrosine kinase inhibitor.299
Analysis of time to achieve a CCRe for imatinib and nilotinib treated patients stratified by 
pCrkL/CrkL ratio at diagnosis is shown in Figure 4.16. 100% of patients treated w ith imatinib 
and a pCrkL/CrkL ratio less than 25 achieved a CCRe, compared to 0% of patients with a 
pCrkL/CrkL ratio greater than 25. Irrespective of the pCrkL/CrkL ratio at diagnosis all 
nilotinib treated patients achieved a CCRe, although patients with a higher pCrkL/CrkL ratio 
took slightly longer to achieve a CCRe.
Figure 4.16. Time to achieve a CCRe
Kaplan-Meier estimate of time to achieve a CCRe for both imatinib (panel A) and nilotinib 
patients (panel B), stratified by pCrkL/CrkL ratio at diagnosis.
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4.3.2. Measurement of pCrkL/CrkL ratio following in vitro treatment with 
imatinib
An assay was developed using MNC derived from untreated patients, to assess whether the in 
vitro effects of imatinib on BCR-ABL1 tyrosine kinase activity (pCrkL/CrkL ratio) were 
predictive of clinical outcome following in vivo imatinib treatment (Figure 4.17A). Following 
24 hours of treatment with 5pM imatinib, samples from patients destined to achieve CCRe 
following 12 months of imatinib treatment had a similar pCrkL/CrkL ratio to those who 
failed to achieve a CCRe (p=0.491). These data demonstrate that an in vitro imatinib assay 
performed using freshly isolated MNCs does not reliably predict patients’ clinical outcome.
Figure 4.17. Measurement of pCrkL/CrkL ratio following in vitro imatinib 
treatment and serial monitoring of pCrkL/CrkL ratio
Panel A: pCrkL/CrkL ratio in MNC from 14 newly diagnosed patients following treatment 
with 5|iM imatinib for 24 hours, stratified by clinical outcome following 12 months of 
imatinib treatment. Panel B, C and D: serial monitoring of the pCrkL/CrkL ratio in samples 
(n=12) following 1, 3, and 6 months of imatinib treatment.
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4.3.3. Serial monitoring of pCrkL/CrkL ratio following treatment with imatinib 
Levels of pCrkL and CrkL were evaluated at 1, 3 and 6 months following commencement of 
imatinib treatment, using freshly isolated MNC at each time point. Although levels of both 
pCrkL and CrkL varied with time following treatment, these did not correlate with clinical 
outcome, thus the prognostic significance of the pCrkL/CrkL ratio is lost once treatment is 
initiated (Figure 4.17 B, C and D). These data suggest that measuring the pCrkL/CrkL at 
diagnosis is the critical time point for predicting which patients are likely to achieve a CCRe.
4.3.4 Tyrosine phosphorylation and clinical outcome
After developing the pCrkL/CrkL FACS assay, an ELISA method for the detection of 
phosphorylated tyrosine activity was published and the authors suggested that the results 
were comparable to their pCrkL FACS and Western blotting techniques.294 This alternative 
method was tested initially using K562 cells. K562 cells were incubated for 24 hours with 
various TKls at clinically achievable concentrations. These results show that following 
treatment with imatinib, dasatinib and nilotinib, phosphorylated tyrosine (p-Tyr) levels 
decreased (Figure 4.18A). Diagnostic samples from CP CML patients were then analysed and 
stratified by clinical outcome following 12 months of treatment. Figure 4.18B demonstrates 
that levels of p-Tyr at diagnosis of CML are not statistically significant between CCRe and 
No-CCRe groups. No correlation was observed between the pCrkL/CrkL ratio and p-Tyr 
levels assessed at diagnosis (Figure 4.18C).
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Figure 4.18. Total tyrosine phosphorylation ELISA.
Panel A: Assessment of phosphorylated tyrosine activity in K562 cells treated with imatinib, 
dasatinib and nilotinib. Panel B: Total tyrosine phosphorylation in CML MNC at diagnosis, 
stratified by the clinical outcome at 12 months (n=14). Panel C: No correlation was observed 
between pCrkL/CrkL ratio assessed by FACS and total tyrosine phosphorylation assessed by 
an ELISA in MNC at diagnosis.
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4.3.5 Total BCR-ABL1 protein.
As discussed, it is difficult to assess the total amount of BCR-ABL1 protein in primary cells 
by conventional techniques such as Western blotting. Demonstrating BCR-ABL1 protein has 
been technically difficult up to now because of BCR-ABL1 protein instability,189 and the lack 
of a specific antibody that can reliably distinguish BCR-ABL1 protein from its normal ABL1 
counterpart. The BCR-ABL1 Protein kit (BD) has been developed to detect all frequently 
occurring BCR-ABL1 fusion variants in human blood, including pi90, p210 and p230. The 
kit uses an antibody recognising BCR attached to a capture bead and an ABL1-directed 
phycoerythrin (PE)-conjugated detection antibody. The presence of BCR-ABL1 protein 
results in a sandwich complex comprising of both the capture bead and the detection 
fluorophore, detectable by flow cytometry. The design of the capture and detection antibodies 
permits the detection of all BCR-ABL1 variants. Total BCR-ABL1 protein was assessed 
using the BD BCR-ABL1 protein kit.300 No difference was observed between the diagnostic 
BCR-ABL1 protein level and response to imatinib treatment. These data suggest that it is the 
BCR-ABL1 tyrosine kinase activity, and not the total amount of BCR-ABL1 protein which 
influences a patient’s response (Figure 4.19).
Figure 4.19. Total BCR-ABL1 protein.
Total BCR-ABL1 protein in untreated newly diagnosed CML patients, stratified by clinical 
outcome following 12 months of imatinib treatment (n=41)
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4.3.6 CrkL mRNA expression.
CrkL mRNA gene expression was assessed at diagnosis and following 12 months of imatinib 
treatment. The data are normalised to a normal pool obtained from healthy volunteers. No 
difference in CrkL gene expression was observed at diagnosis or at 12 months for CCRe or 
No-CCRe patients (Figure 4.20). These data suggest that measuring CrkL mRNA expression 
offers no prognostic value.
Figure 4.20. CrkL mRNA expression
CrkL mRNA expression was assessed at diagnosis and following 12 months of imatinib 
treatment, stratified by the eventual clinical outcome.
Normal
Diagnosis 12 months Diagnosis 12 months
CCRe NoCCRe
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4.3.7. Relationship between the pCrkL/CrkL ratio and other prognostic 
parameters
Figure 4.21 A demonstrates that there is no correlation between the pCrkL/CrkL ratio and 
hOCTl expression in imatinib treated patients (n=8). hOCTl gene expression was not 
assessed for nilotinib treated patients since hOCTl is not an influx transporter for nilotinib.298 
Figure 4.21 B and D show that there is no correlation between the pCrkL/CrkL ratio and 
white blood count (WBC) at diagnosis. Figure 4.21C and E show that there is no correlation 
between Sokal score301 and the pCrkL/CrkL ratio thus suggesting the pCrkL/CrkL ratio is an 
independent prognostic biomarker.
Figure 4.21. The pCrkL/CrkL ratio and other clinical parameters
Correlation between the pCrkL/CrkL ratio at diagnosis and A) hOCTl mRNA level. B) white 
blood count (WBC) at diagnosis C) Sokal score for imatinib treated patients. Lower panels 
show correlation between the pCrkL/CrkL ratio at diagnosis and D) WBC at diagnosis E) 
Sokal score for nilotinib treated patients.
pCrkL/CrkL ratio pCrkL/CrkL ratio pCrkL/CrkL ratio
pCrkL/CrkL ratio pCrkl/Crkl ratio
174
4.4.0. DISCUSSION
A considerable amount ot time and effort was involved in the optimisation and validation of 
the pCrkL and CrkL FACS assays. The resultant pCrkL/CrkL assay is now a quick and 
simple assay which is both robust and accurate. Its potential applications within both the 
clinical and research fields are vast. To date it has been used independently and to support six 
publications from our research group.94,147,298’302'304
Imatinib is a tyrosine kinase inhibitor which has become the treatment of choice for newly 
diagnosed patients in chronic phase CML. In chapter three I have shown that in a population 
based study'1 by 24 months 49% of patients will fail imatinib treatment; similar findings were 
recently reported in two single centre studies.287290 This suggests that the identification of 
prognostic markers predictive of treatment response may be useful in order to avoid delay in 
offering alternative treatment such as a second generation TKI or SCT.
In this chapter I have developed a novel FACS based assay for the detection of both pCrkL 
and CrkL. Within this study it has been shown that measurement of the pCrkL/CrkL ratio at 
diagnosis by FACS is predictive of achievement of a CCRe following 12 months of imatinib 
treatment. 100% of patients with an MFI of less than 25 achieved a CCRe (p=0.003). 
Additionally, the pCrkL/CrkL ratio is not only predictive of clinical outcome at 12 months 
but also CCRe at six months, achieved in 75% of patients with an MFI of less than 25. All 
patients who achieved a CCRe remained in CCRe or have a deeper response such as MMR or 
CMR with a minimum follow-up of four years. No patient with an MFI above 25 achieved a 
CCRe following imatinib treatment; all subsequently required alterations in therapy which 
were either dose escalation or switching to an alternative TKI. No BCR-ABL1 domain
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mutations were detected. Furthermore, serial monitoring of pCrkL, CrkL and the pCrkL/CrkL 
ratio following commencement of imatinib treatment was found not to be predictive of long 
term outcome. All patients treated with nilotinib at initial diagnosis all achieved a CCRe or 
MMR irrespective of their pCrkL/CrkL ratio suggesting that since nilotinib is a more potent 
TKI than imatinib it is therefore able to suppress higher tyrosine kinase activity to a greater 
extent.
Khorashad et o/203 reported that measurement of pCrkL levels alone by FACS did not 
correlate with clinical outcome.203 The authors suggest a number of reasons for this 
discrepancy including sample sizes, imatinib affecting different cell populations to varying 
degrees and resistance being due to pathways independent of BCR-ABL1 kinase activity. In 
this study, measuring pCrkL in isolation either at diagnosis or following in vitro imatinib 
treatment supports their findings. Moreover, in the early stages of the optimisation process it 
became apparent that pCrkL and CrkL levels obtained from frozen MNC were not 
reproducible or reliable, and differed from those obtained from fresh cells, therefore all data 
presented here were obtained using freshly isolated MNC. The decision to use only freshly 
isolated cells slowed down this project considerably, firstly because it meant that it would not 
be possible to used samples stored in the CML biobank and secondly because samples had to 
be analysed at diagnosis and then the patient had to receive a minimum of 12 months of 
treatment before the data could be stratified for clinical response.
No correlation was observed between the pCrkL/CrkL ratio and presenting WBC, Sokal 
score or hOCTl mRNA expression levels. This suggests that the pCrkL/CrkL ratio is an 
independent biomarker of clinical outcome. It is interesting to speculate that the response to
176
imatinib therapy is related to BCR-ABL1 tyrosine kinase activity present at diagnosis. A 
given dose of imatinib may therefore suppress the lower kinase activity to a greater 
proportional extent than the higher kinase levels in patients with an MFI above 25. This may 
explain the higher incidence of response following treatment with imatinib in the low 
pCrkL/CrkL group of patients. During this study six additional patients commenced nilotinib 
treatment at initial diagnosis. The pCrkL/CrkL MFI ratios ranged from 7.5 to 47.3. 
Following 12 months of treatment all achieved a CCR or MMR. These data suggest that 
patients with high BCR-ABL1 tyrosine kinase activity (pCrkL/CrkL MFI ratio >25) have a 
low probability of responding to imatinib, but may nevertheless achieve a CCR on nilotinib 
treatment.
In conclusion, the pCrkL/CrkL ratio prior to commencement of treatment is a potent predictor 
of clinical outcome in patients treated with imatinib. Its role as a predictive biomarker of 
response to TKI therapy merits further investigation in larger series, though it is essential that 
this is performed on freshly isolated cells prior to any treatment.
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CHAPTER FIVE - Chronic myeloid leukaemia 
patients with the el3a2 bcr-abll fusion 
transcript have inferior responses to imatinib
than e!4a2 patients
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5.1.0 INTRODUCTION
CML is characterised by a reciprocal translocation between chromosomes 9 and 22, which 
creates the fusion gene BCR-ABL1. Different types of BCR-ABL1 transcript can be detected 
due to differences in the breakpoint. el3a2 and el4a2 are the most frequent BCR-ABL1 
transcript types in CML. The e!3a2 and el4a2 BCR-ABL1 transcript types differ in length by 
75bp (25 amino acids). Both BCR-ABL1 mRNA molecules encode a 210kDa constitutively 
active protein kinase which is central to the pathogenesis of the disease as discussed in the 
general introduction section I.3.3.47
Previous reports prior to the introduction of imatinib have in general not identified an effect 
of BCR-ABL1 transcript type on clinical outcome.^4'60 In the imatinib era, one small study of 
22 patients at different phases of disease suggested that the el3a2 BCR-ABL1 transcript type 
may be more sensitive to imatinib treatment;61 while a larger study has indicated that patients 
with e!4a2 have a better molecular response to imatinib.62 The clinical significance of the 
BCR-ABL1 transcript type in newly diagnosed chronic phase CML patients treated with 
imatinib remains uncertain. In this chapter I assess if BCR-ABL1 transcript type correlates 
with the clinical outcome by investigating the clinical outcome of 79 newly diagnosed 
patients with chronic phase CML treated with imatinib 400mg.
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5.2.0 PATIENT COHORT
All patients (n=79) aged 16 or over with chronic phase CML newly diagnosed between 
January 1st 2003 and October 31st 2007 receiving imatinib 400mg daily from original 
diagnosis (preceded only by up to six weeks of hydroxycarbamide) and with a minimum of 
12 months follow up were included in this study. The 71 patients who presented with either 
the el3a2 or el4a2 BCR-ABL1 transcript type are the subject of the main investigation; 
patients presenting with both el3a2 and el4a2 transcript are discussed separately (three 
cases). Patients expressing rare transcript types were excluded from the main study (five 
cases; two cases of el9a2, and one case each of e6a2, el3a3, and el4a3 transcript) and will 
be discussed separately in detail on a case by case basis at the end of this chapter, leaving 71 
cases expressing either el3a2 or el4a2 BCR-ABL1 transcript types. Of these 32 presented 
with the BCR-ABL1 transcript type e!3a2 and 39 presented with the el4a2 transcript type. 
Age, sex and Sokal score of all analysed cases are presented in Table 5.1.
Table 5.1. Patient characteristics and response rates.
All patients e!3a2 e!4a2
Number of patients 71 32 39
Age (years) 50(19-81) 48 (19-75) 51 (19-81)
Sex (M/F) 36/35 19/13 17/22
Sokal score High 21 9 12
Intermediate 14 5 9
Low 15 6 9
No data 21 12 9
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5.3.0 RESULTS
5.3.1. Patients expressing el3a2 have inferior responses to imatinib than el4a2 
patients.
Following 12 months of imatinib treatment, 25% of patients with the el3a2 transcript 
achieved a CCRe compared to 54% of el4a2 patients (p=0.01, Table 5.2). At 18 and 24 
months the el3a2 patients continue to achieve lower rates of CCRe compared to el4a2 
patients. Kaplan-Meier analysis of time to achieve CCRe revealed that the patients with the 
el4a2 transcript type demonstrated more rapid response rates compared to el3a2 patients 
(Figure 5.1 A), which continues throughout treatment (p=0.006).
Table 5.2. Patients response rates
CCRe rates for both el3a2 and el4a2 BCR-ABL1 transcript types at 12, 18 and 24 months*
12 months 18 months 24 months
Total CCRe % of total Total CCRe % of total Total CCRe % of total
patients patients patients patients patients patients
achieving achieving achieving
CCRe CCRe CCRe
Transcript
c!3a2 32 8 25.0 23 8 34.8 23 9 39.1
type e!4a2 39 21 53.8 32 18 56.3 26 15 57.7
*At 18 months nine cases of el3a2 and seven cases of e!4a2 are excluded from analysis as 
not yet having received 18 months of imatinib treatment. At 24 months six cases of e!4a2 are 
excluded for the same reason.
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Figure 5.1. Kaplan-Meier estimates of time to achieve CCRe, overall survival and 
event free survival.
Panel A: Kaplan-Meier estimate of time to achieve CCRe for el4a2 and el3a2 BCR-ABL1 
transcript type. (p=0.006). Panel B: Overall survival Panel C: Event-free survival, stratified 
by BCR-ABL1 transcript type. No statistically significant differences were observed (SPSS 
statistical package-Mantel-Cox log-rank test).
A
- el4a2 
■ el3a2
B
8
c
Patients with the el4a2 transcript type demonstrated a non-significant trend toward superior
EFS in the first 12 months of treatment, though overall survival did not differ significantly
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between the transcript types (Figure 5.1 B and C). This trend is consistent with the finding 
that more el3a2 cases progress in the first 12 months of treatment; eight el3a2 cases failed 
imatinib treatment (seven due to disease progression and one case was intolerance), while 
only three el4a2 cases failed (two disease progression and one intolerance ). The Sokal score 
was not predictive of clinical outcome nor did it differ according to transcript type (Table 
5.1). Of interest five additional cases (outside this study) who presented with blast crisis 
CML during the period of study all expressed the el3a2 transcript type.
Three patients presented with both el3a2 and el4a2 BCR-ABL1 transcript types at diagnosis. 
Following 12 months of treatment, two achieved a CCRe, though by 24 months one of the 
cases subsequently lost their CCRe. The patient who failed to achieve a CCRe following 
imatinib treatment was switched to an alternative TKI but again failed to achieve a CCRe. 
Given the limited number of cases in this group it is not possible to form any definitive 
conclusion.
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5.3.2 No correlation between BCR-ABL1 transcript type and the imatinib 
transporter hOCTl.
Imatinib uptake into CML cells is dependent on the uptake transporter hOCTl.165 To 
establish why these two transcript types respond differently to imatinib treatment we 
determined hOCTl mRNA levels in all patients for whom suitable material was available 
(n=51). No relationship was seen between transcript type and hOCTl mRNA levels. The 
degree of imatinib uptake between the two transcript types was not statistically significant, 
although there was a trend for hOCTl expression in el4a2 patients (Figure 5.2). (hOCTl and 
ABCB1 mRNA expression studies were carried out by Dr Athina Giannoudis)
Figure 5.2. hOCTl mRNA for el3a2 and el4a2 patients.
hOCTl mRNA expression level was measured pre-treatment in 51 newly diagnosed CP CML 
patients. This demonstrates that el3a2 and el4a2 patients have similar levels of hOCTl.
BCR-ABL1 transcript type
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The expression of the imatinib efflux transporter ABCB1 (MDR1) was assessed in all 
patients for whom suitable material was available (n=47). No correlation was observed 
between ABCB1 gene expression and BCR-ABL1 transcript type (Figure 5.3). In summary, 
these data demonstrate that patients with the el3a2 transcript have an inferior response to 
imatinib treatment and that this was not related to different hOCTl and /or ABCB1 gene 
expression.
Figure 5.3. ABCB1 mRNA for e!3a2 and el4a2 patients.
ABCB1 mRNA expression level was measured pre-treatment in 47 newly diagnosed CP 
CML patients. el3a2 and el4a2 patients have similar levels of ABCB1. ABCB1 expression is 
presented relative to a normal pool, which is shown as one on the graph below.
e13a2
BCR-ABL1 transcript typ*
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5.3.3 el3a2 transcript type patients have higher BCR-ABL1 kinase activity.
The pCrkL/CrkL ratio is a known surrogate marker for BCR-ABL1 tyrosine kinase 
activity. To further investigate why these two transcript types respond differently to 
imatinib treatment the diagnostic pCrkL/CrkL ratio was determined in all patients for whom 
suitable material was available (n=28). These data demonstrate that samples from el3a2 
patients have higher pCrkL/CrkL ratio than those from e!4a2 patients (p=0.017), 
demonstrating higher tyrosine kinase activity (Figure 5.4). Since imatinib is a tyrosine kinase 
inhibitor, these data suggest that imatinib is only able to modestly suppress tyrosine kinase 
activity. Further supporting evidence was presented in chapter four, in which patients with a 
high diagnostic pCrkL/CrkL ratio failed to achieve a CCRe while on imatinib treatment, but 
when switched to the more potent TKI nilotinib, almost all achieved MMR. Moreover, newly 
diagnosed CP patients treated with nilotinib all achieve a CCRe irrespective of the diagnostic 
tyrosine kinase activity or BCR-ABL1 transcript type.
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Figure 5.4. pCrkL/CrkL ratio for e!3a2 and el4a2 patients
The pCrkL/CrkL ratio was measured pre-treatment in 28 newly diagnosed CP CML patients 
as a surrogate marker for BCR-ABL1 tyrosine kinase activity. This illustrates that el3a2 
patients have a higher pCrkL/CrkL ratio than el4a2 patients (p=0.017).
BCR-ABL1 transcript typ*
5.3.4 Does the total amount of BCR-ABL1 protein differ according to transcript 
type?
As discussed in Chapter four, it is difficult to assess the total amount of BCR-ABLl protein 
in primary cells by conventional techniques such as Western blotting. Demonstrating BCR- 
ABLl protein has been technically difficult up to now because of BCR-ABLl protein 
instability,l8) and the lack of a specific antibody that can reliably distinguish BCR-ABLl 
protein from its normal ABLl counterpart. The BCR-ABLl Protein kit (BD) has been 
developed to detect all frequently occurring BCR-ABLl fusion variants in human blood, 
including pl90, p2l0 and p230.300 Utilising this kit, the total amount of BCR-ABLl protein 
was assessed, to see if it differed between BCR-ABLl transcript types (Figure 5.5). There
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was no difference in the total amount of BCR-ABL1 protein between the two BCR-ABL1 
transcript types tested.
Figure 5.5. Analysing BCR-ABL1 protein in different BCR-ABL1 transcript types.
Level of BCR-ABL1 protein stratified by BCR-ABL1 transcript type, el3a2 (n=26) and 
el4a2 (n=34).
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5.3.5 The kinetics of response is not different between the two transcript types. 
Previous work by our group has suggested that patients who have an early molecular 
response (defined as a BCR-ABL1 ratio below 10% at three months) have a significantly 
higher chance of achieving a CCRe and a better progression free survival.163 It is therefore 
plausible that early changes in BCR-ABL1 ratio may be related to BCR-ABL1 transcript 
type. Figure 5.6 shows that there is no significant difference in the kinetics of response 
between the two transcript types (p=0.073).
Figure 5.6. Early changes in BCR-ABL1 mRNA and BCR-ABL1 transcript type.
Changes in the BCR-ABL1 ratio between diagnosis and following three months of imatinib 
treatment according to BCR-ABL1 transcript type. No statistically significant difference was 
observed (p=0.073). Analysis was performed on all patients where a diagnostic and three 
month sample was available (n=51).
el3a2 el4a2
“ 50
y 25
Diagnosis 3 months 3 monthsDiagnosis
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5.3.6 Variant BCR-ABL1 transcripts and clinical outcome.
The above data investigating the effects of BCR-ABL1 transcript type on clinical outcome 
have demonstrated that patients expressing the el4a2 BCR-ABL1 transcript type respond 
better to imatinib. “ However, not surprisingly due to their rarity, few data are available on 
rare/variant transcripts types and their response to imatinib treatment. This section will focus 
on five patients with rare BCR-ABL1 transcript types and their response to imatinib. None of 
the five patients described achieved a sustained CCRe on imatinib, and four died within 20 
months of starting imatinib. Patient characteristics are displayed in Table 5.3.
Table 5.3. Variant transcript type patient characteristics.
Patient Age
/Sex
BCR-
ABL1
transcript
type
CML 
phase at 
diagnosis
First line 
therapy
Duration
of
imatinib
treatment
(months)
Achievement 
of CCRe
Clinical outcome Overall
sunival
1 61/M cl9a2 Chronic 1FN 7 No Blast crisis Died
2 52/F el9a2 Accelerated IFN 48 No Blast crisis Died
3 65/M e6a2 Blast crisis imatinib 1.5 No No response Died
4 57/F el3a3 Chronic imatinib 18 Transient Extramedullary relapse 
and T315I mutation
Died
5 59/M e!4a3 Chronic imatinib 8 No Switched to dastinib 
and currently in CMR
Alive
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The el9a2 BCR-ABL1 transcript type has been suggested to correlate with a more aggressive, 
unfavourable prognosis305 and cytogenetic relapse has been reported when treated with 
imatinib, although another single case report suggested that el9a2 patients may exhibit a 
clinical course similar to typical CML.306:307 Two patients presented here expressing el9a2 
did not achieve a CCRe or a durable response while on imatinib.
The e6a2 BCR-ABL1 transcript type has been reported to correlate with more aggressive 
disease and to be unresponsive to imatinib,308 which is consistent with the findings here.
Reports of CML involving ABL1 exon a3 instead of exon a2 fusing to BCR are rare. el3a3 
has been reported to confer a more aggressive disease course309 while others have reported 
that it responds well to imatinib.310 Conversely there are currently no data about the el4a3 
BCR-ABL1 transcript type and its response to imatinib therapy.
In general, data about rare BCR-ABL1 transcripts are sparse and mainly limited to single 
case reports. Attempts were made to investigate rare/variant transcript types from other UK 
institutions; however due to the rarity of these cases, there was a lack of samples with clinical 
data attached, making a large scale study not feasible.
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5.4.0 DISCUSSION
In the pre-imatinib era, numerous studies addressed the significance of the BCR-ABL1 
transcript type on CML, with conflicting results. The disparity can be explained by 
differences in sample size, sample selection, treatment and racial differences, as well as 
differences in statistical analysis.5^ Confusion can arise because some studies pooled el3a2 
and el4a2 transcript types as 5’ breakpoints; which were then compared to 3’ breakpoints. 
These 3’ breakpoints include ela2 fusion transcripts that encode a pi90 protein, which is 
associated with acute lymphoblastic leukaemia which has a poorer outcome than classical 
chronic phases CML. In general no difference in outcome of CP CML has been found in the 
pre-imatinib era between el3a2 and el4a2. However, surprisingly little data are available on 
the effects of these transcripts on response to imatinib treatment. This chapter has focused on 
comparisons between the el3a2 and el4a2 BCR-ABL1 transcript types.
Studies in the pre-imatinib era suggest that the el3a2 junction may be more prevalent in 
men, though not necessarily in all ethnic groups, and is associated with blast crisis of 
myeloid phenotype.^ The el4a2 transcript type has been correlated with a higher platelet 
count both in adults56’58 and children.31 “ Additionally it has been associated with a longer 
chronic phase and survival, possibly related to the less aggressive course of chronic phase in 
this transcript type.31^ Furthermore, the el4a2 transcript type demonstrates a higher level of 
5’ ABL1 deletions as an additional chromosomal abnormality, when compared to el3a2 
patients.'^ Other reports found no correlations with the above, or with any other clinical or 
haematological parameters.111313'315
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Overall, data from the pre-imatinib era suggest that transcript type has no influence on 
clinical outcome.54'60 However, only two series have addressed the effect of transcript type on 
the clinical outcome of imatinib treatment. One small study of 22 patients in Brazil with 
variable disease status reported a significant difference in response to treatment at six months 
(p=0.03), with el3a2 responding better than el4a2 patients.61 A much larger study of 251 
patients in CP treated with imatinib concluded that patients with el4a2 had a higher 
probability of achieving a major molecular response, and had a greater reduction in overall 
transcript levels in response to imatinib than el3a2 patients.62 In spite of these interesting 
findings the authors offered no explanation as to why these transcript types respond 
differently to imatinib. Clearly the influence of transcript type on outcome following imatinib 
treatment warranted further investigation.
These data presented within this chapter support the view that patients with the el4a2 
transcript may respond better to imatinib 400mg daily. Following 12 months of imatinib 
el4a2 patients not only achieve significantly higher CCRe rates than el3a2 patients but also 
achieve their CCRe at a faster rate. This was not related to the patients age, sex or Sokal score 
(which takes into consideration standard haematological parameters).155 Additionally hOCTl 
or ABCB1 mRNA expression did not differ between el3a2 and el4a2 patients; thus the 
degree of imatinib uptake and efflux between the two transcript types is similar and does not 
account for the differences in clinical responses observed. The reason for the difference in 
response to imatinib therapy observed therefore appears to be unrelated to differences in 
imatinib transport between transcript types. It is likely however that the effect is due to 
differences in the drug target. Using the pCrkL/CrkL ratio as an assessment of BCR-ABL1 
tyrosine kinase activity, 1 el3a2 transcript type patients have a higher activity compared
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to e!4a2. A fixed dose of imatinib may therefore suppress the lower kinase activity in el4a2 
patients to a greater proportional extent than the higher kinase levels in el3a2 patients. This 
may explain the higher incidence of CCRe following treatment with imatinib in el4a2 
patients.
With respect to patients with variant BCR-ABL1 transcript types, all patients failed to achieve 
a sustained CCRe on imatinib therapy, which is consistent with other similar reports. Four out 
of five patients reported in this study were diagnosed at a time when second generation 
tyrosine kinase inhibitors were not available at our institution. After failing imatinib 
treatment the patient expressing the el4a3 BCR-ABL1 transcript type was switched to 
dasatinib and within six months had achieved a CCRe and MMR; she currently remains in 
CMR.
In this chapter I have shown that patients with el4a2 have lower intrinsic BCR-ABL1 
tyrosine kinase activity at diagnosis and hence respond well to imatinib, while el3a2 patients 
with a higher BCR-ABL1 tyrosine kinase activity respond poorly. It is possible that the BCR- 
ABL1 tyrosine kinase activity in variant BCR-ABL1 transcripts is high thus resulting in a 
poor response to imatinib and a high incidence of disease progression; this hypothesis is 
supported by the data from the el4a3 patient who failed imatinib treatment but remains well 
on dasatinib (a more potent tyrosine kinase inhibitor). Alternatively varying breakpoints 
might change the tertiary structure of the BCR-ABL1 fusion protein which may alter protein: 
drug interactions.
194
Following the publication of the data of this chapter,302 Suttorp et r//316 published a letter in 
Haematologica in response. The authors investigated the predictive value of BCR-ABL1 
transcript type on clinical outcome in 30 CP CML paediatric patients. Their study found that 
patients with the el4a2 transcript exhibited a more rapid decline in BCR-ABL1 mRNA and 
that this group of patients responded better to imatinib, confirming the findings within this 
chapter. Recently, at the EHA 2011 conference Castagnetti et a/317 analysed the effect of 
BCR-ABL1 transcript type on behalf of the GIMEMA CML working party. The clinical 
outcomes of 493 patients were assessed. No significant differences in sex, age, Sokal/Hasford 
score, or clonal chromosomal abnormalities were observed between the two transcript types. 
No significant differences in CCR rates at 12 months were observed. However, time to 
achieve MMR was significantly shorter for patients with el4a2 transcript. The OS, PFS and 
EFS were superior for el4a2 patients. The authors suggested that the el3a2 transcript could 
be an adverse prognostic factor in CP CML patients treated with imatinib first-line.
In conclusion, patients with the BCR-ABL1 transcript type e!4a2 have a higher response rate 
to imatinib when the CCRe rate is compared to patients who express the el3a2 transcript 
type. This suggests that this may be due to el3a2 patients having a higher BCR-ABL1 
tyrosine kinase activity. Knowledge of patient transcript type may yield clinically useful data, 
and should be included in future clinical trials of tyrosine kinase inhibitors.
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CHAPTER SIX - The role of ALOX5 in CML
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6.1.0 INTRODUCTION
Malignancies are thought to be initiated by a single neoplastic cell, which is capable of self­
replication; these cancer / leukaemic stem cells are thus the ideal therapeutic target. The role 
of ALOX5 in the arachidonic acid pathway and CML is detailed more fully in section 1.7.0. 
Briefly, the ALOX5 gene encodes a member of the lipoxygenase gene family and plays a role 
in the synthesis of leukotrienes from arachidonic acid. ALOX5 catalyses the conversion of 
arachidonic acid to 5-HEPTE, and further to LTA4. LTA4 is unstable and is converted to 
LTB4 which is more stable. 5-HEPTE and LTA4 negatively regulate ALOX5 expression; 
positive regulation of ALOX5 occurs when LTB4 binds to its receptor BLT1.
ALOX5 has been reported to be up-regulated in mouse ESC, and this up-regulation is not 
inhibited by imatinib. Furthermore, mice transplanted with ALOX5 deficient BCR-ABL1 + 
bone marrow cells were resistant to the induction of CML.253 ALOX5 deficiency was found to 
have no effect on BCR-ABL1 negative cells. This suggests that ALOX5 is important for 
mouse ESC growth and is essential for the development of CML in the mouse model studied.
The hypothesis proposed in this study was that CML cells have high levels of ALOX5 and 
that the level of ALOX5 predicts a patient's response to imatinib treatment. If this hypothesis 
were correct, then ALOX5 may be a new therapeutic target. Zileuton is an ALOX5 inhibitor 
which is currently licensed for the treatment of asthma. Zileuton alone or in combination with 
imatinib might be clinically beneficial in CML, since mice were resistant to the induction of 
CML when transplanted with ALOX5 deficient BCR-ABL1+ bone marrow cells. The role of
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ALOX5 in human CML is unknown. The aim of this chapter is to investigate the role of 
ALOX5 in imatinib treated CML patients.
6.2.0. PATIENT COHORT
All patients (n=49) aged 16 or over with newly diagnosed chronic phase CML and with a 
minimum of 12 months follow up were included in this study.
Table 6.1. Patient characteristics
Sokal score
CCRe
No.
patients
25
M/F
11/14
Mean age 
(range)
43 (19-60)
Low
15
Intermediate
3
High
5
Unknown
2
No CCRe 17 8/9 49 (23-67) 4 3 7 3
BC 7 6/1 37 (24-59) 1 2 2 2
Total 49 25/24 44(19-67) 20 8 14 7
Due to the specific sample requirement for this project, samples were not available from all 
patients for every experiment. For the study of ALOX5 and BLT1 expression in CD34+ cells, 
these were only available from three CCRe and three No-CCRe patients. For the ALOX5 
protein assay, fresh peripheral blood was available from 12 patients. For the LTB4 ELISA, 
diagnostic plasma was available from 18 CCRe, 7 No-CCRe and 2 BC patients. For the 
assessment of the LTB4 receptor BLT1, fresh peripheral blood was used from 22 patients.
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6.3.0 RESULTS
6.3.1 ALOX5 mRNA expression and clinical outcome
In order to determine whether ALOX5 expression was also elevated in CML patients, and if 
the levels were related to related to clinical outcome, ALOX5 expression was measured at 
diagnosis and following 3, 6 and 12 months of imatinib treatment. This was also studied in 
samples from four healthy volunteers. At diagnosis the expression level of ALOX5 was below 
the level observed in normal healthy volunteers. This was the case in patients destined to 
achieve CCRe, No-CCRe or to later progress to blast crisis, as previously defined (Figure 
6.1). In patients destined to achieve a CCRe, once imatinib treatment had commenced, the 
expression level of ALOX5 increased to normal levels and remained at the normal level 
throughout treatment. The increase in ALOX5 expression compared with diagnosis was 
statistically significant at 3, 6 and 12 months (p=0.003, p=<0.001 and p=0.024 respectively). 
These data suggest that ALOX5 expression in patients who subsequently achieve a CCRe is 
restored (Figure 6.1 A). A similar trend in ALOX5 expression was observed in the No-CCRe 
group (Figure 6.IB), with ALOX5 expression increasing once treatment had commenced. 
Again the increase mALOXS expression compared with diagnosis was statistically significant 
at 3, 6 and 12 months (p=0.013, p=0.030 and p=0.008 respectively). In patients destined to 
subsequently progress to BC, imatinib treatment failed to increase ALOX5 expression and the 
level of expression remained below the normal level.
These data may suggest that a failure to increase ALOX5 expression following three months 
of imatinib treatment may indicate a higher risk of disease progression (Figure 6.1C). No 
difference in ALOX5 expression was observed at diagnosis between those patients destined to
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progress to blast crisis and the CCRe and No-CCRe groups, suggesting that AWX5 
expression at diagnosis is not predictive of the outcome of imatinib treated patients.
When the same experiment was repeated on diagnostic CD34+ cells (from the same patients), 
no difference in ALOX5 expression was observed between responders and non-responders. 
ALOX5 expression was lower in CD34+ cells than in total leukocytes, although similar 
overall results were obtained, confirming that ALOX5 is down-regulated in CML patients in 
both CD34+ and mature cell compartments (Figure 6.ID).
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Figure (s.\. ALOX5 expression
Panel A: ALOX5 expression levels in the CCRe group. Panel B: ALOX5 expression levels in 
the No-CCRe group. Panel C: ALOX5 expression levels in the BC group. Panel D: ALOX5 
expression levels in CD34+ cells taken at diagnosis and stratified by the patients’ eventual 
clinical response. The normal level was determined using four healthy volunteers. Statistical 
analysis (Mann-Whitney U test) compared diagnostic values against 3, 6 and 12 month 
values.
A B
p=<0.001
3 monthsDiagnosis 6 months 12 months
p=0.030
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To determine whether ALOX5 (5-LOX) protein levels were a function of ALOX5 gene 
expression, ALOX5 protein expression was assessed by FACS. As patients respond to 
imatinib treatment and achieve a MMR, there was a trend for an increase in the amount of 
detectable ALOX5 protein (Figure 6.2); this is consistent with the increase in mRNA 
expression observed in Figure 6.1.
Figure 6.2 ALOX5 protein expression
ALOX5 protein was assessed by FACS using fresh leukocytes. ALOX5 expression is higher 
in CML patients with no detectable BCR-ABL1 as determined by qRT-PCR.
6.3.2 ALOX5 function - LTB4 levels in CML patients
Plasma levels of LTB4 can be used as a marker of ALOX5 functional activity (as described by 
Chen et al253). Preliminary work was carried out to determine the normal circulating level of 
LTB4 as well as the appropriate time point to measure the LTB4 levels in patients on 
treatment (Figure 6.3). LTB4 levels from 15 healthy volunteers with no signs of any
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infection were assessed and the mean normal level was determined as 300pg/ml (data not 
shown). LTB4 levels were also investigated in plasma samples taken at diagnosis, 1, 3, 6, 9, 
and 12 months following imatinib treatment. The results suggested that measuring LTB4 at 
diagnosis, three and six months post imatinib treatment would show the greatest differences 
between optimal responders, failure patients and those destined to develop blast crisis.
LTB4 levels were measured at diagnosis, three and six months in 27 patients of known 
subsequent clinical outcome (18 CCRe, 7 No-CCRe and 2 BC) (Figure 6.3.A). LTB4 levels 
increased in all three patient groups following imatinib treatment. At diagnosis the LTB4 
level in patients destined to progress to blast crisis (BC group) was the lowest of the three 
patient groups. Conversely, once imatinib treatment commenced the LTB4 level increased to 
the highest level compared to the other two clinical groups (Figure 6.3A). The levels of LTB4 
in the CML patients were in general higher than normal; this may indicate an accumulation of 
LTB4 and a potential block in the arachidonic acid pathway (given in Figure 6.5).
Since LTB4 levels increased in all patients assessed, it was necessary to confirm whether this 
was a direct physiological response to imatinib treatment, or if it was due to the disease. To 
address this issue, MNC from five healthy volunteers were treated with 5jj,M imatinib for 24 
hours and the changes in LTB4 levels were measured. The data are shown in Figure 6.3B. 
No significant difference was observed between the untreated and imatinib treated normal 
samples, thus suggesting that changes in LTB4 observed in CML patients may be attributed 
to the leukaemia and not as a physiological response to imatinib treatment (Figure 6.3B). It 
was not possible to exclude continuous imatinib treatment as a cause for the increase in LTB4 
(as this would have required healthy volunteers to take imatinib).
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Figure 6.3. LTB4 levels following imatinib treatment.
A. Mean plasma LTB4 levels of 27 patients stratified by clinical outcome; 18 CCRe, 7 No- 
CCRe and 2 BC. Samples were taken during chronic phase at diagnosis, 3 and 6 months after 
commencement of imatinib treatment. B. Effects of 24 hours of 5pM imatinib treatment on 
LTB4 levels in five samples from healthy volunteers.
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6.3.3 AL0X5 function in chronic phase and blast crisis
ALOX5 function was assessed using samples from patients diagnosed in chronic phase and 
from patients actually in blast crisis (Figure 6.4). LTB4 levels were found to be elevated in 
samples taken at blast crisis compared to chronic phase samples, but this difference was not 
statistically significant. The increase in LTB4 observed coincided with a decrease in ALOX5 
expression.
Figure 6.4. Comparing LTB4 levels in chronic phase with blast crisis.
Plasma LTB4 levels from chronic phase (n=27) and blast crisis patients (n=10).
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6.3.4 LTB4 receptor BLT1
The original hypothesis proposed in this study was that CML patients would have high levels 
ofALOX5. The data presented thus far are in opposition to both this hypothesis and the study 
presented by Chen et al,253 which demonstrated that mice transplanted with BCR-ABL1 
positive bone marrow cells lacking the ALOX5 gene were resistant to the induction of CML, 
suggesting that ALOX5 was essential for the induction and development of CML.253 
However, that study was performed using a mouse model, and the experiments have not yet 
been carried out on human CML samples, which could explain the discrepancies between the 
present data and those of Chen et air'2. In order to further explain the differences between the 
two studies, the LTB4 pathway was interrogated further. Figure 6.5 demonstrates the 
arachidonic acid metabolism pathway. Prior to conversion to LTB4, arachidonic acid is 
converted into two intermediate products, 5-HEPTE and then LTA4. Both 5-HEPTE and 
LTA4 negatively regulate ALOX5 expression, while LTB4 is known to positively regulate 
ALOX5 expression.318 In order for LTB4 to mediate its positive effect on ALOX5 expression 
it must bind to BLT1, the LTB4 receptor.
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In the CML clinical samples investigated it is apparent that ALOX5 expression is suppressed 
below normal. Furthermore, the LTB4 levels in the CML samples were elevated compared to 
normal healthy controls, suggesting an accumulation of LTB4. Since LTB4 needs to bind to 
its receptor BLT1 to positively regulate ALOX5 expression, these data suggest that BLT1 
expression or function may be abnormal in CML.
BLT1 protein expression was therefore measured by cell surface FACS analysis, and was 
found to be lower in MNC cells compared to a total leukocyte preparation. This is because 
LTB4 and hence ALOX5 are important in neutrophils, which are lost in the preparation of 
MNC. This therefore meant that fresh blood samples were required to study BLT1 protein 
(rather than stored MNC preparations).
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BLT1 surface expression was found to be very low in newly diagnosed CP CML samples 
(Figure 6.6). When the level of BLT1 was compared between newly diagnosed patients and 
patients responding to TKI treatment (defined as a BCR-ABL1 ratio of 1-10%), then BLT1 
expression was significantly lower at diagnosis (p=0.004). When the comparison was made 
between BLT1 levels in newly diagnosed CML patients and either those in CCRe or in 
normal controls, again the difference was statistically significant (p=0.001 and p=<0.0001 
respectively). These data suggest that there is an inverse relationship between BLT1 protein 
and BCR-ABL1 mRNA expression. BLT1 protein is very low at diagnosis but increases 
towards normal as the BCR-ABL1 mRNA expression decreases.
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Figure 6.6. LTB4 receptor (BLT) protein level.
BLT1 surface expression was measured in newly diagnosed chronic phase CML patients 
(n=5), a patient in BC (n=l), patients currently responding to imatinib treatment (n=6), 
patients in CCRe (n=10) and healthy volunteers (n=15). BLT1 cell surface expression was 
found to be low in newly diagnosed chronic phase CML patients compared to patients 
responding to treatment or healthy volunteers.
100.00
p=<0.0001
Diagnosis CP BC 1-10% CCRe Normal
6.3.5 BLT1 mRNA expression
BLT1 mRNA expression was found to be lowest in CP diagnostic samples compared to 
patients who had received 12 months of imatinib treatment (Figure 6.7). In the CCRe group 
the BLT1 expression increased more than that observed in the No-CCRe group, although this 
was not statistically significant. When BLT1 mRNA expression was assessed in samples 
from patients in BC at the time of sampling, BLT1 mRNA expression was much lower than 
the diagnostic CP group and the 12 month samples. BLT1 mRNA expression was not 
statistically significant at diagnosis, nor did it predict a patient’s clinical outcome (data not 
shown).
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As patients progress to BC, ALOX5 gene expression is suppressed, possibly due to an 
accumulation of pathway intermediates (5-HEPE and LTA4) and a decrease in BLT1. This 
idea is supported by the BLT1 protein data and the accumulation of LTB4 in blast crisis. 
BLT1 mRNA expression was also assessed in CD34+ cells taken at diagnosis (Figure 6.7B). 
No difference in BLT1 expression was observed between those patients who later achieved a 
CCRe and those who did not.
Figure 6.7. LTB4 receptor (BLT1) mRNA expression.
Panel A: BLT1 mRNA expression was measured in newly diagnosed chronic phase CML 
patients (n=24), patients treated with imatinib for twelve months who achieved a CCRe 
(n=10) and No-CCRe (n=8), as well as patients who were in BC (n=6). Panel B: BLT1 
mRNA expression in diagnostic CD34+ cells stratified by the patient's clinical outcome.
A
B
I:
&
4000-
30 00-
30 00“
CC** No-CC*#
210
6.4.0 DISCUSSION
The identification of proteins which discriminate leukaemic from normal stem cells is a 
challenging concept. Successful identification and therapeutic targeting of leukaemic stem 
cells remains the ultimate goal in eradicating CML.
The present data suggest that although ALOX5 has been identified as being essential for the 
development of CML in mice, this is not the case in human CML. Initial assessment of 
ALOX5 expression pre and post imatinib treatment in human CML demonstrated that ALOX5 
was down-regulated below normal, unlike the mouse model of CML which showed that 
ALOX5 was up-regulated. Following imatinib treatment, ALOX5 mRNA expression 
increased in the CCRe and No-CCRe groups. In patients who subsequently progressed to BC, 
no change in ALOX5 expression was observed. The failure to increase ALOX5 expression 
following 3 months of imatinib treatment may identify those patients at risk of disease 
progression.
ALOX5 function was assessed by measuring plasma LTB4. LTB4 was found to increase in all 
three groups of patients following imatinib treatment. LTB4 was also found to be increased in 
BC compared to CP. These data suggest that the arachidonic acid pathway (Figure 6.5) is 
functionally active to the point of LTB4 production.
To determine the differences between the ALOX5 pathway observed in mice and the clinical 
samples studied, the LTB4 receptor BLT1 was investigated. LTB4 acts by binding to BLT1 
in order to mediate its positive role on ALOX5. At diagnosis of CML patients had very low 
levels of BLT1 protein compared to normal samples. Following imatinib treatment BLT1
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levels increased towards normal, and in the one BC case studied BLT1 protein was further 
suppressed. These findings help to explain the data seen in CML patients. At diagnosis of 
CML, ALOX5 gene expression was found to be suppressed and there was an accumulation of 
LTB4. The accumulation of LTB4 is likely due to lack of the LTB4 receptor BLT1. A lack of 
BLT1 allows the intermediates of the pathway namely 5-HEPTE and LTA4 to suppress 
ALOX5 gene expression, and thus LTB4 accumulates as it has no receptor to bind to. 
Following imatinib treatment BLT1 protein increases; thus LTB4 can bind to its receptor and 
positively regulate ALOX5 as demonstrated by an increase in ALOX5 protein and gene 
expression.
In patients with atherosclerosis the binding of LTB4 to BLT1 induces the rapid 
phosphorylation of mitogen activated protein kinases (MAPK, ERK1/2 and JNK1/2), and 
PI3K/AKT, and also increases NF-kB activation,245 which are all targets of BCR-ABL1. It is 
therefore interesting to speculate that CML cells attempt to switch off excessive signalling 
via these pathways by down-regulating BLT1 in order to try and maintain cellular 
homeostasis. This hypothesis warrants further investigation but is outside the scope of this 
thesis.
In conclusion, it is apparent that two different pathways exist with regards to ALOX5 between 
the CML mouse model and CML patients. This accounts for the difference between the 
clinical samples studied herein and the results of the Chen et al253 paper. Early in this study, it 
became clear that the pursuit ALOX5 as a therapeutic target in CML using the ALOX5 
inhibitor zileuton was not feasible, and this aspect of the study was abandoned.
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CHAPTER SEVEN - The role of PP2A and its
inhibitor SET in CML patients
213
7.1.0 INTRODUCTION
The majority of CML patients present in a chronic phase, which is nowadays readily 
controlled by imatinib and related agents. However, at least one-third of CML patients treated 
with imatinib will eventually fail treatment.21287 and a significant proportion of these will 
progress towards blast crisis. Poor response to imatinib and progression to blast crisis have 
been linked to high BCR-ABL1 tyrosine kinase activity,303 but why one patient can remain in 
well controlled chronic phase for decades, whereas another rapidly progresses to blast crisis 
is poorly understood.
Many cells utilise reversible phosphorylation as a mechanism of post-translational 
modification for activating and deactivating key regulatory molecules involved in cell 
signalling.2^4 A major cellular serine/threonine phosphatase working in opposition to kinases 
is the Protein Phosphatase 2A (PP2A).2M PP2A plays an important role in regulating cell 
proliferation, differentiation and survival; loss of function has been associated with cellular 
transformation; thus it is also known as a tumour suppressor (as discussed in section 1.8.0).256 
This chapter investigates the predictive value of assessing the tumour suppressor PP2A and 
its inhibitory protein SET (and its binding protein SETBP1) in newly diagnosed CML 
patients at diagnosis and following imatinib treatment.
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7.2.0 PATIENT COHORT
Patients were only included in this study if they had received imatinib 400mg from initial 
diagnosis. Additionally, patients also needed to have paired MNC and cDNA samples, at both 
diagnosis and at 12 months of treatment, or at disease progression. 31 patients fulfilled these 
criteria; their characteristics are described in Table 7.1.
Table 7.1. Patient clinical characteristics.
Sokal score
No.
patients M/F
Mean age 
(range) Low Intermediate High Unknown
CCRe 14 7/7 45 (19-60) 6 1 4 3
No CCRe 11 7/4 48 (23-67) 2 2 5 2
BC 6 5/1 37 (24-59) 1 2 2 1
Total 31 19/12 44(19-67) 9 5 11 6
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7.3.0 RESULTS
7.3.1 Optimisation of FACS methodology for the detection of PP2A, pY307-PP2A 
and SET.
Fixation and permeabilisation optimisation for CML cells has been addressed in chapter four. 
All antibody concentrations were optimised to ensure maximal signal intensity (data not 
shown). To validate the PP2A detection methodology, K562 cells were treated with imatinib 
to reactivate PP2A264 and okadaic acid, a known inhibitor of PP2A. Imatinib treatment 
resulted in an increase in PP2A as demonstrated by a peak shift to the right, and conversely 
okadaic acid inhibited PP2A as demonstrated by a peak shift to the left (Figures 7.1 A and B 
respectively). PP2A is inactive when phosphorylated at tyrosine 307 (pY307-PP2A). Imatinib 
reduced and conversely okadaic acid increased PP2A phosphorylation, further inactivating 
PP2A (Figures 7.1C and D). Reactivation of PP2A following imatinib treatment also 
coincided with a decrease in the inhibitor SET (Figure 7.3E).
Figure 7.1. Optimisation of PP2A, pY307-PP2A and SET FACS assays.
K562 cells treated with 5pM imatinib and 6nM okadaic acid (inhibitor of PP2A) for 24 hours
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Reactivation of PP2A was investigated further using imatinib, dasatinib and the PP2A 
activator FI Y720. Confocal analysis of K562 cells treated with imatinib showed an increase 
in PP2A accompanied by a decrease in pY307-PP2A. Imatinib resulted in an increase in SET; 
although at first sight this is surprising, this will be discussed later in relation to No-CCRe 
patient samples (section 7.3.7). Dasatinib treatment increased PP2A protein, and this 
increase was superior to that observed with imatinib. Both pY307-PP2A and SET also 
decreased significantly, compared to the untreated control. The results of FTY720 treatment 
were similar to those observed with dasatinib (Figure 7.2).
Figure 7.2. Changes in PP2A, pY307-PP2A and SET following imatinib, dasatinib 
and FTY720 treatment in K562 cells.
Following 24 hours of imatinib treatment PP2A protein increases and the amount of pY307- 
PP2A decreases but SET increases. Dasatinib and FTY720 treatment resulted in an increase 
in PP2A protein and a decrease in both pY307-PP2A and SET leading to the reactivation of 
PP2A.
217
7.3.2 PP2A activity
PP2A activity was assessed using K562 cells treated with imatinib, FTY720 and okadaic acid 
for 24 hours using a methodology kindly supplied by Professor Danilo Perrotti, Ohio State 
University, Columbus, Ohio, USA (Figure 7.3). Untreated K562 cells had a baseline 
phosphatase activity of 15.96 pico-moles, and following imatinib and FTY720 treatment this 
increased slightly by 2 and 5.5 pico-moles respectively. As expected okadaic acid resulted in 
a decrease in PP2A activity to 4.67 pico-moles. Although these treatments altered the PP2A 
activity as anticipated, the changes were small (2-5 pico-moles) and were not statistically 
significant.
Figure 7.3. PP2 A activity in K562 cells.
Following 24 hours of imatinib, FTY720 and okadaic acid treatment PP2A activity was 
assessed. Imatinib and FTY720 increased PP2A activity while okadaic acid decreased PP2A 
activity.
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Detection of PP2A activity is extremely difficult to determine. Prior to adopting the 
methodology of Professor Perrotti, a commercial kit was used unsuccessfully and given the 
insignificant changes observed in the CML cell line, it was decided not to extend this assay to 
precious primary clinical material. Other groups working on PP2A have also experienced 
problems reliably detecting PP2A activity in primary material.264265,319 They have used 
PP2A phosphorylation status instead, since PP2A is inactive when phosphorylated at tyrosine 
307.
7.3.3 Determining the normal level of PP2A, pY307-PP2A and SET.
Before investigating the level of PP2A, pY307-PP2A and SET in CML samples it was 
important to determine the normal level of each protein. To do this, MNC from 10 healthy 
volunteers were collected and each protein was assessed by FACS. The normal levels were 
determined as: PP2A 21.4 MF1 (range 17.1-25.7), pY307-PP2A 1.6 (range 0.8-2.3) and SET 
0.2 MFI (range 0.1-0.3).
7.3.4 PP2A protein is elevated during blast crisis.
Previous work by others has implicated PP2A function in the pathophysiology of CML and 
AML.264,265 To further investigate the importance of PP2A protein expression, PP2A levels in 
the MNC from CML patients in chronic phase and blast crisis were compared (Figure 7.4.). 
PP2A protein was found to be significantly elevated in the cells from patients in blast crisis 
(p=0.05). These data suggest a potential importance for PP2A. In view of PP2A's role as a 
tumour suppressor, these results were not anticipated.
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Figure 7.4. Level of PP2A protein at chronic phase and blast crisis.
PP2A protein is higher in blast crisis samples compared to chronic phase samples.
p=0.005
CP BC
7.3.5 PP2A protein expression is increased in MNC and CD34+ cells from patients 
destined to progress to blast crisis.
In order to determine whether PP2A protein levels were indicative of disease progression, 
PP2A protein was analysed in MNC of 31 patients who were in chronic phase at diagnosis 
and again in the same patients after 12 months of treatment or at transformation. The clinical 
response of these patients was stratified into three groups depending on outcome; CCRe, No- 
CCRe and BC. No BCR-ABL1 kinase domain mutations were detected in any patients. At 
diagnosis the mean PP2A protein level in patients who later achieve CCRe was not 
significantly different from that in normal MNC, whereas that in patients destined not to 
achieve CCRe (No-CCRe) was significantly lower than in normal cells (p=0.02) (Figure 7.5). 
In both groups of patients PP2A levels increase following 12 months of treatment. In contrast 
to the CCRe and No-CCRe patients, PP2A levels in patients destined to progress into blast 
crisis were much higher (p=<0.001 compared to the No-CCRe group), and these levels did 
not change following treatment (Figure 7.5A). When the same experiment was performed on
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CD34+ cells from the same patients, similar results were obtained (Figure 7.5B); PP2A 
protein was elevated in the diagnostic CD34+ cells from patients who subsequently progress 
into BC compared to the CCRe and No-CCRe groups. These data suggest that PP2A is not 
only elevated at BC but also at diagnosis in patients destined to progress to blast crisis. 
Furthermore, increased PP2A protein expression in MNC and CD34+ cells at diagnosis may 
indicate a higher probability of disease progression.
To determine whether PP2A protein levels were a function of PP2A gene expression, qRT- 
PCR was used to measure expression of the gene coding for the PP2A catalytic subunit. The 
pattern of PP2A gene expression was similar to that of PP2A protein expression in the CCRe 
and No-CCRe groups. PP2A mRNA levels were lower at diagnosis and increased 
significantly following 12 months of treatment (p=<0.001), whereas in the BC group 
diagnostic PP2A mRNA levels were higher than in the CCRe and No-CCRe groups but did 
not change during treatment (Figure 7.5C). Interestingly, PP2A gene expression in all three 
groups, regardless of whether the sample was taken at diagnosis or after treatment, was lower 
than that observed in normal cells. Since protein levels of PP2A in the MNC from the BC 
group were higher than in normal MNC, this suggests a role for post-translational 
modification in the stabilisation of PP2A protein expression in the BC group.
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Figure 7.5. PP2A protein expression is increased in MNC and CD34+ cells from 
patients destined to progress to blast crisis.
The horizontal line represents the mean normal level observed in ten healthy volunteers. 
Panel A: Levels of PP2A protein as assessed by flow cytometry. The level of PP2A is high 
in patients destined to progress to blast crisis, in comparison to No-CCRe patients 
(p=<0.001). * denotes a statistically significant difference between No-CCRe and normal
(p=0.002).
Panel B: Level of PP2A protein in diagnostic CD34+ cells. The level of PP2A is high in 
patients destined to progress to blast crisis.
Panel C: Expression of the PP2A catalytic subunit, as assessed by qRT-PCR. Expression was 
lower than in normal MNC for all three response groups at both diagnosis and at 12 
month/transformation follow up. Expression significantly increased following imatinib 
treatment in both the CCRe and No-CCRe groups (p=<0.001) but no change was observed in 
the BC group.
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7.3.6 pY307-PP2A status is increased in MNC and CD34+ cells from patients 
destined to progress to blast crisis.
PP2A is inactive when phosphorylated at tyrosine 307 (pY307-PP2A), and this can be used to 
indicate its activity level.264,265'319 Phosphorylated levels of PP2A were significantly greater 
at diagnosis in the CCRe (p=0.01) and No-CCRe (p=0.002) groups, and in patients who 
progressed into BC (p=0.012) and at BC (p=0.004), compared to normal MNC (Figure 7.6A). 
Next, the PP2A phosphorylation status was assessed in CD34+ cells from patients in these 
response groups. pY307-PP2A was elevated in cells from the CCRe and No-CCRe response 
groups, but dramatically increased levels were found in cells from patients destined to 
progress (Figure 7.9B). Thus, although Figure 7.5A demonstrated high PP2A protein levels 
in patients destined to progress, this was found to be functionally inactive (phosphorylated). 
These data support the conclusions of a previous report indicating a role for PP2A 
inactivation in the pathology of CML.“64 Taken together, these data demonstrate that PP2A is 
functionally inactive in the MNC and CD34+ cells of patients destined to progress to blast 
crisis.
223
Figure 7.6. pY307-PP2A at diagnosis and following 12 months of treatment or at 
progression, stratified by response.
Panel A: Level of pY307-PP2A (inactive), as assessed by flow cytometry. The mean level in 
10 healthy subjects = 1.6 (range 0.8-2.3). Phosphorylated levels of PP2A were greater at 
diagnosis in CCRe (p=0.01) and No-CCRe (p=0.002) groups, and in patients who progressed 
into BC (p=0.012) and at BC (p=0.004), compared to normal MNC. Panel B: Level of pY307- 
PP2A (inactive) in CD34+ cells. The degree of phosphorylation is greater patients destined to 
progress into blast crisis.
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7.3.7 SET and SET binding protein 1 (SETBP1) levels are not indicative of clinical 
outcome.
SET and SETBP1 have respectively been implicated in regulating PP2A activity in the 
leukaemic cells of CML and AML.264,265 SET and SETBP1 expression were assessed at 
diagnosis and again following 12 months of treatment or at transformation. No statistically 
significant difference in SETBP1 expression was observed between the CCRe, No-CCRe and 
BC clinical groupings of CML (Figure 7.7A). Interestingly, SETBP1 expression increased 
significantly following 12 months treatment in the CCRe and No-CCRe groups but not in the 
BC group (p=0.001 and p=0.006 respectively). Moreover, and unlike in the leukaemic cells
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of AML,265 SETBP1 gene expression levels were lower in CML samples when compared to 
those from healthy volunteers.
SET protein levels (Figure 7.7B) were significantly higher at diagnosis in the CCRe and No- 
CCRe groups compared to normal (p=:<0.001 and p=0.01 respectively). In patients who 
subsequently progressed to BC there was a trend for lower SET levels. This trend was also 
seen for SET mRNA levels (Figure 7.7D), since samples from patients who later progressed 
had lower levels of SET mRNA than did samples from either CCRe or No-CCRe patients. 
Interestingly, in BC samples at transformation, SET protein levels increased to become 
spread over a higher range than at diagnosis, and may suggest that SET plays a role during 
disease progression. This observation contrasts with the fall in SET expression observed in 
samples from patients within the CCRe and No-CCRe groups following 12 months of 
treatment. SET protein expression was also assessed in diagnostic CD34+ cells and no 
apparent difference between the three clinical groups was observed (Figure 7.7C).
Taken together, these results are broadly in agreement with previously reported data,264 but 
also suggest that SET may not be the only factor inhibiting PP2A in the malignant cell, 
especially in the case of patients destined to progress to blast crisis. This implies that another 
mechanism may be inhibiting PP2A in this group of patients.
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Figure 7.7. SET and SETBP1 at diagnosis and follow-up.
SET protein is low at diagnosis in patients who subsequently progress to blast crisis. 
Panel A: mRNA expression of SET binding protein (SETBPJ). No significant differences in 
SETBP1 expression were observed between the three response groups. Following 12 months 
of imatinib treatment SETBP1 expression increases in the CCRe and No-CCRe groups 
(p=0.001 and 0.006 respectively). Panel B: Levels of SET protein. SET protein levels are 
higher than in normal MNC in the CCRe and No-CCRe groups (p=<0.001 and p=0.01 
respectively). Panel C: Levels of SET protein in CD34+ cells. No difference observed. 
Panel D: SET mRNA expression.
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7.3.8 Inactive PP2A functions to stabilises c-Myc
Under normal conditions PP2A functions to dephosphorylate kinases including c-Myc. c- 
Myc cannot be degraded when phosphorylated at serine 62, and remains oncogenic.271 To test 
whether pS "c-Myc is a factor in CML pathophysiology, an ELISA assay was used to 
measure the levels of pS62-Myc in diagnostic samples. MNC from patients destined to 
progress into BC had significantly higher levels of pS62c-Myc than did those from patients 
within either the CCRe or No-CCRe groups (Figure 7.8A, p=0.04). Since S62 phosphorylation 
of c-Myc stabilises this protein against degradation,271 the total c-Myc protein level was also 
measured in the same samples, to determine if increased stabilisation also gave rise to 
increased protein levels, and similar results were observed. c-Myc protein levels were 
significantly higher in the cells of patients who subsequently progress to blast crisis (Figure 
7.8B, p=0.002). These data strongly suggest that high levels of c-Myc and phosphorylation at 
serine 62 indicate a high risk of disease progression. Since PP2A is the major phosphatase 
that dephosphorylates c-Myc, these results further suggest that PP2A function is inhibited at 
diagnosis.
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Figure 7.8. Assessing PP2A function - c-Myc is elevated at diagnosis in patients 
destined to progress into blast crisis.
Panel A: Levels of pS<l2c-Myc. Panel B: Total c-Myc protein levels, stratified by clinical 
outcome. CCRe n=10, No-CCRe n=5 and BC group n=5.
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7.4.0 DISCUSSION
The data presented in this chapter demonstrate that at diagnosis patients destined to achieve a 
response to imatinib treatment (CCRe group) had low levels of PP2A protein, low PP2A 
activity (as indicated by high levels of pY307-PP2A) and high levels of SET protein, 
indicating impaired PP2A function controlled by the PP2A inhibitor SET. Following 12 
months of imatinib treatment the levels of PP2A increased, pY,07-PP2A decreased and the 
levels of SET decreased - all leading to an environment permitting achievement of CCRe. 
This is consistent with previously reported cell line data264 which demonstrated that PP2A is 
inhibited by SET, and that function can be restored by imatinib treatment in vitro. The 
present data are additive to the current literature, confirming the cell line findings of Neviani 
et al264 in our clinical material.
In the No-CCRe group the level of PP2A was significantly lower than that observed in 
normal blood and its activity was low (high pY307-PP2A). SET protein levels were also high 
thus inhibiting PP2A. Following imatinib treatment PP2A levels increased and the amount of 
pY’07-PP2A decreased, suggesting that the activity of PP2A had been restored. However, 
these changes were not accompanied by an alteration in levels of the inhibitory protein SET 
suggesting that PP2A function may be only partially restored compared to diagnosis. This 
may contribute to why this group of patients have not achieved a CCRe.
In sharp contrast, patients at diagnosis who were destined to later progress into blast crisis 
were found to have significantly higher levels of PP2A both at diagnosis and at blast crisis. 
The degree of pY307-PP2A was higher (low activity) than normals. Interestingly at diagnosis 
SET levels were virtually undetectable, although SET did increase during transformation, 
suggesting that SET does not play a role in inhibiting PP2A function in this particular group
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of patients. The PP2A and pY307-PP2A trends observed in MNC were confirmed in CD34+
cells.
Given that PP2A function is not inhibited by SET in those patients destined to progress to 
blast crisis, an alternative mechanisms of PP2A inhibition was investigated, namely SETBPL 
Overexpression of SETBP1, the binding protein for SET, predicts adverse outcome in elderly 
patients with acute myeloid leukaemia (AML).265 Although SET has been shown to play a 
role in inhibiting PP2A in the CCRe group, the data presented here suggest that, in contrast to 
AML, SETBPJ is not a diagnostic prognostic marker of clinical outcome following imatinib 
treatment in CML. Other factors may therefore be of greater importance /influence in the 
regulation of PP2A in CML.
Patients destined to progress into blast crisis had high levels of PP2A, which did not fit the 
prediction that PP2A levels would be low in CML samples. Patients destined to progress 
have high PP2A that is not functionally inhibited by either SET or SETBPL It was therefore 
necessary to confirm that PP2A function was indeed impaired, pS62c-Myc was used as a 
functional readout of PP2A activity. Under normal conditions PP2A dephosphorylates c-Myc 
and thus targets c-Myc for degradation. In this chapter I have demonstrated that pS62c-Myc 
and total c-Myc protein are high in patients destined to progress, confirming that PP2A is 
functionally inactive. It is known that c-Myc may contribute to disease progression in CML, 
mediated through aneuploidy.96,97,320,321 c-Myc has a critical role in enhancing cell 
proliferation and it is therefore possible that this results in an increase in DNA mismatch 
repair errors leading to an increase in genomic instability.96
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In conclusion, it is apparent that PP2A is functionally inactivated at diagnosis in patients 
destined to subsequently progress to BC; however, the mechanism responsible for this 
remains unclear. This will be addressed in the following chapter.
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CHAPTER EIGHT - Cancerous inhibitor of PP2A
(CIP2A) at diagnosis of chronic myeloid 
leukaemia is a critical determinant of disease
progression
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8.1.0 INTRODUCTION
In the previous chapter it was apparent that PP2A is functionally inactivated at diagnosis. In 
patients destined to achieve a CCRe, PP2A is inhibited by SET. However, the mechanism of 
PP2A inactivation in patients destined to progress remains unclear and does not appear to be 
due to SET. The aim of this chapter is to further dissect the PP2A signalling pathway, to 
understand how PP2A is inactivated in patients destined to progress into blast crisis.
CIP2A was first described in 2007 as an alternative inhibitor of PP2A.271 CIP2A has since 
been shown to be an adverse prognostic feature in both breast9’ and gastric272 cancer. The 
role of CIP2A is detailed more fully in section 1.8.6. This chapter investigates the role of 
CIP2A in CML patients at diagnosis and following imatinib treatment.
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8.2.0. RESULTS
8.2.1. CIP2A mRNA expression does not correlate with clinical outcome.
The patient cohort previously described in section 7.2.0 was used in this study. Figure 8.1 A 
shows CIP2A gene expression as assessed by qRT-PCR at diagnosis and following 12 
months of imatinib treatment or at disease progression. No statistically significant difference 
was observed between any of the three response groups or at either time point, nor were any 
of these different from normal MNC. Given the previous report in both breast and gastric 
cancers that C1P2A mRNA expression correlated with clinical outcome,91’91 this is not the 
case in the CML samples studies. Using an in vitro assay, MNC from 18 newly diagnosed 
CML patients were cultured with either 5pM imatinib, 150nM dasatinib or 5pM nilotinib for 
24 hours and changes in CIP2A mRNA expression were measured (Figure 8.IB). Following 
TKI treatment no change in CIP2A mRNA expression was observed.
Figure 8.1. CIP2A expression levels at diagnosis and follow-up.
Panel A: mRNA expression of CIP2A. No statistically significant difference was observed 
between any of the three response groups. Panel B: Changes in CIP2A mRNA expression in 
newly diagnosed CML patients following in vitro treatment with TKI. No statistically 
significant difference was observed (n=18).
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8.2.2 Cancerous inhibitor of PP2A (CIP2A) protein levels predict blast crisis.
In sharp contrast. Figure 8.2A demonstrates that CIP2A protein levels in MNC taken at 
diagnosis were significantly higher in patients who later progressed to blast crisis than in 
patients from the CCRe and No-CCRe groups (p=<0.0001 and p=0.01 respectively). This 
observation was also confirmed in CD34+ cells; samples from patients destined to progress 
into BC had much higher levels of CIP2A than either CCRe or No-CCRe patients (p=0.017. 
Figure 8.2B). No correlation was seen between CIP2A expression and Sokal score (data not 
shown). These results suggest that CIP2A may be important in inhibiting PP2A function in 
CML patients who progress to blast crisis. The importance of increased C1P2A protein 
expression in disease progression is further exemplified following 12 months of treatment; 
whereas CIP2A protein levels remain essentially unchanged in samples from the CCRe and 
No-CCRe groups, the level increases further at disease progression (p=0.008. Figure 8.2A).
One patient in the No-CCRe had uncharacteristically high CIP2A protein levels (outlier in 
Figure 8.2A), although this patient did not progress into blast crisis. There are a number of 
factors to consider in this case. Firstly, unlike the other patients in this study this patient 
received interferon as part of the SPIRIT 1 clinical trial which might have modified his 
treatment response from that with imatinib alone.322 Secondly, this patient switched to a 
second generation TKI as part of his treatment, thus possibly preventing disease progression 
and finally, this patient is diabetic and received metformin as part of his treatment. Metformin 
is also transported by hOCTl and may therefore have competed with imatinib for access into 
CML cells; nilotinib transport is not hOCTl dependent.298 Metformin has also recently been 
reported to reactivate PP2A.
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Figure 8.2. CIP2A protein level in MNC and CD34+ at diagnosis is predictive of 
blast crisis.
Panel A: Levels of CIP2A protein. CIP2A protein levels at diagnosis were significantly 
higher at diagnosis in patients who later progressed to blast crisis than in CCRe or No-CCRe 
patients (p =<0.0001 and 0.01 respectively). As a patient progresses into BC the CIP2A 
protein level increases further (p=0.008). Panel B: Level of C1P2A protein in diagnostic 
CD34+ cells stratified by the patients’ clinical outcome. CIP2A is elevated in CD34+ cells 
from patients destined to progress into BC. Panel C: Kaplan Meier plot of disease 
progression, stratified by C1P2A level at diagnosis. Patients with a high diagnostic C1P2A 
protein level (MFI >5) have 100% probability of progressing to blast crisis by 21 months
(p=<0.0001).
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To test whether high expression of CIP2A protein is predictive of disease progression, 
progression free survival was compared between patients with high (defined as a MFI greater 
than 5) and low diagnostic CIP2A protein levels. Figure 8.2C shows that the median time to 
disease progression in patients with high CIP2A protein levels is 13 months, and their 
probability of progression is 100% at 21 months. Five of these six patients have died of 
disease progression. In contrast, during the same time period none of the patients with low 
diagnostic CIP2A levels progressed, and all remain progression-free and alive at their latest 
follow-up (average follow-up 47 months). These data indicate that CIP2A protein expression 
is a biomarker of disease progression in CML.
8.2.3 CIP2A protein correlates with high BCR-ABL1 tyrosine kinase activity.
CrkL phosphorylation status is a marker of BCR-ABL1 tyrosine kinase activity.197,303 Where 
available, the pCrkL/CrkL ratio was measured at diagnosis using fresh material as previously 
described (n=l O).303 BCR-ABL1 activity was highest in patients destined to progress into 
blast crisis (Figure 8.3), demonstrating that high CIP2A protein level and high BCR-ABL1 
activity appear to be correlated.
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Figure 8.3. BCR-ABL1 tyrosine kinase activity (pCrkL/CrkL ratio) is higher at 
diagnosis in patients destined to progress into blast crisis.
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8.2.4 Is CIP2A protein regulated by BCR-ABL1?
BCR-ABL1 activity is predictive of treatment response in CML.30j To see whether BCR- 
ABL1 tyrosine kinase activity was a factor controlling CIP2A protein levels, the BCR-ABL1 
positive cells lines K562, KCL22 and KY01 together with the BCR-ABL1-negative gastric 
cancer cell line AGS (used as a CIP2A positive control)272 were treated with 5pM imatinib 
for 24 hours. The results (Figure 8.4) show that imatinib treatment of the BCR-ABL1 positive 
cell lines resulted in a significant down-regulation of CIP2A protein levels (p=0.002 for 
K562, p=0.001 for KCL22 and p=0.024 for KYOl), but had no effect on CIP2A expression in 
AGS cells. Thus, BCR-ABL1 activity may be an important factor in the regulation of CIP2A 
protein expression.
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Figure 8.4. Is CIP2A protein regulated by BCR-ABL1?
CIP2A protein levels (mean + SEM) in CML cell lines K562, KCL22, KY01 and a CIP2A 
positive gastric cancer cell line AGS, before and after treatment with 5pM imatinib(n=6).
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8.2.5 CIP2A inhibits PP2A function and stabilises c-Myc
As discussed in chapter seven c-Myc cannot be degraded when phosphorylated at serine 62, 
and remains oncogenic (Figure 7.8). Patients who subsequently progress to blast crisis exhibit 
significantly higher levels of pS(,2c-Myc as compared to levels seen in the CCRe and No- 
CCRe groups. Patients in the BC group also had higher total c-Myc protein levels, which was 
also statistically significant when compared to the No-CCRe group (p=0.002). These data 
demonstrate that in chronic phase patients who subsequently progress to blast crisis, c-Myc 
remains phosphorylated at serine 62 thereby stabilising it from degradation. Since PP2A is 
the major phosphatase dephosphorylating c-Myc, these results further suggest that PP2A 
function is inhibited by high expression of C1P2A.
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8.2.6 PIM1, a surrogate marker for PP2A function and activity.
PIM1 is a protein kinase that can phosphorylate and stabilise c-Myc.92 P1M1 is itself 
phosphorylated, and in this state it is active and its expression is stable.274 However, this 
protein is a target for PP2A, and once it is dephosphorylated by PP2A, it is rapidly degraded 
in the proteasome (Figure 8.5A).324 To further confirm that PP2A is functionally inactive in 
CML, PIMlwas investigated as another target of PP2A. Initially K562 cells were treated with 
5fiM imatinib for 24 hours as this is known to result in the reactivation of PP2A via the 
suppression of CIP2A (as demonstrated in Figure 8.4). Reactivation of PP2A resulted in a 
decrease in PIM1 protein (p=0.02. Figure 8.5B). A similar trend was also observed with the 
PP2A activators FTY720 and forskolin (Figure 8.5B).
Figure 8.5. PIM1
Panel A: Possible mechanisms by which PIM1 could stabilise c-Myc. PIM1 may act as an 
intermediate step in the stabilisation of c-Myc. Panel B: Changes in PIM1 protein level 
following imatinib, FTY720 and forskolin treatment. K562 cells treated were incubated with 
imatinib, FTY720 and forskolin for 24 hours (n=4).
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In MNC and CD34+ there was a trend for patients destined to progress into BC to have 
higher levels of PIM1 compared to the CCRe and No-CCRe groups (Figure 8.6A and B). 
Higher levels of PIM1 protein were observed in CD34+ cells compared to MNC cells. These 
data are consistent with the view that PP2A is functionally inactive at diagnosis of CML in 
patients destined to progress into BC. No statistically significant difference was observed in 
PIM1 mRNA expression (Figure 8.6C). PIM1 expression was below normal in all three 
clinical groups suggesting that it is regulated post-translationally.
Figure 8.6. PIM1 protein and mRNA expression in MNC and CD34+ cells at 
diagnosis.
Panel A: Levels of PIM1 protein in MNC. PIM1 is higher at diagnosis in patients destined to 
progress into BC. Panel B: Levels of PIM1 protein in CD34+ cells. PIM1 is higher at 
diagnosis in patients destined to progress into BC. Panel C: PIM1 expression.
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8.2.7. CIP2A plays a key role in regulating PP2A and BCR-ABL1 tyrosine kinase 
activity in CML cells.
To further investigate the effect of CIP2A on CML cells, K562 cells were treated with small 
interfering RNA (siRNA) targeted at C1P2A (n=5; Figure 8.8). Following siRNA treatment 
the mean knockdown of the CIP2A protein was 60% (p=0.02; Figure 8.8A). Inhibition of 
CIP2A resulted in a 63% decrease in BCR-ABL1 tyrosine kinase activity as assessed by the 
pCrkL/CrkL ratio as previously described’03 (p=0.03; Figure 8.8B). PP2A protein levels 
remained unchanged (Figure 8.8C), but the degree of PP2A phosphorylation (at Y307, 
indicating inactivity) decreased by 53%, indicative of an increase in PP2A function (Figure 
8.8D). Additionally, SET and JAK2 decreased by 48% and 37% respectively with CIP2A 
siRNA treatment, indicating that CIP2A acts upstream of JAK2 and SET (Figure 8.8E and F). 
pS “c-Myc and total c-Myc protein also decreased by approximately 50% (Figure 8.8G and 
H). Key results from these experiments were also confirmed by Western blotting, using an 
alternative siRNA sequence, and on the additional CML cell line LAMA84 (Figure 8.9). 
These data confirm that PP2A is functionally inactivated by CIP2A and that decreasing the 
level of CIP2A protein removes the block on PP2A function and decreases BCR-ABL1 
activity.
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Figure 8.8. Effect of CIP2A inhibition by siRNA. Inhibition of CIP2A decreases 
BCR-ABL1 tyrosine kinase activity.
K562 cells were treated with CIP2A siRNA for 72 hours (n=5). The effects are shown on: 
CIP2A protein levels as a control (panel A); BCR-ABL1 activity as assessed by the 
pCrkL/CrkL ratio (panel B); PP2A and phosphorylated PP2A (panels C and D); SET (panel 
E) and JAK2 (panel F); c-Myc phosphorylation at serine 62 and total c-Myc protein (panel G 
and H).
A.CIP2A B. BCR-ABL1 tyrosine kinase 
activity
D. Phospho PP2A E.SET F.JAK2
G. c-Myc serine 62 H. c-Myc
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Figure 8.9. CIP2A knockdown in LAMA84 cells - confirms the key siRNA data 
presented in figure 8.8.
LAMA84 cells were treated with C1P2A siRNA for 72 hours. Key results presented in Figure 
8.8 have been confirmed using a different cell line, a different CIP2A siRNA and by a 
different methodology. CIP2A knockdown in LAMA84 cells reduces Y307PP2A thus 
reactivating PP2A, and importantly the pCrkL level decreases indicating a decrease in BCR- 
ABL1 tyrosine kinase activity.
CIP2A
(3-actin
8.2.8 Model mechanisms by which CIP2A regulates PP2A and BCR-ABL1 signalling 
proteins.
The present data suggest that two different signalling mechanisms may be controlling PP2A 
in patients with CML. Figure 8.10 summarises the present data and postulates possible 
mechanisms of how PP2A is inhibited in CML. In most patients, PP2A is suppressed by SET, 
which is driven by BCR-ABL1 via JAK2. When imatinib treatment is commenced, BCR- 
ABL1 activity decreases, and leads to removal of PP2A inhibition. This removal of PP2A 
inhibition permits the dephosphorylation of serine 62 on c-Myc, leading to a decrease in the 
prevailing c-Myc level. Flowever, in a few patients at diagnosis, CIP2A is present at a high 
level, and contributes to PP2A suppression. When treatment commences, C1P2A levels may 
remain high despite a fall in BCR-ABL1 and thus PP2A remains suppressed. c-Myc therefore 
remains at a higher level.
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Figure 8.10. Model mechanisms by which CIP2A regulates PP2A and BCR-ABL1 
signalling proteins.
Possible mechanism of PP2A inhibition in CML. In most patients PP2A is suppressed by 
SET, which is driven by BCR-ABL1 via JAK2. In patients destined to progress into blast 
crisis PP2A is inhibited by CIP2A.
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8.3.0 DISCUSSION
Despite the dramatic effect of imatinib, CML remains a fatal disease for the proportion of 
patients who progress from chronic phase to blast crisis. Recent data suggest that the second 
generation TK.I nilotinib decreases the rate of progression to BC in the first 12-24 
months,152 325 but it remains to be seen whether this benefit is maintained at later time points. 
The previous biomarker data on the pCrkL/CrkL ratio (chapter four) and BCR-ABL1 
transcript type (chapter five) can only predict patients likely to achieve a CCR, and cannot 
predict patients destined to progress to blast crisis.302,303 Various techniques have been used 
on diagnostic chronic phase samples to predict who will develop blast crisis,261 and a variety 
of novel genomic lesions have been identified at blast crisis.326 It is however not possible at 
diagnosis to reliably predict which patients will develop disease progression. This is in part 
due to a poor understanding of the factors facilitating development of the novel genomic 
lesions that lead to disease progression.
The present data suggest that CIP2A is an important detenninant of future disease 
progression in CML. High CIP2A protein levels are present in diagnostic MNC and CD34+ 
cells of patients destined to progress into blast crisis, and following imatinib treatment CIP2A 
levels increase further. The probability of disease progression is 100% at 21 months in 
patients with high CIP2A protein. Interestingly, no correlation was observed between CIP2A 
expression and Sokal score, suggesting that the presence of high levels of this protein is an 
independent biomarker of blast crisis. In particular, of the six patients in this study who 
progressed to blast crisis only two had high Sokal scores (Table 7.1), while in the CCRe 
group, four of the fourteen patients had a high Sokal score but all achieved a CCRe.
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CIP2A functions as a regulator of PP2A activity, and high expression of this protein is 
reported to suppress the phosphatase activity of PP2A.271 Using specific siRNA and imatinib 
to reduce CIP2A levels in K562 cells resulted in a decrease in protein level of two important 
PP2A targets, c-Myc and PIM1. These proteins are important because PIM1 is a kinase that 
acts to phosphorylate c-Myc and stabilise its expression.92’327 When PIM1 is 
dephosphorylated by PP2A it becomes degraded within the proteasome.327 Similarly, c-Myc 
is also degraded in the proteasome once it is dephosphorylated by PP2A.271 The reductions in 
PIM1 and c-Myc (and concomitant reduction of pS62c-Myc) expression therefore suggest that 
PP2A activity increases. This notion is supported by the present observation that pY307-PP2A 
levels decreased without affecting PP2A protein levels in the treated cells. Phosphorylation of 
PP2A on Y307 deactivates this phosphatase, and removal of this phosphate by PP2A-mediated 
auto-dephosphorylation results in its reactivation.254 Taken together, the results of these 
experiments therefore suggest a mechanistic connection between high CIP2A expression, 
PP2A phosphorylation and suppression of activity (illustrated by high levels of pY307-PP2A) 
and high levels of pS62c-Myc and of c-Myc and PIM1 protein.
In the clinical samples analysed high CIP2A protein levels corresponded with high levels of 
Y307 and S62 phosphorylation of PP2A and c-Myc respectively. Moreover, the patient samples 
containing high levels of CIP2A also had high levels of c-Myc and PIM1. Taken together 
with the cell line findings, these data connect CIP2A to c-Myc and PIM1 in primary CML 
cells, and suggest that CIP2A, c-Myc and PIM1 could be prognostic biomarkers.
High levels of pS62c-Myc and c-Myc protein may have important consequences. c-Myc has a 
critical role in cell proliferation, and increased levels of this protein within cells promote
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entry into cell cycle. Thus, diagnostic chronic phase cells with high c-Myc are likely to have 
a greater proliferative potential. This notion is supported by studies of clinical gastric cancer 
biopsies in which aggressive (proliferative) disease is associated with high expression of 
CIP2A and c-Myc.265 Deregulated cell division is known to result in increased DNA 
mismatch repair errors and in genomic instability.96 This is also observed in CML, since c- 
Myc may contribute to disease progression by promoting aneuploidy.96’97,320,321
Whether CIPlA-mediated inhibition of PP2A acts directly to block dephosphorylation of 
c-Myc, or acts at a stage upstream of c-Myc remains to be determined. Junttila et al provide 
evidence suggesting that CIP2A binds directly to c-Myc and is recruited as a result of S62 
phosphorylation.271 However, this is complex since the reduction of CIP2A resulted in a 
decrease in BCR-ABL1 activity; this would then result in a decrease in the signals that are 
necessary to induce stable expression of c-Myc.
In the present study, patients from the CCRe group had high levels of SET protein in samples 
taken at diagnosis. At 12 month sampling, SET protein levels in the MNC from these patients 
were restored almost to normal levels. This is consistent with the in vitro findings of Neviani 
et al,264 which demonstrated that PP2A is inhibited by SET, and that PP2A function can be 
restored by a reduction in SET levels caused by imatinib-induced inhibition of BCR-ABL1 
and JAK2. Broadly similar data were seen in the No-CCRe group, who also did not undergo 
disease progression. However, patients in the BC group had lower SET levels than did 
patients who do not progress. This suggests that PP2A activity may be regulated differently 
in cells of CCRe and BC patients; in the former group of patients PP2A activity is regulated 
predominantly by SET, while in the latter group PP2A activity is regulated also by CIP2A.
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Figure 8.10 summarises the present findings and postulates possible mechanisms of how 
PP2A is inhibited in CML. In patients who respond to imatinib therapy PP2A activity in the 
malignant cells is suppressed by SET, and SET expression is regulated by BCR-ABL1 via 
JAK2.264 When imatinib is commenced, BCR-ABL1 activity decreases and this leads to 
removal of PP2A inhibition through a decrease in SET protein levels. However, in patients 
who progress to blast crisis CIP2A is present at a high level and contributes to (and may 
dominate) PP2A suppression. Imatinib therapy does not affect CIP2A levels in the malignant 
cells of these patients and PP2A remains suppressed. c-Myc expression therefore remains at a 
higher level, increasing the probability of subsequent genetic damage through increased cell 
proliferation and thus disease progression to blast crisis.
In summary, the present data demonstrate that CIP2A is an important determinant of future 
disease progression, and its use as a biomarker of blast crisis needs to be tested both in animal 
models and prospectively in clinical samples. Therapeutic targeting of CIP2A (which is a 
tumour associated protein) would be a more acceptable approach than targeting either PP2A 
or c-Myc which also have important functions in normal non-malignant cells.
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CHAPTER NINE - General discussion
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The aim of this thesis was to investigate whether patients destined to respond poorly to 
imatinib can be prospectively identified. Imatinib has undoubtedly revolutionised treatment 
for CML patients. However, at the time of starting this thesis the only data available on the 
efficacy of imatinib for newly diagnosed CML patients was from a single trial, IRIS, which 
was carried out under the supervision of the imatinib manufacturer Novartis. It was therefore 
important to establish if the IRIS trial outcome data could be reproduced in a more general, 
unselected CML population. The data presented in chapter three indicate that within our 
geographical area, following 24 months of imatinib treatment, the CCRe rate is 51%, 
meaning that nearly half of all patients will fail treatment by two years. This differs from the 
response rates seen within the IRIS study, which demonstrated that after five years of 
imatinib therapy the CCR rate was 87%.18 The discrepancy between the present population 
study and the IRIS trial results may be explained in numerous ways. Firstly, there is a bias for 
low Sokal score patients within the IRIS trial. Secondly, there was an upper age limit and 
exclusion criteria for various concurrent medical conditions in IRIS, while in my population 
based study all adult patients were included, thus reflecting the typical range of patients seen 
in CML clinics on a regular basis. Thirdly, the IRIS trial censored patients at the point of 
imatinib discontinuation, thus with increasing follow-up the IRIS dataset becomes 
progressively selected for patients who have done well. The findings of this population study 
were later substantiated later by two independent studies. ’ In summary, half of all 
patients will fail imatinib treatment by two years, thus identification of prognostic markers 
predictive of treatment response may be useful in order to avoid delay in offering alternative 
treatment such as a second generation TKI or SCT.
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The first biomarker investigated was the pCrkL/CrkL ratio as a surrogate marker for BCR- 
ABL1 tyrosine kinase activity (chapter four). The rationale behind this work was that 
imatinib is a TKI and thus an assay which measures the degree of BCR-ABL1 tyrosine kinase 
activity and how imatinib modifies this either in vivo or in vitro may offer additional 
prognostic information.
The assay demonstrated that FACS assessment of the pCrkL/CrkL ratio at diagnosis was 
predictive of achievement of a CCRe following 12 months of imatinib treatment. 100% of 
patients with an MFI of less than 25 achieved a CCRe, and importantly no patient lost their 
CCRe at any point, with a minimum follow-up of four years. No patient with an MFI above 
25 achieved a CCRe following imatinib treatment; all subsequently required alterations in 
therapy which were either dose escalation or switching to a second generation TKI. 
Conversely all patients treated with nilotinib at initial diagnosis achieved a CCRe irrespective 
of their diagnostic pCrkL/CrkL ratio. No correlation was observed between the pCrkL/CrkL 
ratio and presenting WBC, Sokal score or hOCTl mRNA expression levels, suggesting that 
the pCrkL/CrkL ratio is an independent biomarker of clinical outcome. These data suggest 
that the response to imatinib therapy is related to BCR-ABL1 tyrosine kinase activity present 
at diagnosis. A given dose of imatinib may therefore suppress the lower kinase activity to a 
greater proportional extent than the higher kinase levels in patients with an MFI above 25.303
However, there are some limitations with this assay. Firstly, a considerable amount of time 
was spent optimising the assay. One of the critical factors identified in the optimisation 
process was that the assay must be performed using fresh peripheral blood at diagnosis prior 
to any treatment. The logistics of getting a fresh blood sample to the laboratory for
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assessment may pose some difficulties, thus it may only be possible to perform this assay at 
larger hospitals with a dedicated CML team. Furthermore, given that this study was 
performed on a small cohort of patients the findings need to be confirmed prospectively 
possibly as part of a large clinical trial. Nevertheless, in our laboratory it can be used to 
predict those patients who will achieve a CCRe and the technique is a valuable research tool.
Previous reports prior to the introduction of imatinib have in general, failed to identify any 
effect of BCR-ABL1 transcript type on clinical outcome.54'60 Chapter five investigated the 
role of BCR-ABL1 transcript type on clinical outcome in the imatinib era. The major 
conclusions from the study were that patients with the el4a2 transcript may respond better to 
imatinib (400mg daily) than el3a2 patients, with the el4a2 patients exhibiting a superior time 
to achieve CCRe rate. Using the pCrkL/CrkL ratio at diagnosis as a surrogate for BCR-ABL1 
tyrosine kinase activity, ’ it was determined that patients with the el3a2 transcript type 
had a higher BCR-ABL1 tyrosine kinase activity compared to el4a2 patients. It is therefore 
plausible that a standard dose of imatinib is only able to suppress the lower kinase activity i.e. 
that observed in the el4a2 patients and is insufficient at suppressing the higher kinase activity 
in el3a2 patients, thus el4a2 patients have a superior CCRe rate. The findings of this BCR- 
ABL1 transcript type study were later substantiated by two independent studies conducted in 
Germany and Italy.316,317
There are many advantages of measuring BCR-ABL1 transcript type compared to the 
pCrkL/CrkL ratio at diagnosis. Determination of BCR-ABL1 transcript type is generally 
performed routinely at diagnosis in molecular diagnostic laboratories, thus the data are 
readily available and do not require a lengthy optimisation process or a special sample being
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taken. However, the predictive power of the BCR-ABL1 transcript type is not perfect. At 12 
months 25% of patients with the el3a2 transcript and 53.8% of patients with the el4a2 
transcript achieved a CCRe. These data suggest that patients with the el3a2 transcript type 
should be monitored carefully due to a high risk of imatinib failure. Knowledge of patient 
transcript type may therefore yield clinically useful data.302
The next potential biomarker to be investigated was ALOX5. The data provided by Chen et 
at in a mouse model were interesting, and the fact that the data had not been substantiated 
in clinical samples made this an attractive area to pursue. As discussed in chapter six, the 
initial observations in primary CML samples were contradictory to the finding of Chen et 
al.253 In the CML samples investigated ALOX5 mRNA expression was down-regulated and 
not up-regulated as expected. Furthermore investigation of the ALOX5 pathway, using LTB4 
as a marker of ALOX5 function (as performed by Chen et al253) revealed that there was an 
accumulation of LTB4 in the CML patients. LTB4 positively regulates ALOX5, therefore the 
results observed were puzzling. To investigate this further, the levels of the LTB4 receptor 
BLT1 were determined, since LTB4 can only positively regulate ALOX5 by binding to its 
receptor BLT1. BLT1 protein in newly diagnosed patients was significantly lower than the 
level observed in patients responding to imatinib treatment and those patients who achieved a 
CCRe. The lack of BLT1 in CML patients allows the intermediates of the pathway, namely 
5-HEPTE and LTA4, to suppress ALOX5 gene expression and thus LTB4 accumulates as it 
has no receptor to bind to. The key finding here is that CML patients lack the LTB4 receptor 
BLT1, which is present in mice. The lack of BLT1 in CML patients means that the ALOX5 
pathway studied in the CML mouse model does not function in the same way in human 
CML, which accounts for the difference observed between the clinical samples studied herein
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and the Chen et al253 study. At the start of this project, one of the potential long term aims 
was to use the ALOX5 inhibitor zileuton in combination with imatinib to treat patients 
responding poorly to imatinib alone. Given that ALOX5 is down-regulated in CML patients 
further inhibition would not be beneficial. These data suggest that we should be careful when 
extrapolating CML mouse model data into human CML.
The biomarker data presented in chapters four and five utilising the pCrkL/CrkL ratio or 
BCR-ABL1 transcript type can only predict patients likely to achieve a CCRe and cannot 
predict patients destined to subsequently progress into blast crisis.302’303 Chapters seven and 
eight investigated the role of PP2A and its inhibitors SET, SETBP1 and CIP2A in CML. The 
critical findings of this work were that CIP2A protein is an important determinant of future 
disease progression in CML. High CIP2A protein levels were present in diagnostic MNC 
and CD34+ cells of patients destined to subsequently progress into blast crisis, and following 
imatinib treatment CIP2A levels increased further. The probability of disease progression was 
found to be 100% at 21 months in patients with high CIP2A protein. No correlation was 
observed between CIP2A expression and Sokal score, suggesting that the presence of high 
levels of this protein is an independent biomarker of blast crisis.
CIP2A functions as a regulator of PP2A activity, and high expression of this protein is 
reported to suppress the phosphatase activity of PP2A.271 Using specific siRNA and imatinib 
to reduce CIP2A levels in K562 cells resulted in a decrease in BCR-ABL1 tyrosine kinase 
activity and restoration of PP2A activity and a decrease in the expression of two important 
PP2A targets, c-Myc and PIM1.
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In the clinical samples analysed high CIP2A protein levels corresponded with high levels of 
Y307 and S62 phosphorylation of PP2A and c-Myc respectively. Moreover, the patient samples 
containing high levels of CIP2A also had high levels of c-Myc and PIM1. Taken together 
with the cell line findings, these data connect CIP2A to c-Myc and PIM1 in primary CML 
cells, and suggest that in addition to CIP2A, c-Myc and PIM1 could be prognostic 
biomarkers.
High levels of pS62c-Myc and c-Myc protein may have important consequences. c-Myc has a 
critical role in cell proliferation, and increased levels of this protein within cells promote 
entry into cell cycle. Thus, diagnostic chronic phase cells with high c-Myc are likely to have 
a greater proliferative potential. Deregulated cell division is known to result in increased 
DNA mismatch repair errors and in genomic instability.96 This is also observed in CML,
Qf rj’-* ‘i'}/"! 'lot
since c-Myc may contribute to disease progression by promoting aneuploidy. * ’ ■
At the time of conducting the CIP2A study, CIP2A had only been reported as a poor 
prognostic indicator in breast93 and gastric272 cancers. It has since been reported to be a poor 
prognostic indicator in tongue cancer,329 NSCLC,330 other lung cancer,331 oral carcinoma and 
dysplasia, oesophageal squamous cell carcinoma, prostate cancer, cervical cancer
335and AML. However, the mechanism by which CIP2A is up-regulated in cancer cells 
remains unknown.
Therapeutically targeting CIP2A, PP2A or c-Myc, in addition to BCR-ABL1 are all potential 
options to prevent disease progression. CIP2A, a tumour associated protein (arguably a
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tumour specific protein), is probably the most attractive target, especially since it has been 
shown to play a role in other malignancies. There are many questions which remain 
unanswered with regard to CIP2A. Examples include: what causes it to be up-regulated in 
malignant cells? What is its normal function? What other proteins does it interact with? These 
questions need addressing before attempting to inhibit CIP2A function. An alternative 
approach would be to target either PP2A or c-Myc but this would need to be done cautiously 
as both are known to have normal functions in non-malignant cells.
PP2A is an important phosphatase in normal as well as malignant cells, with roles in cell 
growth and proliferation, DNA replication and repair, metabolism, neural signalling and 
apoptosis. Furthermore, PP2A protein exists as a trimeric complex consisting of a scaffolding 
subunit A, catalytic subunit C and a B subunit. Due to various isoforms of each subunit a 
variety of combinations are feasible, thus specifically targeting PP2A would be difficult. The 
PP2A inhibitor fostriecin has demonstrated cytotoxic effects in L1210 and P388 mouse 
lymphocytic leukaemia cell lines. Fostriecin was tested in a clinical trial but was found to be 
quite toxic and no clinical benefits were observed.336 FTY720 is an immunomodulating drug 
approved for treating multiple sclerosis and has been reported to reactivate PP2A in CML cell 
lines.337 Plowever, FTY720 is inactivated when phosphorylated, and unfortunately in vitro 
data suggest that PP2A inhibition in CML patients would require a dose far greater than that 
which can practically be achieved. Therefore, targeting PP2A directly may be extremely 
difficult and thus targeting its inhibitory proteins may be more feasible option.
c-Myc expression is essential for all proliferating cells. The majority of malignant cells are c- 
Myc dependent and require continuous c-Myc expression to sustain tumour proliferation and
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viability.338 In 20 human cancer cells lines, shRNA-mediated depletion of c-Myc resulted in 
permanent proliferative arrest, with cells accumulating in S or G2/M phases. Inhibition of c- 
Myc in normal cells resulted in Gq/Gi arrest.339 c-Myc knock-out mice die in utero at E9.5 
and 10.5, exhibiting pleiotropic phenotypes including small size, developmental delay, 
enlarged heart and pericardium, decreased yolk sac circulation, and aberrant neural tube 
closure.340 In 2002 the embryonic lethality of c-Myc knock-out mice was attributed to defects 
in vasculogenesis, angiogenesis, and primitive erythropoiesis in the yolk sac and in the 
embryo proper.341 A major concern with an anti-cancer strategy involving c-Myc inhibition 
would be the toxic effects on normal cells. Nevertheless, most normal cells are quiescent and 
express very little c-Myc, so it is plausible that a c-Myc inhibitor might have little effect on 
normal cells.
Figure 9.1 Biomarker flow chart
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In this thesis numerous potential biomarkers have been identified. Some biomarkers predict 
the achievement of a CCRe while others predict disease progression, however no single 
biomarker can predict cytogenetic response and disease progression. Figure 9.1 shows a 
biomarker flow chart and suggests when each test should be performed. At diagnosis the 
pCrkL/CrkL ratio can predict achievement of a CCRe. If a patient has a pCrkL/CrkL ratio 
MFI less than 25 then that patient is likely to achieve a CCRe while on imatinib treatment 
and no further tests are required. If however, a patient has a pCrkL/CrkL ratio MFI greater 
than 25 then this patient will not achieve a CCRe but whether or not the patients will progress 
into blast crisis cannot be determined using the pCrkL/CrkL ratio. To determine if a patient 
is at a high risk of disease progression assessment of CIP2A protein level at diagnosis will 
identify those patients who will subsequently progress into blast crisis, for whom a more 
aggressive treatment strategy may be appropriate. If however, assessment of the pCrkL/CrkL 
ratio is not possible then knowledge of the BCR-ABL1 transcript type could provide 
additional information. The prognosis is poor for patients with the e!3a2 transcript type, 
these patients have only a 25% chance of achieving a CCRe. Therefore, these patients should 
have their CIP2A status assessed at diagnosis in order to determine if they are at risk of future 
disease progression.
Numerous biomarkers have been identified in CML by other groups, as discussed throughout 
this thesis and are summarised in Table 9.1. Some proteins are elevated at disease 
progression but at diagnosis offer no prognostic value. The clinical value of a protein which 
is either up or down-regulated as a patient progresses is small, as this information could be 
provided by simple methods such as looking at the FBC or morphology, or by serial trends in 
BCR-ABL1 quantitation or marrow cytogenetics. Proteins or genes which are differentially 
expressed at diagnosis and have been associated with clinical outcome post imatinib
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treatment make ideal biomarkers. Many of the biomarkers reported to predict a patient’s 
clinical outcome have been tested on a limited cohort of patients. Nevertheless, these 
biomarkers have shown significant promise and warrant further investigation as part of a 
large clinical trial. Table 9.1 lists the current biomarkers and whether or not, in my opinion, 
further investigation of them would be worthy.
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Table 9.1 Summary of identified biomarkers in CML
Biomarker
Discussed in
section
Candidate
for further
investigation
Reasoning
CIP2A 94 1.8.6 and 8.2.0 Yes
This novel biomarker of blast crisis needs
to be confirmed on a larger cohort.
This biomarker, with its serine 62
c-Myc94 1.4.3 and 7.3.8 Yes phosphorylation status needs to be
confirmed on a larger cohort.
PIM192,94,274 1.8.7 and 8.2.6 Yes
This biomarker needs to be confirmed on
a larger cohort using CD34+ cells.
This biomarker needs to be confirmed on
PP2A94 1.8.3 and 7.3.0 Yes a larger cohort using both MNC and
CD34+ cells.94
pCrkL/CrkL
ratio197,303
1.6.8 and 4.3.0 Yes
This needs to be tested prospectively
using fresh MNC.
Additional Considered markers of disease
chromosome 1.4.3 Yes progression and an indication of genomic
abnormalities82 instability.
BCR-ABL1 transcript 
type302,317316
1.3.4 and 5.3.0 Yes This needs to be tested prospectively.
Eutos score160 1.6.2.1 Yes
This novel score needs to be tested
prospectively as part of a clinical trial.
Radich gene array 
signature228
1.6.9.1 Yes
This could be assessed as part of a
clinical trial.
nvisn223 1.6.9.2 Yes
Potentially novel biomarker of imatinib
resistance.22’
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Yong gene array 
signature206
This needs to be tested prospectively 
Yes
using MNC and CD34+ cells..
ALOX5 1.7.1 and 6.3.0 No Offers no prognostic value in CML.
BCR-ABL1 KD 
mutations
CEBPa and hnRNPE2
EV1-1212
1147,166,342443
1.6.7 No
1.4.5 No
1.6.9.1 No
1.6.5 No
Mutations are rarely detected at diagnosis 
and not all mutations confer drug 
resistance.
Offers no prognostic value, increases 
during blast crisis, but has not been tested 
prospectively. ,08’218 
EV1-1 expression predicts clinical 
outcome in imatinib resistant patients 
treated with a second generation TKI.212
Multiple studies have confirmed the 
prognostic value of hOCTll47’166’342’343
JAK2216 1.4.1 No
Plasma monitoring173'
176 1.6.6 No
SET94,264 1.8.4 and 7.3.7 No
Influenced by other proteins in addition to 
BCR-ABLl.216-344'346
Data suggest that a number of variables 
can influence the plasma level of 
imatinib.173-176
Offers no prognostic value, increases 
during blast crisis.94 264
SETBP194’265'347 1.8.5 and 7.3.7 No Offers no prognostic value in CML.94,347
Sokal Score155 1.6.1.1 and 3.3.3 No
Data suggest that Sokal score is a poor 
prognostic indicator in imatinib treated 
patients21,160
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1.4.1STATS74’75
Not immediately downstream of BCR- 
AB LI.348,349
Offers no prognostic value, increases
WT12'3 1.6.9 No
during blast crisis.213
The prime biomarker which warrants further investigation is CIP2A. CIP2A is the only 
biomarker reported at diagnosis to predict those patients who will subsequently progress into 
blast crisis.94 However, the present data are confined to patients treated with imatinib from 
original diagnosis. It remains to be seen whether its predictive value holds for patients treated 
first-line by a more potent TKI such as nilotinib or dasatinib. c-Myc, PIM1, PP2A and the 
pCrkL/CrkL ratio have all been shown to indicate patients destined to fair poorly on imatinib 
treatment.94,303 It is possible however that changes observed in c-Myc, P1M1, PP2A and 
pCrkL/CrkL ratio are simply a reflection of CIP2A activity and are therefore not independent 
biomarkers. Potentially assessing CIP2A at diagnosis may be the only parameter required to 
determine if a patients is at risk of disease progression.
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The original aims of this thesis have been addressed as follows:
1. To establish if IRIS and other clinical trial data can be extrapolated to an 
unselected CML population. This will be done by determining Teal’ rates of 
CCR and MMR, and thus the rate of imatinib failure, for patients treated within 
our region.
This has been addressed in chapter three. In an unselected CML population, the 
dramatic results of the IRIS clinical trial are still seen but the ‘real’ rates of CCR and 
MMR are much lower..
2. To evaluate recently reported biomarkers for CML outcome for their 
significance in determining outcome of modern CML therapy:
a. Whether BCR-ABLI tyrosine kinase activity can predict outcome.
Assessing the BCR-ABLI tyrosine kinase activity at diagnosis as described in 
chapter four can identify those patients who will achieve a CCRe following 12 
months of imatinib treatment.
b. Whether the BCR-ABLI transcript type affects outcome.
The BCR-ABLI transcript type provides additional clinical information. Patients 
with the el3a2 transcript type have an inferior response to imatinib compared to 
e!4a2 patients. This is due to e!3a2 patients having much higher BCR-ABLI 
tyrosine kinase activity, as shown in chapter five.
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3. To investigate new biomarkers for their predictive value on outcome.
a. Investigate the role of ALOXS in human CML for the first time.
ALOX5 expression or function provides no prognostic clinical information. 
This is attributed to differences in the ALOX5 pathway in humans and CML 
mouse models, as discussed in chapter six.
b. Investigate the role of PP2A and its inhibitory proteins (SET, SETBP1 
and CIP2A) in CML cells and ascertain whether any /all are predictive of 
clinical outcome.
CIP2A is a novel biomarker of blast crisis in CML as described in chapter 
eight. Assessment of SET or SETBP1 at diagnosis was not predictive of 
clinical outcome in the CML patients investigated. PP2A, c-Myc and PIM1 
protein expression were also indicative of a patient’s eventual clinical 
outcome.
In conclusion, in identifying patients likely to achieve a CCRe on imatinib treatment the most 
promising biomarker investigated was the pCrkL/CrkL ratio. 100% of patients with an MFI 
less than 25 achieved a CCRe. If assessment of the pCrkL/CrkL ratio was not possible then 
alternatively a patient’s BCR-ABL1 transcript type can provide additional information. 
Identification of patients who will subsequently progress into blast crisis on imatinib 
treatment is now possible, by assessment of the CIP2A protein at diagnosis. Collectively, the 
biomarkers studied in this thesis can potentially predict the outcome of CML patients treated 
with imatinib first-line.
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APPENDIX - Publications arising from this thesis
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Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is 
a critical determinant of disease progression
Claire M. Lucas,1 Robert J. Harris,1 Athina Giannoudis,1 Mhairi Copland,2 Joseph R. Slupsky,1 and Richard E. Clark1
’Department of Haematology, University of Liverpool, Liverpool, United Kingdom; and 2Paul O’Gorman Leukaemia Research Centre, College of Medical, 
Veterinary and Life Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, United Kingdom
Prospective identification of patients 
whose chronic myeloid leukemia (CML) 
will progress to blast crisis is currently 
not possible. PP2A is a phosphatase and 
tumor suppressor that regulates cell pro­
liferation, differentiation, and survival. 
Cancerous inhibitor of PP2A (CIP2A) is a 
recently described inhibitor of PP2A in 
breast and gastric cancer. The aim of this 
study was to investigate whether CIP2A 
played a role In CML and whether PP2A or
Introduction ______________
its inhibitor proteins CIP2A or SET could 
predict clinical outcome. At the time of 
diagnosis of CML, patients who will later 
progress to blast crisis have significantly 
higher levels of CIP2A protein (P < .0001) 
than patients who do not progress, sug­
gesting that PP2Ais functionally inactive. 
We show that the potential mechanism 
for disease progression is via altered 
phosphorylation of the oncogene c-Myc. 
Knockdown of CIP2A results in increased
PP2A activity, decreased c-Myc levels, 
and a decrease in BCR-ABL1 tyrosine 
kinase activity. We demonstrate that 
CIP2A levels at diagnosis can consis­
tently predict patients who will progress 
to blast crisis. The data show that CIP2A 
is biologically and clinically important in 
CML and may be a novel therapeutic 
target. (Blood. 2011 ;117(24):6660-6668)
Chronic myeloid leukemia (CML) is a malignant disease of the 
primitive hematologic cell, characterized by inappropriate expan­
sion of myeloid cells. Although this disease is readily controlled by 
imatinib, approximately one-third of patients will eventually fail 
treatment1,2; and a significant proportion of these will progress 
toward blast crisis (BC), which is usually rapidly fatal. Poor 
response to imatinib and progression to BC have been linked to 
high BCR-ABL1 tyrosine kinase activity,3 but why one patient can 
remain in well-controlled chronic phase for decades whereas 
another may rapidly progress to BC is poorly understood.
The BCR-ABL1 tyrosine kinase in CML is responsible for 
growth and survival of the malignant cells through activation of 
signaling pathways, such as the mitogen-activated protein kinase 
cascade and the PI3K pathway.4,5 A major cellular serine/threonine 
phosphatase working to down-regulate activation of these path­
ways is the tumor suppressor protein phosphatase 2A (PP2A),6 In 
CML cells, PP2A is a key target of BCR-ABL1 signaling; this 
protein becomes inactivated in these cells because BCR-ABL1 
stimulates prevention of its auto-dephosphorylation at tyrosine307.7,8 
Maintenance of pY307-PP2A levels in CML cells feeds back to 
BCR-ABL1 and facilitates increased and sustained kinase activity. 
Inhibition of BCR-ABL1 by imatinib results in reactivation of 
PP2A, inducing both suppression of growth and enhanced 
apoptosis of the leukemic cells.8 However, it is unknown whether 
Y307 in PP2A is a direct substrate of BCR-ABL1, and the 
mechanism regulating phosphorylation of PP2A at this site is not 
clearly defined.
One proposal for the mechanism through which BCR-ABL1 
regulates PP2A activity in CML cells involves expression of the 
PP2A inhibitor protein SET. In CML cell lines, increased expres­
sion of BCR-ABL1 increases expression of SET through a process 
that is mediated by JAK2.9 Furthermore, Neviani et al8 also 
observed that SET levels rose at evolution of BC in chronic phase 
and BC primary CML samples, and that incubation with imatinib 
decreased SET levels in primary CML cells from a single patient 
undergoing BC.
Two additional proteins have been shown to inhibit PP2A 
activity. Overexpression of SET binding protein 1 (SETBPl) 
protects SET from protease cleavage and permits formation of a 
SETBP1-SET-PP2A complex, which inhibits PP2A phosphatase 
activity. However, although one report has indicated that high 
levels of SETBPl expression predict adverse outcome in elderly 
patients with acute myeloid leukemia (AML),10 we have recently 
demonstrated that SETBPl expression does not correlate with 
clinical outcome in CML.11 Thus, SETBPl expression is probably 
not the inhibitory block on PP2A function in CML. The second 
protein of interest, called cancerous inhibitor of PP2A (CIP2A), 
functions in a cancer setting to prevent PP2A-mediated dephosphor­
ylation of c-Myc at serine 62. pS62-Myc is stabilized against 
degradation, and CIP2A therefore promotes deregulated cell 
growth.12 High expression levels of CIP2A correlate with aggres­
siveness of breast and gastric cancers,1315 and CIP2A depletion 
decreases growth of cells from these cancers.13,15 In mouse neural 
progenitor cells, overexpression of CIP2A increases progenitor cell 
self-renewal and proliferation.16 CIF2A has recently been shown to 
be overexpressed in AML patients and correlated with relapse after 
treatment.17 A single case study has reported a CIP2A-MLL 
translocation in infant AML.18 Nothing is known about CIP2A 
expression and function in CML.
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Table 1. Patient characteristics
No. of patients Male/female Average age, y Low
Sokal score
Intermediate High Unknown
CCR 14 7/7 45 6 1 4 3
No-CCR 11 7/4 48 2 2 5 2
BC 6 5/1 37 1 2 2 1
Total 31 31 44 9 5 11 6
OCR indicates complete cytogenetic response; No-CCR, patients who had achieved a complete hematologic response but not a OCR by 12 months and who had not 
progressed; and BC, patients presented in CP but subsequently progressed to BC.
Here we have investigated the expression of PP2A and its 
inhibitory proteins SET and CIP2A in CML patients at diagnosis 
and at 12 months after diagnosis or at disease progression. We show 
that the levels of these proteins are distinctly different according to 
the later outcome of the patient. In particular, we identify CIP2A as 
a potential predictive biomarker of disease progression because 
CIP2A protein levels are significantly higher in CML patients who 
later progress to BC than in patients who do not. Furthermore, we 
also show that high CIP2A levels in primary CML cells correlate 
with high levels of pS62-Myc, suggesting a link between high 
CIP2A expression, increased growth potential, and genetic instabil­
ity. Finally, we support our clinical observations with mechanistic 
data; we show that small interfering RNA (siRNA)-mediated 
knockdown of CIP2A expression in K562 cells results in increased 
PP2A activity, decreased c-Myc levels, and a decrease in BCR- 
ABL1 tyrosine kinase activity. To our knowledge, this is the first 
report of CIP2A dictating outcome in any hematologic malignancy.
Methods
Patient cohort
All 31 CML patients included in this study were diagnosed in chronic phase 
at our center. The study was approved by the Liverpool Local Research 
Ethics Committee, and informed consent in accordance with the declaration 
of Helsinki was obtained from each patient. All were 18 or more years of 
age at diagnosis and were positive by metaphase cytogenetic analysis for 
the t(9;22) (Philadelphia) translocation. Quantitative RT-PCR was used to 
quantify BCR-ABL1 gene fusion transcripts as previously described.19 
Patient characteristics are described in Table 1. All cases started imatinib 
treatment within 4 weeks of first presentation.
Clinical response
Patients were stratified into 3 clinical outcomes:
CCR. Complete cytogenetic response (CCR) = no Philadelphia­
positive metaphases among at least 20 marrow metaphases after 12 months 
of imatinib treatment. In some cases, serial cytogenetic data were not 
available, and achievement of CCR is based on a BCR-ABL1/ABL1 
transcript ratio of < 1%, which we have previously shown20 to be tightly 
coreelated with cytogenetically defined CCR (n = 14).
No-CCR. Patients who had achieved a complete hematologic response 
but not a CCR by 12 months and who had not progressed (n = 11).
BC. Patients presented in chronic phase but who subsequently 
progressed into BC (n = 6).
Sample collection and preparation
Mononuclear cells (MNCs) were separated from peripheral blood at 
diagnosis and after 12 months of imatinib treatment or at disease progression, by 
density-dependent centrifugation (Lymphoprep Axis-Shield), washed in RPMI 
1640 (BioSera), and resuspended in 10% DMSQ/10% FCS serum (BioSera)/ 
RPMI at 4°C and cryopreserved in liquid nitrogen. When required, the cells 
were thawed and resuspended in culture media as previously described.19 
K562, LAMA84, KCL22, and KY01 cell lines were used as BCR-ABL1-
positive cell lines. The gastric cancer cell line AGS was used as a 
ClP2A-positive BCR-ABLl-negative control.
Samples were enriched for CD34 * cells using CliniMACS (Miltenyi 
Biotec) according to the manufacturer’s instructions. All CD34+ cells were 
collected at diagnosis and then grouped according to the patients' eventual 
clinical outcome; CCR (n = 3). No-CCR (n = 4), or BC (n = 3).
Measurement of PP2A, phosphorylated PP2A, SET, CIP2A, 
and PIM1
Flow cytometric assays were used for the detection of PP2A. phosphory­
lated PP2A, SET, CIP2A, and PIM1 as previously described.1 using 
anti-PP2A antibody (Millipore). PP2A Y307 (Epitomics). SET (Santa Cruz 
Biotechnology), CIP2A (Santa Cruz Biotechnology). PIM1 (Abeam), and 
anti-mouse and anti-rabbit AlexFluor-488 (Invitrogen). Supplemental 
Figure 1 (available on the Blood Web site; see the Supplemental Materials 
link at the top of the online article) shows the optimization of the flow 
cytometry assay. Western blotting was used to confirm all findings in both 
K562 and LAMA84 CML cell lines.
Measurement of CrKL phosphorylation
Levels of pCrKL and CrKL (CT10 regulator of kinase-like) were measured 
by FACS as previously described.1
TaqMan gene expression assay of PP2A (catalytic subunit),
SET, and SETBP1
Predesigned TaqMan quantitative RT-PCR assays were used in a 384-well 
assay plate. Each assay consists of a forward and reverse primer at 900nM 
each and a 6-FAM dye-labeled TaqMan MGB probe at 250nM. The assay’s 
ID numbers are: PP2A (catalytic subunit), Hs00427259ml, SET 
Hs00853870gl, SEJBP1 Hs00210209ml, and GAPDH Hs99999905ml. 
The relative expression level was calculated by the comparative Ct method 
that uses the 2-AAQ formula to achieve results for relative quantification.21
CIP2A mRNA expression
The expression of CIP2A was measured using quantitative RT-PCR on a 
LightCycler 1.5 using LightCycler FastStart DNA MasterPlus S YBR Green 
1 (Roche Diagnostics). CIP2A primers and PCR conditions were as 
previously described.11
c-Myc protein and phosphorylation status
Whole-cell lysates were prepared from MNCs. using NP40 lysis buffer. 
ELISA methodology was adapted from Hamilton et al22 using anti-Myc 
ser62 antibody21 (Abeam) and anti-Myc antibody (New England Biolabs).
CIP2A siRNA treatment
A total of 1 X 106 K562 cells were resuspended in 100-p,L solution 
V Nucleofeclor Kit V (Amaxa Biosystems); lOOnM siRNA was added to 
solution V (C1P2A siRNA and control siRNA; Santa Cruz Biotechnology). 
In each case, samples were nucleofected using the Amaxa instrument preset 
program T16. After nucleofection, the cells were cultured for 72 hours in a 
24-well plate before analysis. In addition, these experiments were repeated
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using a different CIP2A siRNA (Integrated DNA Technologies) and a 
different CML cell line LAMA84.
Statistical analysis
Statistical analysis and comparisons were performed by Mann-Whitney and 
Student t tests using SPSS Version 16.0 (SPSS).
Results
PP2A protein expression and phosphorylation are increased 
in MNCs and CD34+ cells from patients destined to progress 
to BC
In initial experiments, PP2A protein levels were compared between 
chronic phase and established BC. Significantly elevated levels 
were seen in BC cells (supplemental Figure 2).
To determine whether PP2A protein levels were indicative of 
disease progression, we analyzed PP2A protein in MNCs of 
31 patients who were in chronic phase at diagnosis and again in the 
same patients after 12 months of treatment or at transformation. 
The clinical response of these patients was stratified into 3 groups 
depending on outcome: CCR, No-CCR, and BC. No BCR-ABL1 
kinase domain mutations were detected in any patients. At diagno­
sis, the mean PP2A protein level in patients destined to achieve 
CCR was not significantly different from that in normal MNCs, 
whereas that in patients destined not to achieve CCR (No-CCR) 
was significantly lower than that in normal cells (P = .02; Figure 
1A). In both groups of patients, PP2A levels increase after 
12 months of treatment. In contrast to the CCR and No-CCR 
patients, PP2A levels in patients destined to progress into BC were 
much higher (P < .001 compared with the No-CCR group), and 
these levels did not change after treatment (Figure 1A). When the 
same experiment was performed on CD34+ cells from the same 
patients, similar results were obtained (Figure IB); PP2A protein 
was elevated in the diagnostic CD34+ cells from patients who 
subsequently progress into BC compared with the CCR and 
No-CCR groups. These results suggest that increased PP2A protein 
expression at diagnosis indicates a high probability of disease 
progression.
We next investigated whether PP2A protein levels were a 
function of PP2A gene expression. Quantitative RT-PCR was used 
to measure expression of the gene coding for the PP2A catalytic 
subunit. The pattern of PP2A gene expression was similar to that of 
PP2A protein expression. Interestingly, PP2A gene expression in 
all 3 groups, regardless of whether the sample was taken at 
diagnosis or after treatment, was lower than that observed in 
normal cells. Because protein levels of PP2Ain the MNCs from the 
BC group were higher than in normal MNCs, this suggests a role 
for posttranslational modification in the stabilization of PP2A 
protein expression in the BC group (supplemental Figure 3).
PP2A is inactive when phosphorylated at tyrosine 307, and this 
can be used to indicate its activity level.8,10,24 Phosphorylated levels 
of PP2A were significantly greater at diagnosis in the CCR 
{P = .01), No-CCR (P = .002), and patients who progressed into 
BC (P = .012) and at BC (P = .004), compared with normal 
MNCs (Figure 1C). We next analyzed PP2Aphosphorylation status 
in CD34'1' cells from patients in these response groups and found 
elevated levels of pY307-PP2A in cells from the CCR and No-CCR 
response groups but dramatically increased levels of this phospho- 
protein in cells from patients destined to progress (Figure ID). 
These data support the conclusions of a previous report indicating a
role for PP2A inactivation in the pathology of CML.8 Taken 
together, these data demonstrate that PP2A proteins and phosphor­
ylation levels are increased in the MNCs and CD34+ cells of 
patients destined to progress to BC.
SET and SETBP1 expression is not indicative of clinical 
outcome
SET and SETBP1 have, respectively been implicated in regulating 
PP2A activity in the leukemic cells of CML and AML.8,10 We 
therefore measured the expression of SET and SETBP1 at diagnosis 
and again after 12 months of treatment or at transformation. In line 
with our previously reported data on SETBP1 expression,11 we 
found that expression of SETBP1 did not differ between the CCR, 
No-CCR, and BC clinical groupings of CML (Figure 2A). More­
over, and unlike in the leukemic cells of AML,10 SETBP1 gene 
expression levels were lower in CML samples compared with those 
from normal subjects. Interestingly, SETBP1 expression increased 
after 12 months of treatment in the CCR and No-CCR groups.
SET protein levels (Figure 2B) were significantly higher at 
diagnosis in the CCR and No-CCR groups compared with normal 
(P < .001 and P = .01, respectively). In patients who subsequently 
progressed to BC, there was a trend for lower SET levels. This 
trend was also seen for SET mRNA levels (Figure 2C) because 
samples from patients who later progressed had lower levels of SET 
mRNA than did samples from either CCR or No-CCR patients. 
Interestingly, in BC samples at transformation, SET protein levels 
increased to become spread over a higher range than at diagnosis 
and may suggest that SET plays a role during disease progression. 
This observation contrasts with the fall in SET expression observed 
in samples from patients within the CCR and No-CCR groups after 
12 months of treatment. When we examined SET protein expres­
sion in diagnostic CD34+ cells, there was no apparent difference 
between the 3 clinical groups, although all patients were receiving 
imatinib treatment at 12 months or at disease progression follow-up 
(Figure 2D). Taken together, these results are broadly in agreement 
with previously reported data8 but also suggest that SET may not be 
the only factor inhibiting PP2A in tire malignant cells from patients 
destined to progress to BC (compared with those from patients who do 
not). This implies that another mechanism may be inhibiting PP2A in 
this group of patients.
CIP2A protein level in MNCs and CD34'1' at diagnosis is 
predictive of BC
An additional protein shown to regulate PP2A activity in some 
cancers that may have a role to play in CML is CIP2A.12'14 Figure 
3 A shows that CIP2A gene expression is not significantly different 
in any of the 3 response groups from that in normal MNCs. No 
statistically significant difference was observed between any of the 
3 response groups or at either time point, nor were any of these 
different from normal MNCs.
In sharp contrast. Figure 3B demonstrates that CIP2A protein 
levels in MNC taken at diagnosis were significantly higher in 
patients who later progressed to BC than in patients from the CCR 
and No-CCR groups (P < .0001 and P — .01, respectively). This 
observation was also confirmed in CD34+ cells; samples from 
patients destined to progress into BC had much higher levels of 
CIP2A than either CCR or No-CCR patients (Figure 3C). No 
correlation was seen between CIP2A expression and Sokal score 
(data not shown). These results suggest that CIP2A may be 
important in inhibiting PP2A function in CML patients who 
progress to BC. The importance of increased CIP2A protein
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Figure 1. PP2A expression and phosphorylation are Increased In MNC and CD34* cells from patients destined to progress to BC. The horizontal line represents the 
mean normal level observed in 10 healthy volunteers. (A) Levels of PP2A protein as assessed by flow cytometry. Mean level in 10 healthy subjects = 21.4 (range, 17.1-25.7). 
The level of PP2A is high in patients destined to progress to BC, compared with nonresponding patients (P = .001). ’Statistically significant difference between No-CCR and 
normal (P= .002). CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (B) Level of PP2A protein in CD34* cells. The level of PP2Ais high in CD34' cells in patients destined to 
progress to BC. CCR, n = 3; No-CCR, n = 4; and BC, n = 3. (C) Level of phosphoryfated (inactive) PP2A protein, as assessed by flow cytometry (mean level in 10 healthy 
subjects = 1.6; range, 0.8-2.3). Phosphorylated levels of PP2A were greater at diagnosis in CCR (P= .01), No-CCR (P = .002) patients who progressed into BC (P= .012), 
and at BC (P = .004) compared with normal MNCs. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (D) Level of phosphorylated (inactive) PP2A protein in CD43* cells. The 
degree of phosphorylation is greater in the CD34* from patients destined to progress into BC. CCR, n = 3; No-CCR, n = 4; and BC, n = 3.
expression in disease progression is further exemplified after 
12 months of treatment; whereas CIP2A protein levels remain 
essentially unchanged in samples from the CCR and No-CCR 
groups, the level increases further at disease progression (P — .008, 
Figure 3B).
To test whether high expression of CIP2A protein is predictive 
of disease progression, progression-free survival was compared 
between patients with high (defined as a mean fluorescence 
intensity > 5) and low diagnostic CIP2A protein levels. Figure 3D 
shows that the median time to disease progression in patients with 
high CIP2A protein levels is 13 months, and their probability of 
progression is 100% at 21 months. Five of these 6 patients have 
died of their progression. In contrast, during the same time period,
none of the patients with low diagnostic CIP2A levels progressed, 
and all remain progression-free and alive at their latest follow-up 
(average follow-up, 47 months). These data indicate that CIP2A 
protein expression is a biomarker of disease progression in CML.
We have previously demonstrated that BCR-ABL1 activity 
levels are also predictive of treatment response in CML.3 To see 
whether BCR-ABL1 was a factor controlling CIP2A protein levels, 
we treated the BCR-ABL1-positive cells lines K562, KCL22, and 
KY01 together with the BCR-ABL-negative gastric cancer cell line 
AGS (used as a CIP2A positive control)14 with the tyrosine kinase 
inhibitor imatinib for 24 hours. We found that imatinib treatment of 
the BCR-ABL1-positive cell lines resulted in a significant down- 
regulation of CIP2A protein levels (P = .002 for K562, P = .001
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Figure 2. SET and SETBP1 at diagnosis and follow-up. SET protein is low at diagnosis in patients who subsequently progress to BC. (A) mRNA expression of SETBP1. 
No significant differences in SETBP1 expression were observed between the 3 response groups. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (B) Levels of SET protein. 
SET protein levels are higher than in normal MNCs (mean level in 10 healthy subjects = 0.2; range, 0.1-0.3) in the CCR and No-CCR groups (P < .001 and P - .01, 
respectively). CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (C) SET mRNA expression. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (D) Level of SET protein in CD34' 
cells. The level of SET protein assessed at diagnosis does not correlate with the patients' eventual clinical outcome, although this outcome is based on only 3 patients who later 
progressed while on imatinib treatment. CCR, n = 3; No-CCR, n = 4; and BC, n = 3.
for KCL22, and P = .024 for KY01) but had no effect on CIP2A 
expression in AGS cells. Thus, BCR-ABL1 activity may be an 
important factor in the regulation of CIP2A protein expression 
(Figure 3E).
c-Myc protein is elevated at diagnosis in patients destined to 
progress to BC
One of the prescribed functions of CIP2A in cancer cells is to 
prevent PP2A-mediated dephosphorylation of c-Myc.12 To test 
whether c-Myc phosphorylation is a factor in CML pathophysiol­
ogy, we used an ELISA to measure the levels of pS62-Myc in 
diagnostic samples. MNCs from patients destined to progress to 
BC had significantly higher levels of pS62-Myc than did those from 
patients within either the CCR or No-CCR groups (Figure 4A; 
P = .04). Because S62 phosphorylation of c-Myc stabilizes this
protein against degradation,12 we also measured levels of total 
c-Myc protein in the same sample. We observed similar results; 
c-Myc protein levels were significantly higher in the cells of 
patients who subsequently progress to BC (Figure 4B; P = .002). 
These data demonstrate that high levels of c-Myc and phosphoryla­
tion at serine 62 indicate a high risk of disease progression. 
Because PP2A is the major phosphatase that dephosphorylates 
c-Myc, these results further suggest that PP2A function may be 
inhibited, possibly by high expression of CIP2A.
PIM1 is a protein kinase that can phosphorylate and stabilize 
c-Myc.22 PIM1 is itself phosphorylated, and in this state it is active 
and its expression is stable.22 However, this protein is a target for 
PP2A; and once it is dephosphorylated by PP2A, it is rapidly 
degraded in the proteasome.26 To further confirm that PP2A is 
functionally inactive in CML, we investigated PIM1 as another
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Figure 3. CIP2A protein level In MNCs and 0034* at diagnosis Is predictive of BC. (A) mRNA expression of CIP2A. No statistically significant difference was observed 
between any of the 3 response groups. OCR, n = 9; No-CCR, n = 9; and BC, n = 6. (B) Levels of CIP2A protein (mean level in 10 healthy subjects = 0.4; range. 0.17-0.63). 
CIP2A protein levels at diagnosis were significantly higher at diagnosis in patients who later progressed to BC than in CCR or No-CCR patients (P < .0001 and P= .01, 
respectively). As a patient progresses into BC, the CIP2A protein level increases further (P = .008). CCR, n = 11; No-CCR, n = 9; and BC, n = 6. (C) Level of CIP2A protein in 
diagnostic CD34* cells stratified by the patients' clinical outcome. CIP2A Is elevated in CD34 from patients destined to progress into BC. CCR, n = 3; No-CCR, n = 4; and BC, 
n = 3. (D) Kaplan-Meier plot of disease progression, stratified by CIP2A level at diagnosis. Patients with a high diagnostic CIP2A protein level (mean fluorescence intensity 
[MFI] > 5) have 100% probability of progressing to BC by 21 months (P < .0001). (E) CIP2A levels (mean r SEM) in CML cell lines K562, KCL22. KY01, and a CIP2A-positive 
gastric cancer cell line AGS, before and after treatment with 5pM imatinib for 24 hours (n = 6).
target of PP2A. Flow cytometry was used to measure PIM1 
expression in CD34+ cells from diagnosis. PIM1 was elevated in 
patients destined to progress into BC compared with the CCR and 
No-CCR patients (Figure 4C). In addition, analysis undertaken in 
K562 cells revealed that activation of PP2A, either by addition of a 
PP2A activator or inhibition of CIP2A by imatinib, also decreased 
PIM1 levels (data not shown). Considering the role of PP2A in 
regulating PIM1 protein levels, these data provide further evidence
that PP2A activity is suppressed in the CD34+ cells of patients at 
high risk of developing BC.
Finally, previous work by others has indicated that suppression 
of PP2A activity feeds back on BCR-ABL1 to facilitate increased 
and sustained kinase activity.8 One of the hallmarks of BCR-ABL1 
activity is phosphorylation of CrkL,3>27 and we have previously 
shown that an increased pCrkL/CrkL ratio is indicative of a poor 
response to imatinib.3 We assessed the pCrkL/CrkL ratio on all
A c-Myc phosphorylation serine 62 Q Total c-Myc protein C P,M1
Figure 4. Assessing PP2A function. c-Myc is elevated at diagnosis in patients destined to progress into BC. Levels of c-Myc phosphorylation on serine 62 (A) and total c-Myc 
protein levels (B). Stratification by clinical outcome and abbreviations as for the previous figures. CCR, n = 10; No-CCR, n = 5; and BC, n = 5. (C) PIM 1 is higher in the CD34+ 
cells from patients who will later progress into BC, confirming that PP2Afunction is inhibited. CCR, n = 3; No-CCR, n = 3; and BC, n = 3.
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Figure 5. CIP2A plays a key role In regulating PP2A In CML cells. K562 cells were treated with CIP2A siRNA for 72 hours (n = 5). The effects are shown on: CIP2A protein 
levels as a control (A), BCR-ABL1 activity as assessed by the pCrkUCrkL ratio (B), PP2A and phosphorylated PP2A (C-D), SET (E), and JAK2 (F). c-Myc phosphorylation at 
serine 62 and total c-Myc protein (G-H).
(n = 10) available samples from the present cohort of patients. 
BCR-ABL1 activity was highest in patients destined to progress 
into BC (supplemental Figure 4).
CIP2A plays a key role in regulating PP2A in CML cells
To confirm a role for PP2A in regulating c-Myc and PIM1 
expression, the CML cell line K562 was treated with imatinib. 
Figure 3E demonstrates that this reduces CIP2A protein expres­
sion. pS62-Myc and PIM1 levels were also reduced in the cells 
treated with imatinib (data not shown). These results are compat­
ible with the notion that CIP2A expression regulated by BCR- 
ABL1 activity has a role in suppression of PP2A activity and in 
downstream activation of PIM1 and c-Myc.
To further investigate the effect of CIP2A on CML cells, K562 
cells were treated with siRNA targeted at CIP2A (n = 5; Figure 5). 
After siRNA treatment, the mean knockdown of the CIP2A protein 
was 60% (P = .02; Figure 5A). Inhibition of CIP2A resulted in a 
63% decrease in BCR-ABL1 tyrosine kinase activity as assessed 
by the pCrkL/CrkL ratio as previously described3 (P = .03; Figure 
5B). PP2A protein levels remained unchanged (Figure 5C), but the 
degree of PP2A phosphorylation (at Y307, indicating inactivity) 
decreased by 53%, indicative of an increase in PP2A function 
(Figure 5D). In addition, SET and JAK2 decreased by 48% and 
37%, respectively, with CIP2A siRNA treatment, indicating that 
CIP2A acts upstream of JAK2 and SET (Figure 5E-F). Phosphory­
lation of c-Myc at serine 62 and total c-Myc protein also decreased 
by approximately 50% (Figure 5G-H). Key results from these 
experiments were also confirmed by Western blotting, using an 
alternative siRNA sequence, and on the additional CML cell line 
LAMA84 (shown in supplemental Figure 5). These data confirm 
that PP2A is functionally inactivated by CIP2A and that decreasing 
the level of CIP2A protein removes the block on PP2 A function and 
decreases BCR-ABL1 activity.
Discussion
Despite the dramatic effect of imatinib, CML remains a fatal 
disease for the proportion of patients who progress from chronic 
phase to BC. Recent data suggest that the second-generation TKI 
nilotinib decreases the rate of progression to BC in the first 
12 months,28 but it remains to be seen whether this benefit is 
maintained at later time points. Our previously published bio- 
marker data on the pCrKL/CrKL ratio and BCR-ABL1 transcript 
type can only predict patients likely to achieve a CCR and cannot 
predict patients destined to progress to BC.3-19 Various techniques 
have been used on diagnostic chronic phase samples to predict who 
will develop BC,29 and a variety of novel genomic lesions have 
been identified at BC.-30 It is however not possible at diagnosis to 
reliably predict which patients will develop disease progression. 
This is in part because of a poor understanding of the factors 
facilitating development of the novel genomic lesions that lead to 
disease progression.
The present data suggest that CIP2A is an important determi­
nant of future disease progression in CML. We show that high 
CIP2A protein levels are present in diagnostic MNCs and CD34+ 
cells of patients destined to progress into BC, and after imatinib 
treatment CIP2A levels increase further. The probability of disease 
progression is 100% at 21 months in patients with high CIP2A 
protein. Interestingly, no correlation was observed between CIP2A 
expression and Sokal score, suggesting that the presence of high 
levels of this protein is an independent biomarker of BC. In 
particular, of the 6 patients in this study who progressed to BC, 
only 2 had high Sokal scores (Table 1), whereas in the CCR group, 
4 of the 14 patients had high Sokal but all achieved a CCR.
CIP2A functions as a regulator of PP2A activity, and high 
expression of this protein is reported to suppress the phosphatase
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activity of PP2A.12 We used specific siRNA and imatinib to reduce 
CIP2A levels in K562 cells and show that this results in a decrease 
in expression of 2 important PP2A targets, c-Myc and PIM1. These 
proteins are important because PIM1 is a kinase that acts to 
phosphorylate c-Myc and stabilize its expression.23-26 When PIM 1 
is dephosphorylated by PP2A, it becomes degraded within the 
proteasome.26 Similarly, c-Myc is also degraded in the proteosome 
once it is dephosphorylated by PP2A.12 The reductions in PIM I and 
c-Myc (and concomitant reduction of pS62-Myc) expression there­
fore suggest that PP2A activity increases. This notion is supported 
by our observation that pY307-PP2A levels decreased without 
affecting PP2A protein levels in the treated cells. Phosphorylation 
of PP2A on Y307 deactivates this phosphatase, and removal of this 
phosphate by PP2A-mediated autodephosphorylation results in its 
reactivation.6 Taken together, the results of these experiments 
therefore suggest a mechanistic connection between high CIP2A 
expression, PP2A phosphorylation, and suppression of activity 
(illustrated by high levels of pY307-PP2A) and high levels of 
pS62-Myc and of c-Myc and PIM 1 protein.
In the clinical samples we analyzed, we found that high CIP2A 
protein levels corresponded with high levels of Y307 and S62 
phosphorylation of PP2A and c-Myc, respectively. Moreover, the 
patient samples containing high levels of CIP2A also had high 
levels of c-Myc and PIM1. Taken together with the cell line 
findings, these data connect CIP2A to c-Myc and PIM 1 in primary 
CML cells and suggest that CIP2A, c-Myc, and PIM1 could be 
prognostic biomarkers.
High levels of pS62-Myc and c-Myc protein may have important 
consequences. c-Myc has a critical role in cell proliferation, and 
increased levels of this protein within cells promote entry into cell 
cycle. Thus, diagnostic chronic phase cells with high c-Myc 
probably have a greater proliferative potential. This notion is 
supported by studies of clinical gastric cancer biopsies in which 
aggressive (proliferative) disease is associated with high expres­
sion of CIP2A and c-Myc.10 Deregulated cell division is known to 
result in increased DNA mismatch repair errors and in genomic 
instability.3' This is also observed in CML because c-Myc may 
contribute to disease progression by promoting aneuploidy.31'34
Whether CIP2A-mediated inhibition of PP2A acts directly to 
block dephosphorylation of c-Myc or acts at a stage upstream of 
c-Myc remains to be determined. Junttila et al provide evidence 
suggesting that CIP2A binds directly to c-Myc and is recruited as a 
result of S62 phosphorylation.12 However, we found that the 
reduction of CIP2A resulted in a decrease in BCR-ABL1 activity, 
and a reduction in kinase activity would result in a decrease in the 
signals that are necessary to induce stable expression of c-Myc.
In the present study, patients from the CCR group had high 
levels of SET protein in samples taken at diagnosis. At the 
12-month sampling, SET protein levels in the MNC from these 
patients were restored to almost normal levels. This is consistent 
with the in vitro findings of Neviani et al,8 which demonstrated that 
PP2A is inhibited by SET and that PP2A function can be restored 
by a reduction in SET levels caused by imatinib-induced inhibition 
of BCR-ABL1 and JAK2. Broadly similar data were seen in the 
No-CCR group, who also did not undergo disease progression. 
However, patients in the BC group had lower SET levels than did 
patients who do not progress. This suggests that PP2A activity may 
be regulated differently in cells of CCR and BC patients; in the 
former group of patients, PP2A activity is regulated predominantly 
by SET, whereas in the latter group, PP2A activity is regulated by 
SET and CIP2A. Figure 6 summarizes the present findings and 
postulates possible mechanisms of how PP2A is inhibited in CML.
Figure 6. Model mechanisms by which CIP2A regulates PP2A and BCR-ABL1 
signaling proteins. Possible mechanism of PP2A inhibition in CML. In most patients, 
PP2A is suppressed by SET, which is driven by BCR-ABL1 via JAK2. In patients 
destined to progress into BC, PP2A is inhibited by CIP2A both directly as well as 
through BCR-ABL.'
In patients who respond to imatinib therapy, PP2A activity in the 
malignant cells is suppressed by SET, and SET expression is 
regulated by BCR-ABL 1 via JAK2.8 When imatinib is com­
menced, BCR-ABL 1 activity decreases and this leads to removal of 
PP2A inhibition through a decrease in SET protein levels. How­
ever, in patients who progress to BC, CIP2A is present at a high 
level and contributes to PP2A suppression. Imatinib therapy does 
not affect CIP2A levels in the malignant cells of these patients and 
PP2A remains suppressed. c-Myc expression therefore remains at a 
higher level, increasing the probability of subsequent genetic 
damage through increased cell proliferation and thus disease 
progression to BC.
In conclusion, the present data demonstrate that CIP2A is an 
important determinant of future disease progression, and its use as 
a biomarker of BC needs to be tested both in animal models 
and prospectively in clinical samples. The data also suggest that 
CIP2A may be a useful therapeutic target in CML.
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Letters to the Editor
Rapid diagnosis of chronic myeloid leukemia by 
flow cytometric detection of BCR-ABLl protein
A definitive diagnosis of CML requires either the 
demonstration of the t(9;22) Philadelphia chromosome 
translocation (by FISH), or BCR-ABU fusion gene (qRT- 
PCR). Both techniques provide important clinical infor­
mation, but are usually confined to specialist regional 
laboratories as they are costly, require specialist staff to 
produce and interpret, and take severail days to com­
plete. Since most patients with neutrophilia and/or 
thrombocytosis do not have CML, a rapid and simple 
screening test for BCR-ABLl protein would be clinically 
useful. Hitherto, demonstrating the BCR-ABLl protein 
has been technically difficult because of its instability,1 
and the lack of a specific antibody that can reliably dis­
tinguish BCR-ABLl protein from its normal ABL coun­
terpart.
The BCR-ABLl Protein kit (BD Biosciences) has been 
developed to detect all frequently occurring BCR-ABLl 
fusion variants in human blood, including pi90, p210 
and p230. It uses an antibody recognizing BCR attached 
to a capture bead and an ABL-directed phycoerythrin 
(PE)-conjugated detection antibody. The presence of 
BCR-ABLl protein results in a sandwich complex com­
prised of both the capture bead and the detection fluo- 
rophore, detectable by flow cytometry.
In initial optimization experiments on clinical samples, 
it was observed that using too few cells may result in a 
false negative result; thus a minimum of IxlO7 cells is 
recommended (Figure 1A). We compared BCR-ABLl 
protein detection from total leukocytes or from MNC 
(Figure IB). The BCR-ABLl MFI (mean fluorescence 
intensity) signal was greater in MNC than total leuko­
cytes (P=0.014). This may be because the proteolytic 
activity present within mature neutrophils is reduced 
within the MNC cell preparation. Comparing results 
from fresh or frozen MNC, whereby analysis was per­
formed immediately after thawing frozen samples, we 
found no significant difference in detectable BCR-ABLl 
protein. However, if the thawed cells were permitted to 
recover overnight prior to analysis, false negative results 
were seen in 2 out of 5 cases tested. The difference may 
be due to protease activity released from neutrophil 
granules disrupted by cell thawing.
BCR-ABLl protein is known to be particularly sensi­
tive to degradation within primary cells,' a feature that is 
not found in cell lines. It is, therefore, important to 
include a known BCR-ABLl positive patient sample as a 
positive control.
We analyzed 157 samples for both BCR-ABLl protein 
and BCR-ABLl mRNA by qRT-PCR within 24-48 h of 
the sample being taken. These consisted of 110 samples 
from patients presenting with neutrophilia and/or 
thrombocytosis suspected of having CML, and 47 sam­
ples from normal healthy controls the data concerning 
which were kept anonymous. In all samples, the BCR- 
ABLl status as determined by qRT-PCR was confirmed 
by the BCR-ABLl protein assay with 100% concor­
dance. The average MFI values from normal cellular 
samples were 87.7±5.5 giving a cut-off value between 
positives and negatives set at 99 (87.7±2SD) (Figure 2A).
Assay specificity and sensitivity were confirmed in pri­
mary cells by assaying for BCR-ABLl protein in patients 
who had commenced treatment with a TKI. In patients
who were in complete cytogenetic response (CCR, 
defined either by standard metaphase analysis on bone 
marrow or as a BCR-ABLl qRT-PCR <1%)' the 
detectable BCR-ABLl protein was either extremely low 
or undetectable. However, in patients at early stages of 
treatment but not yet in CCR (defined as a BCR-ABLl 
ratio of 1-10%) BCR-ABLl protein was readily detected 
(Figure 2A). In patients with newly diagnosed CML 
(BCR-ABLl ratio >10%) BCR-ABLl protein was 
extremely high (P=<0.0001).
The degree of decrease in BCR-ABLl transcript level 
within the first three months of imatinib treatment can 
predict the subsequent clinical outcome.3 To assess if a 
change in BCR-ABLl protein level could also be predic­
tive of later clinical outcome, fresh MNC taken at origi­
nal diagnosis were cultured in the presence of imatinib 
for 24 h. The change in BCR-ABLl protein level did not 
correlate with achievement of CCR. Furthermore, moni­
toring of the BCR-ABLl protein level once treatment had 
commenced provided no useful clinical information (data 
not shown).
Use of any screening kit in a clinical diagnostic setting 
must be able to reliably detect all BCR-ABLl transcript 
types. BCR-ABLl protein was detected in all transcript 
types tested (ela2, el3a2, el4a2 and both el3a2 and 
el4a2) with no significant differences in signal intensity 
between BCR-ABLl transcript types (data not shown).
The BCR-ABLl protein assay produces a test result 
from lysed cellular material in 4 h. However, access to 
CML primary cells as positive controls are required in 
order to eliminate false negative reporting, and these 
samples may not be readily available outside specialist 
laboratories. To deal with this problem, we have simpli­
fied the methodology by using a plasma based assay 
which eliminates confounding cellular granulocytic
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Figure 1. Optimization of sample source for the detection of BCR- 
ABLl protein. (A) Assessing the number of cells required to detect 
BCR-ABLl protein. (B) Comparison between fresh total leukocytes 
and frozen MNC.
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Figure 2. Screening clinical samples for BCR-ABL1 protein. (A) 
157 cellular samples were screened for the presence of BCR- 
ABL1 protein; results are stratified by the BCR-ABL qRT-PCR 
results for the same sample. The MR for each sample was deter­
mined as the observed MR, minus the MR value of the negative 
control plus two standard deviations. (B) 64 plasma samples were 
screened for the presence of the BCR-ABL1 protein. Fourteen 
from patients with neutrophilia and/or thrombocytosis or healthy 
controls normal plasma and 50 CML patients at diagnosis were 
studied.
degradation effects. It has previously been shown that 
leukemic cells shed their proteins, DNA and RNA into 
plasma.^ Plasma was incubated with the capture beads 
and detector reagent for 6 h then analyzed for the pres­
ence of BCR-ABL1 protein.
Plasma samples were analyzed from 50 newly diag­
nosed CML patients and from 14 patients with neu­
trophilia and/or thrombocytosis or healthy controls. The 
normal plasma sample cut-off value was determined as 
98 (72.4±2SD) MFI. In all cases, and for all transcript 
types tested, samples that were negative by plasma were 
also negative by cell lysate, and the result was always in 
agreement with the prevailing BCR-ABL1 mRNA level as 
defined by qRT-PCR (Figure 2B). These data demonstrate 
that the simplified plasma assay is also 100% accurate at 
detecting BCR-ABL1 protein. The level of BCR-ABL1
protein in a plasma sample did not correlate with the 
sample white blood count (data not shown).
In conclusion, when screening patients presenting 
with high white counts for CML, it is important to have 
a technique which economises on time and cost, since 
most patients will be negative and will not require fur­
ther detailed testing. Furthermore, a rapid and reliable 
screening test will give rise to earlier diagnosis and clin­
ical intervention. The present data show that this assay 
is sufficiently reliable to provide a first-line screening test 
for CML diagnosis. Applying this to a plasma sample 
rather than a cell lysate may provide further simplifica­
tion, and this may be particularly useful in developing 
countries whose hospitals lack definitive facilities for the 
detection of BCR-ABL1.
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SET Binding Protein 1 expression does not predict clinical A 
outcome in elironie myeloid leukaemia
Claire M Lucas^ Scientist Robert j Harris, AtSiina. Oanoootiis, Andrea
Davies and Richard E Clark. 
Department of Haematology; Royal Liverpool Universfty Hospital. Liverpool,, England
L7 8XP
To the Editor,
Recently Cristobal et all reported that overexpression of SETUP! s the 
binding protein for SET, predicts adverse outcome in acute myeloid 
leukaemia (AML). SETBF1 overexpression protects SET from protease 
cleavage, leading to increased amounts of full-length SET and formation of 
a 5ETBF1-SET-PF2A complex, which in turn results in inhibition of the 
tumour suppressor PP2A. Inhibition of PP2A provides abnormal proliferation 
and differentiation in transformed malignant cells. In chronic myeloid 
leukaemia (CML), BCR-ABL has been shown to induce the expression of SET, 
which inhibits PP2A activity.? About one-third of CML patients will 
eventually fail imatinib treatment.3,4
We used the TaqMan gene expression assay system (Applied Biosystems) as 
used by Cristobal et a!;1 cDNA extracted from peripheral blood was studied 
from 4 healthy subjects and 46 chronic phase CML patients treated with 
imatinib 4G0mg from diagnosis to investigate the relationship between SET 
and 5ETBP1 expression and clinical outcome. Their mean age was 4fi years, 
with 22 males and 24 females. Sokal scores were as follows - low = 16; 
intermediate = 13; high = 16; unassigned = 1. Patients diagnostic samples 
were categorised according to their subsequent outcome at 12 months - 1) 
complete cytogenetic response (CCR), 2) no CCR and 3) those who 
progressed to blast crisis (BC).
SETBPi expression was not statistically different between any groups (Table 
1). However, SET expression was lower in the BC group compared to the 
CCR group (p= 0.04). No difference in SET expression was observed 
between no CCR and BC group, or between CCR and no CCR groups. 
Furthermore, unlike AML, SETBPI expression levels in CML samples were 
lower than normal subjects. In contrast to AML, we conclude that SETBPI 
expression at diagnosis is not predictive of clinical outcome following 
imatinib treatment in CML. Other factors may therefore be of greater 
importance in the regulation of PP2A and SET in CML.
Table 1. SET and SETBP1 expression levels at diagnosis in 46 CML patients, 
stratified by clinical outcome following imatinib treatment. Samples 
normalised to normal healthy controls. SET expression was statistically 
significant between patients who achieve a CCR and those who 
subsequently progress to blast crisis (p=0.04 Mann-Whitney U test)
SET mRNA expression SETBP1 mRNA 
expression
Average Range Average Range
Normal
value
n=4 1 1
CCR n=20 0.98 (0.01-
6.10)
0.22 (0.00-
0.16)
No CCR n=21 0.60 (0.01-
3.41)
0.34 (0.01-
1.95)
Blast crisis n=5 0.18 (0.09-
0.31)
0.13 (0.03-
0.42)
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Original Article
Chronic myeloid leukemia patients with the el3a2 BCR-ABL fusion 
transcript have inferior responses to imatinib compared to patients 
with the el4a2 transcript
Claire M. Lucas, Robert J. Harris, Athina Giannoudis, Andrea Davies, Katy Knight, Sarah J. Watmough, 
Lihui Wang, and Richard E. Clark
Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK
ABSTRACT
Background
Chronic myeloid leukemia is characterized by a reciprocal translocation between chromo­
somes 9 and 22, creating the fusion gene BCR-ABL. The clinical significance of the type of 
BCR-ABL transcript in newly diagnosed patients in chronic phase treated with imatinib 
400 mg from initial diagnosis remains unknown.
Design and Methods
We analyzed the clinical outcome of 78 newly diagnosed chronic phase patients, aged 16 
or over, treated with imatinib 400 mg. Of these, 71 expressed either el3a2 or el4a2 tran­
scripts. BCR-ABL transcripts were assayed by quantitative real-time polymerase chain 
reaction.
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Results
After 12 months of treatment, 54% of the el4a2 patients had achieved a complete cyto­
genetic response, compared to 25% of the el3a2 patients (p=0.01). Kaplan-Meier analysis 
of the time to achieve complete cytogenetic response revealed that el4a2 patients had 
more rapid response rates, compared to e!3a2 patients (p=0.006). el4a2 patients had a 
higher event-free survival rate in the first 12 months of treatment, although overall survival 
did not differ significandy between the padents with the two types of transcript. Human 
organic cation transporter protein 1 mRNA levels did not differ between the patients with 
the two types of transcript. The pre-treatment pCrKL/CrKL ratio (a surrogate marker of 
BCR-ABL tyrosine kinase activity) was higher in patients with el3a2 transcripts than in 
those with el4a2 (^=0.017).
Conclusions
Patients expressing the el4a2 transcript type have a higher rate and more rapid complete 
cytogenetic responses than el3a2-expressing patients, which may be due to higher BCR- 
ABL tyrosine kinase activity. Knowledge of the transcript type may yield additional prog­
nostic information, although this requires testing on larger datasets.
Key words: chronic myeloid leukemia, BCR-ABL fusion transcript, imatinib.
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BCR-ABL transcript type and response to imatinib
Introduction
Chronic myeloid leukemia (CML) is characterized by a 
reciprocal translocation between chromosomes 9 and 22, 
which creates the fusion gene BCR-ABL. The breakpoints 
of chromosome 22 cluster within a small (5.8 kb) region, 
spanning exons el2-16 (formally denoted as bl-5) known 
as the major breakpoint cluster region (M-BCR). 
Breakpoint locations almost always fall between either 
exons el3 and el4 or between el4 and el5. Although the 
breakpoints in the ABL gene are also variable, because of 
splicing events, the transcribed mRNA has either an 
el3a2 (b2a2) or an el4a2 (b3a2) junction. The el3a2 and 
el4a2 BCR-ABL transcripts differ in length by 75 bp (25 
amino acids).1 Both BCR-ABL mRNA molecules encode a 
210 kDa constitutively active protein kinase which is 
central to the pathogenesis of the disease.2
Imatinib is a tyrosine kinase inhibitor which has 
become the treatment of choice for newly diagnosed 
patients in chronic phase CML, and a recent report sug­
gests that modem drug treatment may produce superior 
results to allogeneic stem cell transplantation.3 We have 
recently shown in a population-based study4 that by 24 
months 49% of patients will fail imatinib treatment; sim­
ilar findings were recently reported in a single center 
study.3 This suggests that the identification of prognostic 
markers predictive of treatment response may be useful 
in order to avoid delay in offering second-line treatment 
such as stem cell transplantation or second-generation 
tyrosine kinase inhibitors.
Previous studies prior to the introduction of imatinib 
did not, in general, identify an effect of BCR-ABL tran­
script type on clinical outcome.6-12 In the imatinib era one 
small study of 22 patients in different phases of disease 
suggested that patients with the el3a2 BCR-ABL tran­
script may be more sensitive to imatinib treatment;13 
while a larger study indicated that patients with el4a2 
have a better molecular response to imatinib.14 The clini­
cal significance of the type of BCR-ABL transcript in 
newly diagnosed chronic phase CML patients treated 
with imatinib remains uncertain. Here we present the 
results of a population-based study in a single contiguous 
geographical locality investigating the effects of BCR- 
ABL transcript type on clinical outcome in 78 newly diag­
nosed patients with chronic phase CML treated with 
imatinib 400 mg.
Design and Methods
Patients and collection of samples
In our area of the north-west of England, the adjacent 
coastal strip of North Wales and the Isle of Man (total 
population 2 million), all services for adults with hemato­
logic cancers are located in 12 hospitals. The molecular 
diagnosis of CML and monitoring for BCR-ABL tran­
scripts for all CML patients in this geographical area are 
carried out in a single center (Royal Liverpool University 
Hospital). We are, therefore, able to trace the clinical 
course of every CML patient in our area. Peripheral blood 
samples were routinely collected at 3-monthly intervals
for molecular monitoring. Briefly RNA was isolated from 
total white blood cells, cDNA was prepared and BCR- 
ABL transcripts were measured by real-time quantitative 
polymerase chain reaction (PCR), using a LightCycler as 
previously decribed.15
All 78 patients aged 16 or over with chronic phase 
CML newly diagnosed between January 1“ 2003 and 
October 31st 2007 and with a minimum of 12 months fol­
low-up were included in this study. The 71 patients who 
presented with either el3a2 or el4a2 BCR-ABL tran­
scripts are the subject of the main investigation; patients 
presenting with both el3a2 and el4a2 transcripts are dis­
cussed separately (n=3). Patients expressing rare tran­
script types were excluded from this study (n=4; one 
each with ela2, el4a3, el3a3 and one patient who 
expressed both el4a2 and ela2 transcripts). Patients were 
included in the assessment of BCR-ABL transcript type if 
they received imatinib 400 mg daily from original diag­
nosis (preceded only by up to 6 weeks of hydroxycar- 
bamide).
Measurement of CrKL phosphorylation 
by fluorescence-activated cell sorting
Phosphorylation of the CT10 regulator of kinase-like 
adaptor protein (CrKL) was used as a measure of BCR- 
ABL tyrosine kinase activity.16 Cells (-5x1 O') were resus­
pended in 500 pL of 2% paraformaldehyde (VWR, 
Lutterworth, UK) and fixed for 10 min at 37°C. Cells 
were then chilled on ice for 1 min and centrifuged at 770 
g for 3 min. Next, 500 pL of 90% methanol (Fisher 
Scientific, Leicestershire, UK) were added to the cell pel­
let. The cells were vortexed and then incubated on ice for 
30 min. Cells were then washed (throughout with 1 mL 
incubation buffer containing phosphate-buffered saline 
and 0.5% bovine serum albumin), and centrifuged at 
770g for 3 min. Cells were resuspended in 25 pL of incu­
bation buffer and left at room temperature for 10 min. 
pCrKL antibody (28 pg/mL; Cell Signaling Technology, 
Massachusetts, USA) or CrKL antibody (28 pg/mL; Santa 
Cruz Biotechnology, California, USA) was added and 28 
pg/mL anti-normal-rabbit immunoglobulins (R&D 
Systems, Abingdon, UK) used as a control. Cells were 
vortexed and incubated at room temperature for 40 
before being washed twice and resuspended in 100 pL of 
incubation buffer containing 10 pg/mL fluorescein- 
labeled goat anti-rabbit second antibody Alexa Fluor 488 
(Invitrogen, Paisley, UK), incubated at room temperature 
in the dark for 30 min, then washed twice and analyzed 
using flow cytometry (FACScalibur; Becton Dickinson, 
Oxford, UK), with Cellquest Pro software (Becton 
Dickinson) for data analysis. The pCrKL/CrKL ratio of a 
sample was determined using the following equation:
pCrKL. - control
pCrKL/CrKL ratio = ---------------------------- x 100
CrKL - control
Human organic cation transporter protein 1 
mRNA analysis
Levels of human organic cation transporter protein 1 
(hOCTl, SLC22A1) were determined using pre-treat-
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ment cDNA, as previously described, on all suitable 
samples expressing either el3a2 or el4a2 transcripts.17
Clinical response
Responses were defined conventionally:18 complete 
hematologic response was defined as normalization of 
the blood count and resolution of splenomegaly and 
complete cytogenetic response (CCR) was defined as 
no Philadelphia chromosome-positive metaphases 
among at least 20 bone marrow metaphases. In some 
cases serial cytogenetic data were not available and the 
achievement of CCR was determined by a BCR- 
ABL/ABL transcript ratio of less than 1%, which we 
have previously shown to be strongly correlated with 
cytogenetically defined CCR;I? we, therefore, use the 
term CCR equivalence (CCRe) to encompass these 
cases.4
Statistical analysis
Statistical analysis and comparisons were performed 
using the statistical program SPSS 16.0 (SPSS Inc. 
Chicago, USA). Fishers’ test and Mann-Whitney tests 
were used.
Results
During the study 78 patients with newly diagnosed 
chronic phase CML were assessed, of whom four 
expressed a rare/variant transcript type and were, 
therefore, excluded from this analysis. Three cases co­
expressed el3a2 and el4a2 and for the purpose of this 
study they are considered as a separate group, leaving 
71 cases expressing either el3a2 or el4a2 BCR-ABL 
transcripts. Of these, 32 expressed the el3a2 type of 
BCR-ABL transcript type and 39 expressed the el4a2
type of transcript. Age, sex and Sokal score of all cases 
analyzed are presented in Table 1.
Outcome according to transcript type
At 12 months 25% of patients with the el3a2 tran­
script had achieved a CCRe compared to 54% of e!4a2 
patients (^=0.01, Table 2). At 18 and 24 months the 
el3a2 patients continued to have lower rates of CCRe 
compared to those of the el4a2 patients. Kaplan-Meier 
analysis of time to achieve CCRe revealed that the 
patients with the el4a2 transcript type had more rapid 
responses than did the el3a2 patients (Figure 1A), with 
this effect continuing throughout treatment (^=0.006).
Patients with the el4a2 transcript type demonstrat­
ed a non-significant trend toward a higher event-free 
survival rate in the first 12 months of treatment, 
although overall survival rates did not differ signifi­
cantly between patients with the two types of the 
transcript (Figure IB and C). This trend is consistent 
with the finding that more patients with el3a2 pro­
gressed in the first 12 months of treatment; imatinib 
treatment failed in eight patients with el3a2 (7 had 
disease progression and 1 was intolerant to therapy), 
while treatment failed in only three patients with the 
el4a2 transcript (2 had disease progression and 1 was 
intolerant to therapy). The Sokal score was not predic­
tive of clinical outcome nor did it differ according to 
the type of transcript (Table 1). Of interest, five addi­
tional cases outside this study who presented with 
blast crisis CML during the period of the study all 
expressed the el3a2 transcript type.
Additionally three cases presented with both el3a2 
and el4a2 BCR-ABL transcripts at diagnosis. Following 
12 months of treatment two achieved a CCRe, 
although by 24 months one of these patients had sub­
sequently lost the CCRe. The patient who failed to
Table 1. (A) Summary of the patients’ characteristics. 
Number of patients 71
Age (years) 50 (19-81)
32
48 (19-75)
39
51 (19-81)
Sex (male/female)
Sokal score
36/35 19/13 17/22
High 21 9 12
Intermediate 14 5 9
Low 15 6 9
No data 21 12 9
Table 1. (B) CCRe rates for both el3a2 and el4a2 BCR-ABL transcript types at 12,18 and 24 months.*
12 months
Total CCRe % of total 
patients patients
achieving CCRe
Total
patients
18 months
CCRe % of total 
patients 
achieving CCRe
Total
patients
24 months
CCRe % of total 
patients 
achieving CCRe
Tfanscript type
el3a2 32 8 25.0 23 8 34.8 23 9 39.1
el4a2 39 21 53.8 32 18 56.3 26 15 57.7
'At 18 months nine cases with e!3a2 and seven cases with el4a2 are excluded from analysis as not yet having received 18 months of Imatinib treamient. At 24 months six 
further cases with e!4a2 are excluded for the same reason.
1364 | haematologica | 2009; 94(10)
BCR-ABL transcript type and response to imatinib
A Time to achieve CCRe Q Overall survival C Event-free survival
H 40
Time (months)
Time (months)
Figure 1. Kaplan Meier plots. (A) Kaplan Meier estimate of time to achieve CCRe for patients with the el3a2 and el4a2 BCR-ABL tran­
scripts, demonstrating a slower response for el3a2 patients (p-0.006). (B) Overall survival stratified by BCR-ABL transcript type and (C) 
event-free survival; no statistically significant differences were observed (SPSS statistical package Mantel-Cox log-rank test).
achieve a CCRe following imatinib treatment was 
switched to an alternative tyrosine kinase inhibitor but 
failed to achieve a CCRe.
Correlation of transcript type with human organic 
cation transporter protein 1 and BCR-ABL kinase 
activity
Imatinib uptake into CML cells is dependent on 
hOCTl,19 while the pCrKL/CrKL ratio is a surrogate 
marker for BCR-ABL tyrosine kinase activity.16 In an 
attempt to establish why patients with the two differ­
ent types of transcript respond differently to imatinib 
treatment we determined hOCTl mRNA levels (n=51) 
and the pCrKL/CrKL ratio (n=28) in all patients for 
whom suitable material was available. No relationship 
was found between transcript type and hOCTl mRNA 
(data not shown). However, samples from el3a2 patients 
had a higher pCrKL/CrKL ratio than those from el4a2 
patients (p=0.017), demonstrating a higher tyrosine 
kinase activity (Figure 2).
e13a2 e14a2
BCR-ABL transcript type n*28
Figure 2. pCrKL/CrKL ratio for patients with the el3a2 and el4a2 
transcripts pCrKL/CrKL ratio was measured in 28 newly diag­
nosed chronic CML patients prior to treatment as a surrogate 
marker for BCR-ABL tyrosine kinase activity, the pCrKL/CrKL ratio 
was higher in el3a2 patients than in el4a2 patients.
Discussion
In the pre-imatinib era, numerous studies addressed 
the significance of the BCR-ABL transcript type on 
CML outcome. Confusion can arise because some 
studies pooled el3a2 and el4a2 transcript types as 5’ 
breakpoints; which were then compared to 3' break­
points. These 3' breakpoints include ela2 fusion tran­
scripts that encodes a pl90 protein, which is associated 
with acute lymphoblastic leukemia and has a poorer 
outcome than chronic phase CML. In general no differ­
ence in outcome was found in the pre-imatinib era 
between patients with chronic phase CML expressing 
el3a2 or el4a2 transcripts. However, surprisingly litde 
information is available on the effects of these tran­
scripts on response to imatinib treatment. In this study 
we focused on comparisons between outcomes in
patients with el3a2 and el4a2 transcripts.
The el3a2 junction may be more prevalent in men,20 
although not necessarily in all ethnic groups, and has 
been associated with blast crisis of myeloid pheno­
type.7 The el4a2 transcript has been correlated with a 
higher platelet count in both adults810 and children.21 
Additionally it has been associated with a longer 
chronic phase and survival, possibly related to the less 
aggressive course of chronic phase in patients with this 
transcript type.32 Furthermore, patients with the e!4a2 
transcript were found to have a higher level of 5'ABL 
deletions as an additional chromosomal abnormality, 
when compared to e!3a2-expressing patients.7 Other 
studies found no correlations with the above, or with 
any other clinical or hematologic parameters.20,22'24
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Overall, data from the pre-imatinib era suggest that 
transcript type has no influence on clinical outcome.6'12 
However, to our knowledge, only two studies have 
addressed the effect of transcript type on the clinical 
outcome of patients treated with imatinib. One small 
study of 22 patients in Brazil with variable disease sta­
tus found a significant difference in response to treat­
ment at 6 months (^=0.0347), with el3a2-expressing 
patients responding better than those expressing 
el4a2.13 A much larger study of patients in chronic 
phase treated with imatinib concluded that patients 
with el4a2 had a higher probability of achieving a 
major molecular response, and had a greater reduction 
in overall transcript levels in response to imatinib than 
did el3a2-expressing patients.14
Here we present additional data on all the patients in 
our contiguous geographical area. These data support 
the view that patients with the el4a2 transcript may 
respond better to imatinib 400 mg daily. Following 12 
months of imatinib treatment el4a2 patients not only 
achieved significantly higher CCRe rates than el3a2 
patients but also achieved their CCRe at a faster rate. 
This was not related to the patients' age, sex or Sokal 
score which takes into consideration standard hemato­
logic parameters.25 Additionally hOCTl expression did 
not differ between el3a2 and el4a2 patients; thus, the 
degree of imatinib uptake between patients with the 
two types of transcript is similar and does not account 
for the observed differences in clinical responses.
The reason for the difference in response to imatinib 
therapy therefore appears to be unrelated to differ­
ences in imatinib transport between transcript types. It
is, however, likely that the effect is due to differences 
in the drug target. Using the pCrKL/CrKL ratio as 
assessment of BCR-ABL tyrosine kinase activity,16 it 
was found that tyrosine kinase activity is higher in 
el3a2 patients than in patients with el4a2. A fixed 
dose of imatinib may, therefore, suppress the lower 
kinase activity in el4a2 patients to a greater propor­
tional extent than the higher kinase levels in el3a2 
patients. This may explain the higher incidence of 
CCRe following treatment with imatinib in el4a2 
patients.
In conclusion, patients with the el4a2 BCR-ABL 
transcript type have a higher response rate to imatinib 
when the CCRe rate is compared to patients who 
express the el3a2 transcript type. We suggest that this 
maybe due to el3a2 patients having a higher BCR-ABL 
tyrosine kinase activity. Knowledge of patient tran­
script type may yield clinically useful data, and should 
be included in future clinical trials of tyrosine kinase 
inhibitors.
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BCR-ABL1 tyrosine kinase activity at diagnosis, as determined 
via the pCrkL/Crkl ratio, is predictive of clinical outcome in 
chronic myeloid leukaemia
Imatinib has become first-line therapy in chronic myeloid 
leukaemia (CML), but recent studies suggest that more than 
one-third of patients fail imatinib over 2-3 years, (de Lavallade 
et al, 2008; Lucas et al, 2008) It would be clinically helpful to 
prospectively identify patients unlikely to achieve a complete 
cytogenetic response (CCRe) following imatinib treatment. 
Prognostic scoring methods, such as the Sokal score, activity of 
the imatinib uptake transporter, hOCTl (human organic 
cation transporter 1) (Wang et al, 2008) and BCR-ABL1 
transcript type (Lucas et al, 2009) have been shown to correlate 
with clinical outcome. However, none of these parameters are 
sufficiently powerful to reliably prospectively predict patients 
destined to fare poorly. The phosphorylation status of CrkL 
has been identified as a surrogate marker of BCR-ABL1 
tyrosine kinase activity (White et al, 2005), because BCR-ABL1 
tyrosine kinase activity cannot be reliability detected in CML 
patient samples (Patel et al, 2007). White et al (2005) showed, 
by Western blotting, that changes in the level of CrkL 
phosphorylation after 1 month of imatinib treatment corre­
lated with clinical outcome.
In this prospective study we developed a fluorescence- 
activated cell sorting (FACS) protocol to investigate the 
predictive value of measuring pCrkL, CrkL and the pCrkL/ 
CrkL ratio (Lucas et al, 2009) in fresh peripheral blood from 
20 untreated chronic phase CML patients prior to commenc­
ing either imatinib or nilotinib treatment. For CrkL phos­
phorylation determination, cells were resuspended in 500 pi of 
2% paraformaldehyde (VWR, Lutterworth, UK) fixed for 
10 min at 37°C and chilled on ice for 1 min. Cells were 
harvested by centrifugation (770 g, 3 min), 500 pi 90% 
methanol (Fisher Scientific, Loughborough, UK) added, vor- 
texed briefly and incubated on ice for 30 min. Cells were then 
washed (throughout with 1 ml of incubation buffer containing 
phosphate-buffered saline and 0-5% bovine serum albumin), 
harvested, and resuspended in 25 pi incubation buffer and 
incubated at room temperature for 10 min. Antibodies (pCrkL 
antibody Cat# 3181 lot 3 and 4, Cell Signalling Technology, 
Danvers, MA, USA; CrkL Cat#sc-319, Santa Cruz Biotechno­
logy, Santa Cruz, CA, USA; control anti-normal-rabbit 
immunoglobulins Cat#AB-105-C, R8cD Systems, Abingdon, 
UK) were added to a final concentration of 28 pg/ml, vortexed 
and incubated at room temperature for 40 min then washed 
twice, resuspended in fluorescein-labelled goat-anti-rabbit 
second layer antibody Alexa Fluor 488 (10 pg/ml; Invitrogen,
Paisley, UK), and incubated at room temperature in the dark 
for 30 min. Twice washed cells were analysed using flow 
cytometry (FACScalibur; Becton Dickinson, Oxford, UK), with 
cellquest pro software (Becton Dickinson) for data analysis. 
The levels of pCrkL and CrkL present in the sample were 
determined as the geometric mean fluorescence intensity 
(MFI) minus the MFI value of the control sample. The 
pCrKL/CrKL ratio of a sample was determined via:
pCrkL/CrkL ratio =
pCrkL — Control MFI 
CrkL — Control MFI
x 100
Flow cytometry has the advantage that it requires fewer 
patient cells (~103 cells) than Western blotting, produces 
quantitative values, and results can be obtained rapidly. 
Additionally this methodology could be utilized more easily 
at other laboratories. A representative FACS histogram of a 
patient sample is shown in Fig 1.
Our study demonstrated that measuring pCrkL levels alone 
did not correlate with clinical outcome (Fig 2A). Hundred per 
cent of patients with a pre-treatment pCrkL/CrkL ratio <25 
achieved CCRe following 12 months of imatinib treatment 
(Fig 2B). Of these, 75% of patients achieved their CCRe within 
6 months. No patient whose pCrkL/CrkL ratio was greater 
than 25 achieved CCRe following 12 months of imatinib 
treatment (P = 0 0003).
Six out of 14 imatinib-treated patients failed to achieve a 
CCRe following imatinib treatment. Three switched to the 
second generation tyrosine kinase inhibitor nilotinib and the 
other three remain on imatinib. No BCR-ABL1 kinase domain 
mutations were detected in patients who failed to achieve a 
CCRe by 12 months. The remaining eight patients, with a 
diagnostic pCrkL/CrkL ratio below 25 and a maximum follow 
up of 2 years, remain in CCRe.
During this study six patients commenced nilotinib treat­
ment at initial diagnosis. Their pCrkL/CrkL MFI ratios at 
diagnosis ranged from 7-5 to 47-3 Fig 2C. Following 
12 months of treatment all achieved a complete cytogenetic 
response. Patients with a pCrkL/CrkL MFI ratio greater than 
25 who were treated with nilotinib achieved a CCRe compared 
to 0% of imatinib-treated patients (P = 0 03). This is probably 
because nilotinib is more potent BCR-ABL1 tyrosine kinase 
inhibitor (O’Hare et al, 2005). These data suggest that patients 
with high BCR-ABL1 tyrosine kinase activity (pCrkL/CrkL
© 2010 Blackwell Publishing Ltd, British Journal of Haematology
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(A)
Number of patients
Total
20
Imatinib-treated
14
Nilotinib-treated
6
Age years (range) 48(19-72) 48(19-72) 56 (44-67)
Sex (M/F) 9/11 in 2/4
Sokal score High 8 5 3
Intermediate 6 3 3
Low 6 6 0
pCrKL CrKL
10' 10s 
FL1-H
5 judoI/1 Imatinibmmmmmi Control Untrcatcti
Fig 1. Patient characteristics and optimization of pCrKL and CrKL detection by flow cytometry. (A) Summary of patients characteristics. (B) 
Representative FACS plot showing pCrKL and CrKL (C) in a newly diagnosed CML patient and changes following in vitro treatment with 5 pmol/1 
imatinib for 24 h.
pCrKL n= 14 pCrKL/CrKL n= 14 
P = 00003
NoCCRe CCRe NoCCRe CCRe
Clinical outcome Clinical outcome
Imatinib 4 13
Imatinib 6 05 Ye
Imatinib 701 Ye*
Imatinib 11-67 Ye
Imatinib 1477 Yes
imatinib i6 19 Yes
Imatinib 245 Yes
Imatinib 24 74 Yes
Imatinib 2666 No
Imniinib 29 13 No
Imatinib 35 29 No
Imatinib 3957 No
Imatinib 4£ 62 No
imatimb 65 70 No
Nilotinib 749 Yes
NBcninib 1231 Yes
Nilotinib 13 78 Y«
Nilotinib 18 71 Yes
Nilotinib 34 72 Ye*
Nilotinib 47-3 Yes
Fig 2. pCrKL, CrKL and pCrKL/CrKL ratio level at diagnosis and clinical outcome. FACS assessment of pCrKL (A) and pCrKL/CrKL ratio (B) in 
untreated newly diagnosed CML patients, stratified by clinical outcome following 12 months of imatinib treatment. (C) pCrKL/CrKL ratio at 
diagnosis and clinical outcome at 12 months for imatinib- and nilotinib-treated patients. Patients with a pCrKL/CrKL ratio below 25 responded to 
imatinib treatment.
MFI ratio >25) have a low probability of responding to 
imatinib, but may nevertheless achieve a complete cytogenetic 
response on nilotinib treatment. All nilotinib-treated patients 
remained in CCRe with continued treatment.
In addition, serial monitoring of the trends in the pCrklV 
CrkL ratio following commencement of imatinib treatment 
had no predictive value. We analysed the diagnostic pCrkL/ 
CrkL ratio data for both imatinib- and nilotinib-treated
2 © 2010 Blackwell Publishing Ltd, British Journal of Haematology
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patients in relation to other clinical parameters such as white 
blood cell count at diagnosis, Sokal score and hOCTl (for 
imatinib-treated patients only), (Davies el al, 2009) and found 
no correlation. This suggests that the pCrkL/CrkL ratio is an 
independent biomarker of clinical outcome for imatinib 
treated patients.
It is interesting to speculate that the response to imatinib 
therapy is related to BCR-ABLl tyrosine kinase activity present 
at diagnosis. A fixed dose of imatinib may therefore only be able 
to suppress the lower kinase activity i.e. pCrkL/CrkL ratio <25; 
while nilotinib, which is known to be a more potent BCR-ABLl 
kinase inhibitor than imatinib (Kantarjian et al, 2007), may 
suppress the BCR-ABLl tyrosine kinase activity to a greater 
proportional extent. This may explain the higher incidence of 
CCRe following treatment with nilotinib.
In conclusion, the pCrkL/CrkL ratio prior to commence­
ment of treatment is a potent predictor of clinical outcome in 
patients treated with imatinib. Its role as a predictive 
biomarker of response to tyrosine kinase inhibitor therapy 
merits further investigation in larger series, though it is 
essential that this is performed on freshly isolated cells prior to 
any treatment.
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LETTER TO THE EDITOR
A population study of imatinib in chronic myeloid leukaemia demonstrates lower 
efficacy than in clinical trials
Leukemia advance online publication, 28 August 2008; 
doi:10.1038/leu.2008.225
Imatinib is a tyrosine kinase inhibitor that has undoubtedly 
saved and improved the quality of lives of many thousands of 
patients with chronic myeloid leukaemia (CML). It has become 
the treatment of choice for newly diagnosed patients in chronic 
phase, and a recent report suggests that modern drug treatment 
may produce superior results to allogeneic stem cell transplant­
ation (SCI).1 The imatinib-treated cohort within the Interna­
tional Randomized Study of Interferon and STI571 (IRIS) has 
provided valuable information on the longer term effects 
of imatinib treatment. On 400 mg daily, the overall survival at 
5 years is 89%.2 Furthermore, the IRIS data suggest that the rate 
of disease progression may decrease with time. However, these 
data are derived from a clinical trial, and it is therefore important 
to establish if these results can be reproduced in a more general 
CML population. Here we present the results of a population- 
based study of CML treated with 400 mg daily imatinib in our 
health-care area.
In our area of the North West of England, the adjacent North 
Wales coastal strip and the Isle of Man (total population 2 
million), all services for adults with haematological cancer are 
located at 12 hospitals. Molecular diagnosis of CML and 
monitoring for BCR-ABL transcripts are carried out at a single 
centre (RLUH) for all CML patients in this geographical area. We 
are therefore able to trace the clinical course of every CML 
oatient in our area.
All patients aged 16 years or more with CML newly diagnosed 
between 1 January' 2003 and 30 June 2006 are included in this 
itudy. Younger patients were excluded as imatinib usage in 
children is not universal, and earlier patients were excluded as 
:he timing of imatinib approval in 2002 varied across our 
geographical area. Patients were included in the assessment 
af imatinib efficacy if they received imatinib 400 mg daily 
Tom original diagnosis (preceded only by up to 6 weeks of 
aydroxycarbamide).
Considerable effort was made to include all CML cases, first 
rom the records at the molecular diagnostic centre and second 
hrough the specific enquiry of local haematologists. Local 
aaematologists verified that each case had never received prior 
nterferon-a or alternative chemotherapy.
Responses were defined conventionally:3 complete haemato- 
ogical response (CHR) = normalization of the blood count 
md resolution of splenomegaly; complete cytogenetic response 
CCR) = no Ph+ metaphases among at least 20 marrow 
netaphases or a BCR-ABUABL ratio of 1% or less,4 which 
ve have previously shown to be tightly correlated with 
:ytogenetically defined CCR; major molecular response 
MMR) =a BCR-ABUABL ratio of 0.1% or less. Measurement 
>f BCR-ABL transcripts was carried out as described earlier using 
quantitative real-time PCR.4,5 In some cases, serial cytogenetic 
Jala were not available and achievement of CCR is based on a 
JCR-ABL/ABL transcript ratio of below 1%; we have therefore
used the term 'CCR equivalence' (CCRe) to encompass these 
cases.
Over the 42 months of the study, 88 new cases of CML were 
seen, giving an annual incidence of 1.2 cases per 100000 
population per annum. These comprised 41 men and 47 
women, and their median age at diagnosis was 53.4 years 
(range 18.6-86.8 years). Of these, four presented in blast crisis 
and were treated with chemotherapy before imatinib and then 
SCT. Of the 84 presenting in chronic phase, 16 cases were not 
assessable for the effect of imatinib as they first received 
interferon-a (seven cases) or an elective SCT (one case); or 
because insufficient follow-up data were available (eight cases).
A flow diagram of patient outcome is given in Figure 1. 
During the first 12 months of treatment, 3 of the 68 patients who 
received imatinib from original diagnosis progressed to blast 
crisis, of whom two died and one achieved a second chronic 
phase during which she underwent SCT. Two patients had 
serious side effects attributable to imatinib (one Stevens-Johnson 
syndrome, one hepatotoxicity) and were successfully treated 
with an alternative tyrosine kinase inhibitor. One further patient 
lost an initial CHR and proceeded to SCT. Six cases therefore 
failed imatinib before 12 months. Of the 62 cases that were 
assessable for response at 12 months, 28 had achieved CCRe.
Twenty-three of these 28 cytogenetic responders (CCRe) were 
assessable at 18 months of imatinib treatment, and 22 remained 
in CCRe; the remaining case developed central nervous system 
blast crisis. Of the 34 cases who had not achieved CCRe at 
12 months, eight patients achieved CCRe at 18 months.
Twelve of the original 68 imatinib-treated patients were 
unassessable at 18 months (three cases lost their CHR and 
proceeded to SCT, two died of disease progression and seven 
cases had not reached the 18-month assessment point). By 24 
months, a total of six of the original 68 imatinib-treated patients 
had progressed to advanced phase (9%), and 10 further cases 
remained in chronic phase but had received SCT or switched to 
an alternative tyrosine kinase inhibitor, because of intolerance 
(three cases) or failure to achieve/maintain CCRe. The flow 
diagram for all imatinib-treated patients is given in Figure 1.
The overall CCRe rates were 41% (28 of 68 patients) at 12 
months, 49% (30 of 61 assessable cases) at 18 months and 51% 
(28 of 55 assessable cases) at 24 months (Table 1). MMR rates 
were 22% at 12 months, 26% at 18 months and 31% at 
24 months.
Using recommended criteria,3 at 24 months, 49% (27 of 55 
assessable cases) had failed imatinib because of either progres­
sion to blast crisis (six cases; all fatal), failure to achieve/ 
maintain CCRe (19 cases, of which four lost CHR as w'ell) or 
intolerance (two cases). Fourteen of the 15 failures who remain 
in CHR and without disease progression have achieved and 
remain in CCRe at latest follow-up, following either SCT or an 
alternative tyrosine kinase inhibitor. Figure 2 gives the event-free 
survival rate according to Sokal score; no statistically significant 
difference is seen.
Despite several hundred publications on various clinical 
aspects of imatinib, there are, to our knowledge, only three
Letter to the Editor
88 Newly diagnosed patients
4 presented in blast crisis
84 Newly diagnosed chronic phase patients
16 cases did not receive imatinib first line
12 months CCRe
28
r
Ir
lived in
issable
68 Patients recei matinib 400mg
6 failed before 12 months-
62 asse  at 12 
months
3 Disease progression 
2 Intolerant 
1 Loss of CHR
I NoCCRe |
34
5 Ongoing follow-up *1 r 2 Disease progression3 Loss of CHR
1 g 1 Ongoing follow-up
24 months
23 5
CCRe
28
Figure 1 A flow diagram of patient outcome. Abbreviations are as defined in the text.
Table 1 CCRe response rate for all 88 patients and the 68 patients who received imatinib from initial diagnosis
All patients Patients receiving imatinib from initial diagnosis
Total 12 months 18 months 24 months Total 12 months 18 months 24 months
Number of cases assessable 88 83 81 80 68 61 55
Low 20 55% (11/20) 53% (10/53) 42% (8/19) 18 50% (9/18) 52% (9/17) 43% (7/16)
Intermediate 29 24% (6/25) 36% (9/25) 36% (9/25) 22 27% (6/22) 38% (6/21) 42% (8/19)
High 28 48% (13/27) 41% (11/27) 41% (11/27) 23 52% (12/23) 61% (11/18) 68% (11/16)
No data 11 27% (3/11) 40% (4/10) 44% (4/9) 5 20% (1/5) 40% (2/5) 50% (2/4)
Overall CCRe 88 40% (33/83) 42% (34/81) 40% (32/80) 68 41% (28/68) 49% (30/61) 51% (28/55)
Abbreviation: CCRe, complete cytogenetic response equivalence. 
The response rate is also stratified according to Sokal score.
series describing results in previously untreated patients. 
The IRIS trial demonstrated that after 5 years of imatinib 
therapy, the overall survival of patients was 89%, with 87% 
achieving a CCR.2 In a separate study of 279 newly diagnosed 
patients presenting to the MD Anderson Hospital, 87% achieved 
a CCR, with an estimated 3-year survival rate of 96%.6 In a 
recent report in abstract form on 207 consecutive patients
referred to the Hammersmith Hospital in London, the 4-year 
progression-free survival was estimated at 90%, with 34 (16%) 
discontinuing imatinib while still in chronic phase. The 
cumulative incidence of CCR and MMR was 59 and 12% by 
12 months, and 87 and 58% by 48 months, respectively. The 
cumulative incidence of loss of CCR at 48 months was 17%.7 
None of these three studies were population-based.
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Figure 2 Kaplan-Meier estimates of event-free survival, (a) Comparison between all 88 patients and the 68 patients who received imatinib from 
initial diagnosis. Remaining panels: outcome according to Sokal score for all 88 patients (b) and for the 68 patients (c). No statistically significant 
differences were observed (SPSS statistical package-antel-Cox log-rank test).
3
In contrast, our population-based study shows that, by using 
the recommended criteria,3 at 24 months 49% (27 of 55 
assessable cases) had failed or were intolerant of imatinib. The 
data suggest that caution is needed in extrapolating clinical trial 
data to the general CML population.
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